小児内分泌学会ガイドライン集

出版社： 中山書店
著者：
発行日： 2018-02-15
分野： 臨床医学：内科  >  小児科学一般
ISBN： 9784521745756
電子書籍版： 2018-02-15 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

5,060 円(税込)

電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

5,060 円(税込)

購入する

商品紹介

日本小児内分泌学会と，関連する諸学会の協力によってつくられた，この分野のガイドラインを網羅してまとめた，学会初のガイドライン集．小児の成長・発達・成熟にかかわる内分泌分野の疾患は，成長障害や甲状腺疾患，糖尿病など多岐にわたる．これらに関係したガイドラインがひとつにまとまって，付録には成長曲線のグラフを付けるなど，実用書として専門家なら必ず手許に置きたい一冊．

目次

  • I　成長障害
    　日本人小児の体格の評価
    　成長ホルモン分泌不全性低身長症の小児期の成長ホルモン治療から
    　　成人期の成長ホルモン治療への移行ガイドライン
    　SGA性低身長症におけるGH治療の手引き
    　　1．SGA性低身長症におけるGH治療のガイドライン
    　　2．SGA性低身長症におけるGH治療の実施上の注意

    II　性分化疾患と性発達異常を伴う疾患
    　ターナー症候群におけるエストロゲン補充療法ガイドライン
    　性分化疾患初期対応の手引き
    　性分化疾患対応の手引き（小児期）

    III　副腎疾患
    　21-水酸化酵素欠損症の診断・治療のガイドライン（2014年改訂版）
    　21-水酸化酵素欠損症の診断・治療のガイドライン（2014年改訂版）推奨版

    IV　甲状腺疾患
    　先天性甲状腺機能低下症マス・スクリーニングガイドライン（2014年改訂版）
    　先天性甲状腺機能低下症マス・スクリーニングガイドライン（2014年改訂版）推奨版、Q&A
    　小児期発症バセドウ病診療のガイドライン2016
    　小児期発症バセドウ病診療のガイドライン2016推奨版、Q&A

    V　カルシウムとビタミンD関連疾患
    　骨形成不全症の診療ガイドライン
    　ビタミンD欠乏性くる病・低カルシウム血症の診断の手引き

    VI　糖代謝異常症
    　先天性高インスリン血症診療ガイドライン

    VII　疾患と内分泌異常
    　小児がん経験者（CCS）のための内分泌フォローアップガイド

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

(I) 成長障害

P.5 掲載の参考文献
1) 橋本令子, 村田光範. 日本人小児の標準体重を検討するための基礎資料に関する研究. 日児誌 2011 ; 115 : 1055-61.
 
2) http://www.e-stat.go.jp/SG1/estat/NewList.do?tid=000001011648
 
3) 緒方勤, 松尾宣武, 他. 日本人のtarget heightおよびtarget rangeについて (第1編) target heightおよびtarget rangeの設定. 日児誌 1990 ; 94 : 1535-40.
 
4) Ogata T, Tanaka T, Kagami M. Target height and target range for Japanese children : Revisited. Clin Pediatr Endocrinol 2007 ; 16 : 85-7.
PubMed
5) Inokuchi M, Hasegawa T, Anzo M, Matsuo N. Standardized Centile Curves of Body Mass Index for Japanese Children and Adolescents Based on the 1978-1981 National Survey Data. Ann Hum Biol 2007 ; 33 : 444-53.
 
6) Inokuchi M, Matsuo N, Anzo M, Hasegawa T. Body mass index reference value (s mean and SD) for Japanese children. Acta Paediatr 2007 ; 96 : 1674-6.
 
7) 井ノ口美香子. 日本人小児の肥満-診断・頻度・国際比較-. 慶應医学 2009 ; 85 : T53-T85.
 
8) Kato N, Takimoto H, Sudo N. The cubic function for spline smoothed L, S, M values for BMI reference data of Japanese children. Clin Pediatr Endocrinol 2011 ; 20 : 47-9.
 
9) Barlow SE, Dietz WH. Obesity evaluation and treatment : Expert committee recommendations. The Maternal and Child Health Bureau, Health Resources and Services Administration and the Department of Health and Human Service. Pediatrics 1998 ; 102 : E29.
PubMed
10) 磯島豪, 内木康博, 堀川玲子, 横谷進, 田中敏章. Body Mass Index (BMI) Zスコア (SDスコア) と肥満度の相関-内分泌外来を受診した小児における検討-. 成長会誌 2007 ; 13 : 69-76.
 
11) 磯島豪, 内木康博, 堀川玲子, 横谷進, 田中敏章. Body Mass Index (BMI) Zスコアと肥満度の相関-秋田県健常小児における検討-肥満研究 2008 ; 14 : 159-65.
Medical*Online
P.9 掲載の参考文献
1) 平成12年乳幼児身体発育調査報告書. 厚生労働省雇用均等・児童家庭局母子保健課 (監). 財団法人母子衛生研究会 (編). 母子保健事業団. 2002.
 
2) 平成12年度学校保健統計調査報告書. 文部科学省生涯学習政策局調査企画課. 2003.
 
3) Isojima T, Kato N, Ito Y, Kanzaki S, Murata M. Growth standard charts for Japanese children with mean and standard deviation (SD) values based on the year 2000 national survey. Clin Pediatr Endocrinol 2016 ; 25 : 71-6.
PubMed
4) 加藤則子, 村田光範, 河野美穂, 谷口隆, 大竹輝臣. 0歳から18歳までの身体発育基準について-「食を通じた子どもの健全育成のあり方に関する検討会」報告書より-. 小児保健研究 2004 ; 63 : 345-8.
 
5) Ito Y, Fujieda K, Okuno A. Weight-for-height charts for Japanese children based on the year 2000 Report of School Health Statistics Research. Clin Pediatr Endocrinol 2016 ; 25 (2) : 77-82.
PubMed
6) 生魚薫, 橋本令子, 村田光範. 学校保健における新しい体格判定基準の検討 新基準と旧基準の比較, および新基準による肥満傾向児並びに痩身傾向児の出現頻度にみられる1980年度から2006年度にかけての年次推移について. 小児保健研究 2010 ; 69 : 6-13.
 
7) Kato N, Takimoto H, Sudo N. The cubic function for spline smoothed L, S, M values for BMI reference data of Japanese children. Clin Pediatr Endocrinol 2011 ; 20 : 47-9.
 
P.29 掲載の参考文献
1) Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency. Consensus guidelines for the diagnosis, treatment of adults with growth hormone deficiency : summary statement for the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency. J Clin Endocrinol Metab 1998 ; 93 : 379-81.
 
2) Clayton PE, et al. Consensus statement of the management of the GH-treated adolescent in the transition to adult care. Eur J Endocrinol 2005 ; 152 : 165-70.
PubMed
3) Molitch ME, Clemmons DR, Malozowski S, et al. Evaluation and treatment of adult growth hormone deficiency : An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2006 ; 91 : 1621-34.
PubMed
4) 厚生労働省難治性疾患克服研究事業「間脳下垂体機能障害に関する調査研究」. 成人成長ホルモン分泌不全症の診断と治療の手引き (平成17年度改訂).
 
5) Chihara K, et al. Adult GH deficiency in Japanese patients : effect of GH treatment in a randomized, placebo-controlled trial. Eur J Endocrinol 2004 ; 151 : 343-50.
 
6) 島津章, 他. IRMAキットを用いたIGF-I, IGF-II, IGFBP-3測定の臨床的検討. 第1報 成人期における検討. ホルモンと臨床 1996 ; 44 : 1129-38.
 
7) 厚生労働省難治性疾患克服研究事業「間脳下垂体機能障害に関する調査研究」. 成長ホルモン分泌不全性低身長症の診断の手引き (平成17年度改訂).
 
8) 藤枝憲二, 他. IRMAキットを用いたIGF-I, IGF-II, IGFBP-3測定の臨床的検討. 第1報 小児期における検討. ホルモンと臨床 1996 ; 44 : 1229-39.
 
P.33 掲載の参考文献
1) 厚生労働省難治性疾患克服研究事業「間脳下垂体機能障害に関する調査研究」. 成長ホルモン分泌不全性低身長症の診断の手引き (平成17年度改訂).
 
2) 島津章, 他. IRMAキットを用いたIGF-I, IGF-II, IGFBP-3測定の臨床的検討. 第1報 成人期における検討. ホルモンと臨床 1996 ; 44 : 1129-38.
 
3) 厚生労働省難治性疾患克服研究事業「間脳下垂体機能障害に関する調査研究」. 成人成長ホルモン分泌不全症の診断の手引き (平成17年度改訂).
 
P.41 掲載の参考文献
1) Albertsson-Wikland K, Karlberg J. Natural growth in children born small for gestational age with and without catch-up growth. Acta Paediatr Suppl 1994 ; 399 : 64-70.
PubMed
2) Karlberg J, Albertsson-Wikland K. Growth in full-term small-for-gestational-age infants from birth to final height. Pediatr Res 1995 ; 38 : 733-9.
PubMed
3) Hokken-Koelega AC, de Ridder MA, Lemmen RJ, et al. Children born small for gestational age : do they catch up- Pediatr Res 1995 ; 38 : 267-71.
PubMed
4) Tanner JM, Whitehouse RH, Hughes PC, Vince FP. Effect of human growth hormone treatment for 1 to 7 years on growth of 100 children, with growth hormone deficiency, low birthweight, inherited smallness, Turner's syndrome, and other complaints. Arch Dis Child 1971 ; 46 : 745-82.
PubMed
5) Clayton PE, Cianfarani S, Czernichow P, et al. Management of the child born small for gestational age child (SGA) through to adulthood : A Consensus statement of the International Societies of Paediatric Endocrinology and the Growth Hormone Research Society. J Clin Endocrinol Metab 2007 ; 92 : 804-10.
PubMed
6) 日本小児内分泌学会成長ホルモン委員会・日本未熟児新生児学会薬事委員会報告. SGA性低身長症におけるGH治療のガイドライン. 日児誌 2007 ; 111 : 641-6.
 
7) 日本小児科学会新生児委員会. 新生児に関する用語についての勧告. 日児誌 1994 ; 98 : 1946-50.
 
8) Itabashi K, Mishina J, Tada H, et al. Longitudinal follow-up of height up to five years of age in infants born preterm small for gestational age ; comparison to full-term small for gestational age infants. Early Hum Dev 2007 ; 83 : 327-33.
PubMed
9) Leger J, Levy-Marchal C, Bloch J, et al. Reduced final height and indications for early development of insulin resistance in a 20 year old population born small for gestational age : regional cohort study. BMJ 1997 ; 315 : 341-7.
 
10) Gibson AT, Carney S, Cavazzoni E, et al. Neonatal and postnatal growth. Horm Res 2000 ; 53 (suppl 1) : 42-9.
 
11) Leger J, Noel M, Limal JM, et al. Growth factors and intrauterine growth retardation. II. Serum growth hormone, insulin-like growth factor (IGF) I, and IGF-binding protein 3 levels in children with intrauterine growth retardation compared with normal control subjects : prospective study from birth to two years of age. Study Group of IUGR. Pediatr Res 1996 ; 40 : 101-7.
 
12) Rogers I. EURO-BLCS study group. The influence of birth weight and intrauterine environment on adiposity and fat distribution in later life. Int J Obes Relat Metab Disord 2003 ; 27 : 755-77.
 
13) Baird J, Fisher D, Lucas P, et al. Being big or growing fast : systematic review of size and growth in infancy and later obesity. BMJ 2005 ; 331 : 929.
PubMed
14) Monteiro PO, Victora CG. Rapid growth in infancy and childhood and obesity in later life- a systematic review. Obes Rev 2005 ; 6 : 143-54.
PubMed
15) Arenz S, Ruckerl R, Koletzko B, et al. Breast-feeding and childhood obesity. Int J Obes 2004 ; 28 : 1247-56.
 
16) Owen CG, Martin RM, Whincup PH, et al. Effect of infant feeding on the risk of obesity across the life course. Pediatrics 2005 ; 115 : 1367-77.
PubMed
17) Sommerfelt K, Markestad T, Ellertsen B. Neuropsychological performance in low birth weight preschoolers : a population-based, controlled study. Eur J Pediatr 1998 ; 157 : 53-8.
PubMed
18) Lundgren EM, Cnattingius S, Jonsson B, et al. Intellectual and psychological performance in males born small for gestational age with and without catch-up growth. Pediatr Res 2001 ; 50 : 91-6.
PubMed
19) Preece MA. Puberty in children with intrauterine growth retardation. Horm Res 1997 ; 48 (suppl 1) : 30-2.
 
20) Lazar L, Pollak U, Kalter-Leibovici O, et al. Pubertal course of persistently short children born small for gestational age (SGA) compared with idiopathic short children born appropriate for gestationa age (AGA). Eur J Endocrinol 2003 ; 149 : 425-32.
 
21) Lienhardt A, Carel J-C, Preux P-M, et al. Amplitude of pubertal growth in short stature children with intrauterine growth retardation. Horm Res 2002 ; 57 (suppl 2) : 88-94.
 
22) Coutaint R, Carel J-C, Letrait M, et al. Short stature associated with intrauterine growth retardation : final height of untreated and growth hormone-treated children. J Clin Endocrinol Metab 1998 ; 83 : 1070-4.
 
23) Albertsson-Wikland K, Boguszewski M, Karlberg J. Children born small for gestational age : postnatal growth and hormonal status. Horm Res 1998 ; 49 (Suppl 2) : 7-13.
 
24) 田中敏章, 佐藤真理, 石川美香, 他. 思春期低身長児または最終身長低身長者の縦断的解析 第2編 病院における経過観察の検討. 日児誌 1997 ; 101 : 617-23.
 
25) Cianfarani S, Maiorana A, Geremia C, et al. Blood glucose concentrations are reduced in children born small for gestational age (SGA), and thyroid- stimulating hormone levels are increased in SGA with blunted postnatal catch-up growth. J Clin Endocrinol Metab 2003 ; 88 : 2699-705.
PubMed
26) Tenhola S, Halonen P, Jaaskelainen J, et al. Serum markers of GH and insulin action in 12-year-old children born small for gestational age. Eur J Endocrinol 2005 ; 152 : 335-40.
PubMed
27) Woods KA, Camacho-Hubner C, Savage MO, et al. Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene. N Engl J Med 1996 ; 335 : 1363-7.
 
28) Abuzzahab MJ, Schneider A, Goddard A, et al. Intrauterine Growth Retardation (IUGR) Study Group. IGF-I receptor mutations resulting in intrauterine and postnatal growth retardation. N Engl J Med 2003 ; 349 : 2211-22.
 
29) Vaessen N, Janssen JA, Heutink P, et al. Association between genetic variation in the gene for insulin-like growth factor-I and low birthweight. Lancet 2002 ; 359 : 1036-7.
PubMed
30) Arens N, Johnston L, Hokken-Kolega A. Polymorphism in the IGF-I gene : clinical relevance for short children born small for gestational age (SGA). J Clin Endocrinol Metab 2002 ; 87 : 2720.
 
31) Barker DJ, Osmond C, Golding J, et al. Growth in utero, blood pressure in childhood and adult life, and mortality from cardiovascular disease. BMJ 1989 ; 298 : 564-7.
PubMed
32) Murtaugh MA, Jacobs DR JR, Moran A, et al. Relation of birth weight to fasting insulin, insulin resistance, and body size in adolescence. Diabetes Care 2003 ; 26 : 187-92.
PubMed
33) Jaquet D, Deghmoun S, Chevenne D, et al. Dynamic change in adiposity from fetal to postnatal life is involved in the metabolic syndrome associated with reduced fetal growth. Diabetologia 2005 ; 48 : 849-55.
PubMed
34) Soto N, Bazaes RA, Pena V, et al. Insulin sensitivity and secretion are related to catch-up growth in small-for-gestational-age infants at age 1 year : results from a prospective cohort. J Clin Endocrinol Metab 2003 ; 88 : 3645-50.
PubMed
35) Veening MA, van Weissenbruch MM, Delemarre van de Waal HA. Glucose tolerance, insulin sensitivity, and insulin secretion in children born small for gestational age. J Clin Endocrinol Metab 2002 ; 87 : 4657-61.
PubMed
36) Crowther NJ, Cameron N, Trusler J, et al. Association between poor glucose tolerance and rapid post natal weight gain in seven-year old children. Diabetologia 1998 ; 41 : 1163-7.
PubMed
37) Veening MA, van Weissenbruch MM, Delemarrevan de Waal HA. Sequelae of Syndrome X in children born small for gestational age. Horm Res 2004 ; 61 : 103-7.
PubMed
38) Primatesta P, Falaschetti E, Poulter NR. Birth weight and blood pressure in childhood : results from the Health Survey for England. Hypertension 2005 ; 45 : 75-9.
PubMed
39) de Zegher F, Hokken-Koelega A. Growth hormone therapy for children born small for gestational age : height gain is less dose dependent over the long term than over the short term. Pediatrics 2005 ; 115 : e458-62.
 
40) Hokken-Koelega A, van Pareren Y, Arends N. Effects of growth hormone treatment on cognitive function and head circumference in children born small for gestational age. Horm Res 2005 ; 64 (suppl 3) : 95-9.
 
41) Sas T, Mudler P, Hokken-Koelega A. Body composition, blood pressure, and lipid metabolism before and during long-term growth hormone (GH) treatment in children with short stature born small for gestational age either with or without GH deficiency. J Clin Endocrinol Metab 2000 ; 85 : 3786-92.
PubMed
42) Wilson TA, Rose SR, Cohen P, et al. Update of guidelines for the use of growth hormone in children : the Lawson Wilkins Pediatric Endocrinology Society Drug and Therapeutics Committee. J Pediatr 2003 ; 143 : 415-21.
PubMed
43) de Zegher F, du Caju MV, Heinrichs C, et al. Early, discontinuous, high dose growth hormone treatment to normalize height and weight of short children born small for gestational age : results over 6 years. J Clin Endocrinol Metab 1999 ; 84 : 1558-61.
PubMed
44) Cohen P, Bright GM, Rogol AD, et al. Effects of dose and gender on the growth and growth factor response to GH in GH-deficient children : Implications for efficacy and safety. J Clin Endocrinol Metab 2002 ; 87 : 90-8.
PubMed
45) Lee KW, Cohen P. Individualized growth hormone therapy in children : advances beyond weight-based dosing. J Pediatr Endocrinol Metab 2003 ; 16 (suppl 3) : 625-30.
 
46) Sas T, Mulder P, Aanstoot HJ, et al. Carbohydrate metabolism during long-term growth hormone treatment in children with short stature born small for gestational age. Clin Endocrinol 2001 ; 54 : 243-51.
PubMed
47) van Pareren Y, Mulder P, Houdijk M, et al. Effect of discontinuation of growth hormone treatment on risk factors for cardiovascular disease in adolescents born for gestational age. J Clin Endocrinol Metab 2003 ; 88 : 347-53.
PubMed
P.50 掲載の参考文献
1) 田中敏章, 横谷進, 西美和, 他. SGA性低身長症におけるGH治療に関するガイドライン. 日本小児科学会雑誌 2007 ; 111 : 641-6.
 
2) 板橋家頭夫 (研究分担者). 日本人在胎期間別出生時体格基準値の作成に関する研究. 厚生労働科学研究 (子ども家庭総合研究) 「周産期母子医療センターネットワークによる医療の質の評価とフォローアップ・介入による改善・向上に関する研究」 (主任研究者 : 大阪府立母子保健総合医療センター藤村正哲) 2009年度報告書.
 
3) 日本小児科学会新生児委員会. 新しい在胎期間別出生時体格標準値の導入について. 日本小児科学会雑誌 2010 ; 114 : 1271-93.
 
4) Cohen P, Rogol AD, Deal CL, et al. Consensus statement on the diagnosis and treatment of children with idiopathic short stature : A summary of the Growth Hormone Research Society, Lawson Wilkins Pediatric Endocrine Society and the European Society for Pediatric Endocrinology Workshop. J Endocrinol Metab 2008 ; 93 : 4210-7.
 
5) 田中敏章, 横谷進, 藤枝憲二, 清野佳紀, 多田裕, 三科潤. 日本人SGA性低身長症患児に対する成長ホルモンの治療効果と安全性-国内ガイドラインの治療開始基準合致例の検討-. ホルモンと臨床 2008 ; 56 : 961-71.
 
6) 菱木知郎, 檜山英三. 日本における小児肝腫瘍治療の現況. 日本小児科学会雑誌 2010 ; 114 : 946-55.
 
7) Tanimura M, Matsui I, Abe J, et al. Increased risk of hepatoblastoma among immatute children with a lower birth weight. Cancer Res 1998 ; 58 : 3032-5.
PubMed
8) Spector LG, Puumala SE, Susan E. Carozza SE, et al. Cancer risk among children with very low birth weights. Pediatrics 2009 ; 124 : 96-104.
 

(II) 性分化疾患と生発達異常を伴う疾患

P.58 掲載の参考文献
1) Hibi I, Tanae A, Tanaka T. Spontaneous puberty in Turner syndrome : its incidence, influence on final height and endocrinological features. In : Ranke MB, Rosenfeld RG, eds. Turner syndrome : Growth promoting therapies. Amsterdam : Excepta Medica ; 1991. p.75-81.
 
2) Tanaka T, Horikawa R, Tanae A, et al. Final height in girls with Turner syndrome after growth hormone treatment ; Experience at National Children's Hospital. Clin Pediatr Endocrinol 2000 ; 9 : 41-6.
 
3) Tanaka T, Satoh M, Tanae A, et al. Bone age maturation during growth promoting and GnRHa treatment in Turner syndrome. In : Albertsson-Wikland K, Ranke M, eds. Turner Syndrome in a Life-Span Perspective. Amsterdam : Elsevier Science B. V., 1995 : 191-200.
 
4) 佐藤真理, 内木康博, 堀川玲子, 他. ターナー症候群における成長ホルモンの骨成熟作用に関する検討. 日本成長学会誌 2005 ; 11 : 9-13.
 
5) Davenport ML. Evidence for early initiation of growth hormone and transdermal estradiol therapies in girls with Turner syndrome. GH & IGF Res 2006 ; 16 : S91-7.
PubMed
6) Bannink EN, Raat H, Mulder PGH, et al. Quality of life after growth hormone therapy and induced puberty in women with Turner syndrome. J Pediatr 2006 ; 148 : 95-101.
 
7) Carel J-C, Elie C, Ecosse E, et al. Self-esteem and social adjustment in young women with Turner syndrome-influence of pubertal management and sexuality : population-based cohort study. J Clin Endocrinol Metab 2006 ; 91 : 2972-9.
PubMed
8) Saenger P, Wikland KA, Conway GS, et al. Recommendations for the diagnosis and management of Turner syndrome. J Clin Endocrinol Metab 2001 ; 86 : 3061-9.
PubMed
9) Bondy CA. Care of girls and women with Turner syndrome : a guideline of the Turner Syndrome Study Group. J Clin Endocrinol Metab 2007 ; 92 : 10-25.
 
10) Takano K, Tanaka T, Ogawa M, et al. Clinical outcome of GH treatment in Turner girls in Japan : results of multicentre trial. Clin Pediatr Endocrinol 2000 ; 9 (suppl 14) : 15-22.
 
11) Tanaka T, Horikawa R, Tanae A, et al. Final height in girls with Turner syndrome after growth hormone treatment ; Experience at National Children's Hospital. Clin Pediatr Endocrinol 2000 ; 9 : 41-6.
 
12) Tanaka T, Takano K, Ogawa M, et al and the members of Study Groups of GH treatment of Turner syndrome. Final height in Turner syndrome after growth hormone treatment ; Japanese study. In : Saenger P, Albertsson-Wikland K, eds. Optimizing Health Care for Turner Patients in the 21st Century. Amsterdam : Elsevier Science B. V., 2000 : 223-8.
 
13) Tanaka T, Horikawa R, Naiki Y, et al. Prediction of pubertal growth at start of estrogen replacement therapy in Turner syndrome. Clin Pediatr Endocrinol 2008 ; 17 : 9-15.
PubMed
14) 横谷進, 伊藤純子. 12～14歳で段階的エストロゲン補充療法を開始したターナー症候群における性成熟と成人身長. 第41回日本小児内分泌学会学術集会. 横浜. 2007年11月7～9日.
 
15) Rosenfield RL, Perovic N, Devine N, et al. Optimizing estrogen replacement treatment in Turner syndrome. Pediatrics 1988 ; 102 : 486-8.
 
P.60 掲載の参考文献
1) 田中敏章, 他. ターナー症候群におけるエストロゲン補充ガイドライン. 日本小児科学会雑誌 2008 ; 112 : 1048-50.
 
2) Bondy CA. Care of girls and women with Turner syndrome : A guideline of the Turner Syndrome Study Group. J Clin Endocrinol Metab 2007 ; 92 : 10-25.
 
3) Saenger P, et al. Recommendations for the diagnosis and management of Turner syndrome. J Clin Endocrinol Metab 2001 ; 86 : 3061-9.
PubMed
P.76 掲載の参考文献
1) Hughes IA, Houk C, Ahmed SF, Lee PA, et al. LWPES/ESPE Consensus Group. Consensus statement on management of intersex disorders. Arch Dis Child. 91 : 554-63, 2006.
 
2) Lee PA, Houk CP, Ahmed SF, Hughes IA. International Consensus Conference on Intersex organized by the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology. Consensus statement on management of intersex disorders. International Consensus Conference on Intersex. Pediatrics. 11 (8 2) : e488-500, 2006.
 
3) Achermann JC, Ozisik G, Meeks JJ, et al. Genetic causes of human reproductive disease. J Clin Endocrinol Metab. 87 : 2447-54, 2002.
 
4) Forest MG. Diagnosis and treatment of disorders of sexual development. Endocrinology. 5th edition. DeGroot LJ, Jameson JL., Edit. Elsevier Saunders, 2004.
 
5) Migeon CJ, Wisniewski AB, Gearhart JP, et al. Ambiguous genitalia with perineoscrotal hypospadias in 46, XY individuals : long-term medical, surgical, and psychosexual outcome. Pediatrics. 110 : 31-41, 2002.
 
6) Houk CP, Hughes IA, Ahmed SF, Lee PA. Writing Committee for the International Intersex Consensus Conference Participants. Summary of consensus statement on intersex disorders and their management. International Intersex Consensus Conference. Pediatrics. 118 (2) : 753-7, 2006.
PubMed
7) Houk CP, Lee PA. Approach to assigning gender in 46, XX congenital adrenal hyperplasia with male external genitalia : replacing dogmatism with pragmatism. J Clin Endocrinol Metab. 95 (10) : 4501-8, 2010.
PubMed
8) Cools M, Drop SL, Wolffenbuttel KP. Germ cell tumors in the intersex gonad : old paths, new directions, moving frontiers. Endocr Rev. 27 (5) : 468-84, 2006.
PubMed
9) 藤枝憲二. 性の分化と成熟異常. メディカルレビュー社 ; 2002.
 
10) 堀川玲子. 性分化疾患初期対応. 日本小児科学会雑誌 115 : 7-12, 2011.
 
11) Crouch NS, Creighton SM. Transition of care for adolescents with disorders of sex development. Nat Rev Endocrinol. 10 (7) : 436-42, 2014.
PubMed
12) Schober J, Nordenstrom A, Hoebeke P, Lee P, Houk C, Looijenga L, Manzoni G, Reiner W, Woodhouse C. Disorders of sex development : summaries of long-term outcome studies. J Pediatr Urol. 8 (6) : 616-23, 2012.
PubMed
13) Streuli JC, Kohler B, Werner-Rosen K, Mitchell C. DSD and Professionalism from a Multilateral View : Supplementing the Consensus Statement on the Basis of a Qualitative Survey. Adv Urol. 2012 : 185787 m, 2012.
 
14) Pasterski V, Prentice P, Hughes IA. Impact of the consensus statement and the new DSD classification system. Best Pract Res Clin Endocrinol Metab. 24 : 187-95, 2012.
 
15) Pasterski V, Prentice P, Hughes IA. Consequences of the Chicago consensus on disorders of sex development (DSD) : current practices in Europe. Arch Dis Child. 95 (8) : 618-23, 2010.
PubMed

(III) 副腎疾患

P.103 掲載の参考文献
1) Suwa S. Nationwide survey of neonatal mass-screening for congenital adrenal hyperplasia in Japan. Screening. 1994 ; 3 : 141-51.
 
2) Pang SY, Wallace MA, Hofman L, Thuline HC, Dorche C, Lyon IC, Dobbins RH, Kling S, Fujieda K, Suwa S. Worldwide experience in newborn screening for classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Pediatrics. 1988 ; 81 : 866-74.
PubMed
3) 諏訪城三. 先天性副腎過形成. 小児内科 1994 ; 26 : 1967-72.
 
4) 藤枝憲二. 先天性副腎過形成症の新生児マス・スクリーニングの発展の歴史と現状. 小児内科 2001 ; 33 : 1674-8.
 
5) 諏訪城三, 五十嵐良雄, 北川照男, 下澤和彦, 鶴原常雄, 松浦信夫, 藤枝憲二. 新生児マス・スクリーニングにおける先天性副腎過形成症 (21-水酸化酵素欠損) 診断の手引き (1989年). 日本小児科学会雑誌 1989 ; 93 : 1632-3.
 
6) 税所純敬, 横田一郎, 楠田聡, 立花克彦, 五十嵐良雄, 諏訪城三, 梅橋豊蔵, 福士勝, 藤枝憲二. 日本小児内分泌学会マス・スクリーニング委員会先天性副腎過形成症 (21-水酸化酵素欠損症) 新生児マス・スクリーニング陽性者の取り扱い基準-診断の手引き. 日本小児科学会雑誌 1999 ; 103 : 69-71.
 
7) 楠田聡, 立花克彦, 税所純敬, 横田一郎, 五十嵐良雄, 諏訪城三, 藤枝憲二. 日本小児内分泌学会マス・スクリーニング委員会. 新生児マス・スクリーニングで発見された先天性副腎過形成症 (21-水酸化酵素欠損症) の治療指針 (1999年改訂). 日本小児科学会雑誌 1999 ; 103 : 72-5.
 
8) Joint LWPES/ESPE CAH Working Group. Consensus statement on 21-hydroxylase deficiency from the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology. J Clin Endocrinol Metab. 2002 ; 87 : 4048-53.
 
9) Speiser PW, Azziz R, Baskin LS, Ghizzoni L, Hensle TW, Merke DP, Meyer-Bahlburg HF, Miller WL, Montori VM, Oberfield SE, Ritzen M, White PC ; Endocrine Society. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency : an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010 ; 95 : 4133-60.
PubMed
10) Merke DP, Bornstein SR, Avila NA, Chrousos GP. NIH conference. Future directions in the study and management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Ann Intern Med. 2002 ; 136 : 320-34.
 
11) 藤枝憲二. 副腎皮質機能低下症. 小児内分泌学. 日本小児内分泌学会編. 診断と治療社. p.338-61.
 
12) New MI. Nonclassic 21-hydroxylase deficiency. Fertil Steril. 2006 Jul ; 86 (Suppl 1) : S2.
 
13) Wilson RC, Mercado AB, Cheng KC, New MI. Steroid 21-hydroxylase deficiency : genotype may not predict phenotype. J Clin Endocrinol Metab. 1995 ; 80 : 2322-9.
 
14) Tajima T, Fujieda K, Nakae J, Toyoura T, Shimozawa K, Kusuda S, Goji K, Nagashima T, Cutler GB Jr. Molecular basis of nonclassical steroid 21-hydroxylase deficiency detected by neonatal mass screening in Japan. J Clin Endocrinol Metab. 1997 ; 82 : 2350-6.
PubMed
15) 長谷川行洋, 鹿島田健一, 小野真, 石井智弘, 田島敏広, 横田一郎. 本邦における非古典型 21 水酸化酵素欠損症の実態把握と診断・治療指針の作成. 平成23年度厚生労働科学研究費補助金難治性疾患克服研究事業報告書.
 
16) Homma K, Hasegawa T, Nagai T, Adachi M, Horikawa R, Fujiwara I, Tajima T, Takeda R, Fukami M, Ogata T. Urine steroid hormone profile analysis in cytochrome P450 oxidoreductase deficiency : implication for the backdoor pathway to dihydrotestosterone. J Clin Endocrinol Metab. 2006 ; 91 : 2643-9.
PubMed
17) Fluck CE, Meyer-Boni M, Pandey AV, Kempna P, Miller WL, Schoenle EJ, Biason-Lauber A. Why boys will be boys : two pathways of fetal testicular androgen biosynthesis are needed for male sexual differentiation. Am J Hum Genet. 2011 ; 89 : 201-18.
 
18) Kamrath C, Hochberg Z, Hartmann MF, Remer T, Wudy SA. Increased activation of the alternative "backdoor" pathway in patients with 21-hydroxylase deficiency : evidence from urinary steroid hormone analysis. J Clin Endocrinol Metab. 2012 ; 97 : E367-75.
PubMed
19) Tajima T, Fujieda K, Nakayama K, Fujii-Kuriyama Y. Molecular analysis of patient and carrier genes with congenital steroid 21-hydroxylase deficiency by using polymerase chain reaction and single strand conformation polymorphism. J Clin Invest. 1993 ; 92 : 2182-90.
PubMed
20) New MI, Abraham M, Gonzalez B, Dumic M, Razzaghy-Azar M, Chitayat D, Sun L, Zaidi M, Wilson RC, Yuen T. Genotype-phenotype correlation in 1,507 families with congenital adrenal hyperplasia owing to 21-hydroxylase deficiency. Proc Natl Acad Sci USA. 2013 ; 110 : 2611-6.
PubMed
21) Koyama S, Toyoura T, Saisho S, Shimozawa K, Yata J. Genetic analysis of Japanese patients with 21-hydroxylase deficiency : identification of a patient with a new mutation of a homozygous deletion of adenine at codon 246 and patients without demonstrable mutations within the structural gene for CYP21. J Clin Endocrinol Metab. 2002 ; 87 : 2668-73.
PubMed
22) 諏訪城三, 五十嵐良雄, 加藤精彦, 楠智一, 田苗綾子, 新美仁男, 矢田純一. 先天性副腎皮質過形成症の実態調査結果 第1編, 頻度に関する検討. 日本小児科学会雑誌 1981 ; 85 : 204-10.
 
23) 諏訪城三, 五十嵐良雄, 加藤精彦, 楠智一, 田苗綾子, 新美仁男, 矢田純一. 先天性副腎皮質過形成症の実態調査結果 第4編, 主症状の検討. 日本小児科学会雑誌 1982 ; 86 : 2162-7.
 
24) Balsamo A, Cacciari E, Piazzi S, Cassio A, Bozza D, Pirazzoli P, Zappulla F. Congenital adrenal hyperplasia : neonatal mass screening compared with clinical diagnosis only in the Emilia- Romagna region of Italy, 1980-1995. Pediatrics. 1996 ; 98 : 362-7.
 
25) Brosnan PG, Brosnan CA, Kemp SF, Domek DB, Jelley DH, Blackett PR, Riley WJ. Effect of newborn screening for congenital adrenal hyperplasia. Arch Pediatr Adolesc Med. 1999 ; 153 : 1272-8.
PubMed
26) 諏訪誠三, 楠田聡, 豊浦多喜雄, 藤枝憲二, 甲田直也, 西山宋六, 荒木久美子, 衣笠昭彦, 加藤精彦, 大山宣秀, 上村憲司, 大関武彦, 立花克彦. マス・スクリーニング等で新生児期に発見された先天性副腎過形成症 (21-水酸化酵素欠損症) 70例の追跡調査結果. 第1編 治療開始前における臨床所見. 日本小児科学会雑誌 1997 ; 101 : 1149-57.
 
27) TajimaT, Fujikura K, Fukushi M, Hostubo T, Mitsuhashi Y, Neonatal screening for congenital adrenal hyperplasia in Japan. Pediatr Endocr Rev. 2012 ; 10 : 72-8.
 
28) 九曜雅子, 米田豊, 五十嵐 登. 新生児マス・スクリーニング要精密検査児の追跡結果-10年間のまとめ-日本マス・スクリーニング学会誌 2009 ; 19 : 233-42.
Medical*Online
29) 小西薫, 長谷川智美, 穴澤昭, 鹿島田健一, 北川照男. 東京都における先天性副腎過形成 (CAH) マス・スクリーニング23年間の報告. 日本内分泌学会雑誌 2013 ; 89 : 256.
Medical*Online
30) 長崎啓祐, 浅見直, 野村道代, 帆苅恵子, 小田辺なお子. 新潟県における 21 水酸化酵素欠損症スクリーニング20年間のまとめ. 日本マス・スクリーニング学会誌 2010 ; 20 : 223-7.
Medical*Online
31) 久繁哲徳. 平成5年度厚生省心身障害研究 1994. p.63.
 
32) 福士勝, 荒井修, 水嶋好清, 高杉信男, 藤枝憲二, 松浦信夫. 先天性副腎皮質過形成 (21-水酸化酵素欠損症) のマス・スクリーニングに関する研究 第4報 マイクロプレートを用いる乾燥濾紙血液Cortisolの酵素免疫測定法の開発と新生児マス・スクリーニングへの応用. 日本内分泌学会雑誌 1987 ; 63 : 205-14.
Medical*Online
33) Mikami A, Fukushi M, Oda H, Fujita K, Fujieda K. Newborn screening for congenital adrenal hyperplasia in Sapporo City : sixteen years experience. Southeast Asian J Trop Med Public Health. 1999 ; 30 (Suppl 2) : 100-2.
 
34) 小西薫, 原淳, 桜井恭子, 穴澤昭, 鈴木健, 豊浦多喜雄. 低出生体重児における濾紙血 17 健, 豊浦多喜雄 低出生体重児における濾紙血濃度の継時的変化の検討. 日本マス・スクリーニング学会誌 2005 ; 15 : 63-8.
 
35) 山上祐次, 山田幸子, 間島勝徳, 春木英一, 立花克彦, 菅原緒美, 木下洋子, 森雄一, 住吉好雄. 先天性副腎過形成症マス・スクリーニングの問題点-出生体重別カットオフ値は有用か. 予防医学 2005 ; 47 : 65-9.
Medical*Online
36) 安片恭子, 猪股弘明, 皆川真規, 上瀧邦雄, 廣田美和, 稲田佳美, 畑中美緒. 先天性副腎過形成症マス・スクリーニングにおける低出生体重児のカットオフ値の有用性について. 日本マス・スクリーニング学会誌 2006 ; 16 : 57-61.
Medical*Online
37) 山野公明, 市原 侃, 原田正平, 新井純理, 藤枝憲二, 工藤亨, 奥野晃正. 北海道における先天性副腎過形成症マス・スクリーニングの現状と問題点. 日本マス・スクリーニング学会誌 1996 ; 6 : 5-10.
 
38) 立花克彦, 山上祐次. 先天性副腎過形成症マス・スクリーニングにおける低出生体重児の問題点. 日本マス・スクリーニング学会誌 2005 ; 15 : 19-22.
 
39) 安達昌功. 17α水酸化プロゲステロン (17-OHP) -未熟児を含めた陽性者の取り扱い. 小児内科 2004 ; 36 : 1913-6.
 
40) Coulm B, Coste J, Tardy V, Ecosse E, Roussey M, Morel Y, Carel JC ; DHCSF Study Group. Efficiency of Neonatal Screening for Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency in Children Born in Mainland France Between 1996 and 2003. Arch Pediatr Adolesc Med. 2012 ; 166 : 113-20.
 
41) Gurian EA, Kinnamon DD, Henry JJ, Waisbren SE. Expanded newborn screening for biochemical disorders : the effect of a false-positive result. Pediatrics. 2006 ; 117 : 1915-21.
PubMed
42) Matern D, Tortorelli S, Oglesbee D, Gavrilov D, Rinaldo P. Reduction of the false-positive rate in newborn screening by implementation of MS/MS-based second-tier tests : the Mayo Clinic experience (2004-2007). J Inherit Metab Dis. 2007 ; 30 : 585-92.
 
43) Janzen N, Peter M, Sander S, Steuerwald U, Terhardt M, Holtkamp U, Sander J. Newborn screening for congenital adrenal hyperplasia : additional steroid profile using liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metab. 2007 ; 92 : 2581-9.
PubMed
44) Schwarz E, Liu A, Randall H, Haslip C, Keune F, Murray M, Longo N, Pasquali M. Use of steroid profiling by UPLC-MS/MS as a second tier test in newborn screening for congenital adrenal hyperplasia : the Utah experience. Pediatr Res. 2009 ; 66 : 230-5.
 
45) 藤倉かおり, 山岸卓弥, 田上泰子, 野町祥介, 花井潤師, 高橋広夫, 三觜 雄, 田島敏広, 母坪智行, 福士勝. LC-MS/MSによる先天性副腎過形成症スクリーニング確認検査法の検討. 日本マス・スクリーニング学会誌 2013 ; 23 : 85-92.
 
46) 福士勝. 先天性副腎過形成症の新生児スクリーニングーカットオフ値の考え方-平成23年先天性代謝異常症等検査技術者研修会テキスト. 恩賜財団母子愛育会, 2011. p4-15.
 
47) 立花克彦, 猪俣弘明, 青木菊麿, 黒田泰弘, 山上祐次, 市島正夫. 新生児マス・スクリーニングで発見されなかった先天性副腎過形成症 (21-水酸化酵素欠損症) 症例の検討 (全国調査) 及びスクリーニングカットオフ値の検討. 日本マス・スクリーニング学会誌 2001 ; 11 : 47-52.
 
48) Allen DB, Hoffman GL, Fitzpatrick P, Laessig R, Maby S, Slyper A. Improved precision of newborn screening for congenital adrenal hyperplasia using weight-adjusted criteria for 17-hydroxyprogesterone levels. J Pediatr. 1997 ; 130 : 128-33.
 
49) Olgemoller B, Roscher AA, Liebl B, Fingerhut R. Screening for congenital adrenal hyperplasia : adjustment of 17-hydroxyprogesterone cut-off values to both age and birth weight markedly improves the predictive value. J Clin Endocrinol Metab. 2003 ; 88 : 5790-4.
PubMed
50) van der Kamp HJ, Oudshoorn CG, Elvers BH, van Baarle M, Otten BJ, Wit JM, Verkerk PH. Cutoff levels of 17-alpha-hydroxyprogesterone in neonatal screening for congenital adrenal hyperplasia should be based on gestational age rather than on birth weight. J Clin Endocrinol Metab. 2005 ; 90 : 3904-7.
PubMed
51) SteigertM, Schoenle EJ, Biason-Lauber A, TorresaniT. High reliability of neonatal screening for congenital adrenal hyperplasia in Switzerland. J Clin Endocrinol Metab. 2002 ; 87 : 4106-10.
PubMed
52) 戸刈創, 楠田聡. 低出生体重児の新生児マス・スクリーニング検体の採血時期に関する指針. 日本未熟児新生児学会雑誌 2004 ; 16 : 108.
 
53) Sarafoglou K, Banks K, Gaviglio A, Hietala A, McCann M, Thomas W. Comparison of one-tier and two-tier newborn screening metrics for congenital adrenal hyperplasia. Pediatrics. 2012 ; 130 : e1261-8.
PubMed
54) Nordenstrom A, Thilen A, Hagenfeldt L, Larsson A, Wedell A. Genotyping is a valuable diagnostic complement to neonatal screening for congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency. J Clin Endocrinol Metab. 1999 ; 84 : 1505-9.
PubMed
55) Kosel S, Burggraf S, Fingerhut R, Dorr HG, Roscher AA, Olgemoller B. Rapid second-tier molecular genetic analysis for congenital adrenal hyperplasia attributable to steroid 21-hydroxylase deficiency. Clin Chem. 2005 ; 51 : 298-304.
PubMed
56) Mikami A, Tajima T, Yamaguchi A, Sato Y, Fukushi M, Kikuchi Y, Fujieda K. Molecular diagnosis for steroid 21-hydroxylase deficiency by polymerase chain reaction with dried blood spots. Clin Pediatr Endocrinol. 1997 ; 6 : 15-22.
 
57) 三上篤, 福士勝, 藤田晃三, 藤枝憲二. 迅速DNA診断法を用いた点変異検索による21-水酸化酵素欠損症の発生頻度. 日本マス・スクリーニング学会誌 2000 ; 10 : 29-34.
 
58) Votava F, Torok D, Kovacs J, Moslinger D, Baumgartner-Parzer SM, Solyom J, Pribilincova Z, Battelino T, Lebl J, Frisch H, Waldhauser F ; Middle European Society for Paediatric Endocrinology- Congenital Adrenal Hyperplasia (MESPE-CAH) Study Group. Estimation of the false-negative rate in newborn screening for congenital adrenal hyperplasia. Eur. J. Endocrinol. 2005 ; 152 : 869-74.
 
59) Homma K, Hasegawa T, Takeshita E, Watanabe K, Anzo M, Toyoura T, Jinno K, Ohashi T, Hamajima T, Takahashi Y, Takahashi T, Matsuo N. Elevated urine pregnanetriolone definitively establishes the diagnosis of classical 21-hydroxylase deficiency in term and preterm neonates. J Clin Endocrinol Metab. 2004 ; 89 : 6087-91.
PubMed
60) Koyama Y, Homma K, Fukami M, Miwa M, Ikeda K, Ogata T, Hasegawa T, Murata M. Two-step biochemical differential diagnosis of classic 21-hydroxylase deficiency and cytochrome P450 oxidoreductase deficiency in Japanese infants by GC-MS measurement of urinary pregnanetriolone/tetrahydroxycortisone ratio and 11β-hydroxyandrosterone. Clin Chem. 2012 ; 58 : 741-7.
 
61) 藤枝憲二 (主任研究者). 先天性副腎過形成症の診断基準. 厚生労働科学研究費補助金難治性疾患克服研究事業副腎ホルモン産生異常に関する調査研究 平成19年度総括・分担研究報告書. p.173-85, 2008.
 
62) Martinerie L, Viengchareun S, Delezoide AL, Jaubert F, Sinico M, Prevot S, Boileau P, Meduri G, Lombes M. Low renal mineralocorticoid receptor expression at birth contributes to partial aldosterone resistance in neonates. Endocrinology. 2009 ; 150 : 4414-24.
PubMed
63) Nimkarn S, Lin-Su K, Berglind N, Wilson RC, New MI. Aldosterone-to-renin ratio as a marker for disease severity in 21-hydroxylase deficiency congenital adrenal hyperplasia. J Clin Endocrinol Metab. 2007 ; 92 : 137-42.
PubMed
64) Asanuma A, Ohura T, Ogawa E, Sato S, Igarashi Y, Matsubara Y, Iinuma K. Molecular analysis of Japanese patients with steroid 21-hydroxylase deficiency. J Hum Genet. 1999 ; 44 : 312-7.
PubMed
65) Mao R, McDonald J, Cantwell M, Tang W, Ward K. The implication of de novo 21-hydroxylase mutation in clinical and prenatal molecular diagnoses. Genet Test. 2005 ; 9 : 121-5.
PubMed
66) Tusie-Luna MT, White PC. Gene conversions and unequal crossovers between CYP21 (steroid 21-hydroxylase gene) and CYP21P involve different mechanisms. Proc Natl Acad Sci USA. 1995 ; 92 : 10796-800.
PubMed
67) Finkielstain GP, Chen W, Mehta SP, Fujimura FK, Hanna RM, Van Ryzin C, McDonnell NB, Merke DP. Comprehensive genetic analysis of 182 unrelated families with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab. 2011 ; 96 : E161-72.
PubMed
68) 臼井健, 革嶋幸子, 田上哲也, 成瀬光栄, 島津章. 21 水酸化酵素欠損症遺伝子診断の現状と未来. 日本内分泌学会雑誌 2010 ; 86 : 735.
Medical*Online
69) Fluck CE, Tajima T, Pandey AV, Arlt W, Okuhara K, Verge CF, Jabs EW, Mendonca BB, Fujieda K, Miller WL. Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome. Nat Genet. 2004 ; 36 : 228-30.
PubMed
70) Fukami M, Nishimura G, Homma K, Nagai T, Hanaki K, Uematsu A, Ishii T, Numakura C, Sawada H, Nakacho M, Kowase T, Motomura K, Haruna H, Nakamura M, Ohishi A, Adachi M, Tajima T, Hasegawa Y, Hasegawa T, Horikawa R, Fujieda K, Ogata T. Cytochrome P450 oxidoreductase deficiency : identification and characterization of biallelic mutations and genotype-phenotype correlations in 35 Japanese patients. J Clin Endocrinol Metab. 2009 ; 94 : 1723-31.
PubMed
71) Jeandron DD, Sahakitrungruang T. A novel homozygous Q334X mutation in the HSD3B2 gene causing classic 3β-hydroxysteroid dehydrogenase deficiency : an unexpected diagnosis after a positive newborn screen for 21-hydroxylase deficiency. Horm Res Paediatr. 2012 ; 77 : 334-8.
 
72) Nordenstrom A, Forest MG, Wedell A. A case of 3beta-hydroxysteroid dehydrogenase type II (HSD3B2) deficiency picked up by neonatal screening for 21-hydroxylase deficiency : difficulties and delay in etiologic diagnosis. Horm Res. 2007 ; 68 : 204-8.
PubMed
73) White PC. Neonatal screening for congenital adrenal hyperplasia. Nat Rev Endocrinol. 2009 ; 5 : 490-8.
PubMed
74) Valentino R, Tommaselli AP, Rossi R, Lombardi G, Varrone S. A pilot study for neonatal screening of congenital adrenal hyperplasia due to 21-hydroxylase and 11-beta-hydroxylase deficiency in Campania region. J Endocrinol Invest. 1990 ; 13 : 221-5.
PubMed
75) Hishiki T, Kazukawa I, Saito T, Terui K, Mitsunaga T, Nakata M, Matsuura G, Minagawa M, Kohno Y, Yoshida H. Diagnosis of adrenocortical tumor in a neonate by detection of elevated blood 17-hydroxyprogesterone measured as a routine neonatal screening for congenital adrenal hyperplasia : a case report. J Pediatr Surg. 2008 ; 43 (10) : e19-22.
 
76) 佐藤武志, 室谷浩二, 花川純子, 朝倉由美, 松井克之, 丸尾良浩, 安達昌功. 新生児マス・スクリーニングでの17OHP高値を機に見出されたアンドロゲン産生性副腎皮質腫瘍の1男児例. 日本マス・スクリーニング学会誌 2012 ; 22 : 244-9.
Medical*Online
77) Therrell BL Jr, Berenbaum SA, Manter-Kapanke V, Simmank J, Korman K, Prentice L, Gonzalez J, Gunn S. Results of screening 1.9 million Texas newborns for 21-hydroxylase-deficient congenital adrenal hyperplasia. Pediatrics. 1998 ; 101 (4 Pt 1) : 583-90.
 
78) Kashimada K, Ono M, Onishi T, Koyama S, Toyoura T, Imai K, Saisho S, Mizutani S 2008 Clinical course of patients with nonclassical 21-hydroxylase deficiency (21-OHD) diagnosed in infancy and childhood. Endocr J. 2008 ; 55 : 397-404.
PubMed
79) Nagasaki K, Usui T, Asami, Ogawa Y, Kikuchi T, Uchiyama M H62L Mutation of CYP21A2 identified in the non-classical form of 21-hydroxylase feficiency, Cli Pediatr Endocrinol. 2009 ; 18 : 111-3.
 
80) 石井智弘, 鹿島田健一, 長崎啓祐, 田島敏広, 横田一郎, 長谷川行洋. 本邦で小児期に診断された非古典型21-水酸化酵素欠損症の頻度と臨床像. 第46回日本小児内分泌学会学術集会抄録集. p.118, 2012年, 大阪
 
81) 長谷川行洋, 鹿島田健一, 小野真, 石井智弘, 田島敏弘, 横田一郎. 本邦における非古典型 21 水酸化酵素欠損症の実態把握と診断・治療指針の作成. 厚生労働科学研究費補助金難治性疾患克服研究事業 平成23年度総括・分担研究報告書. p.19-31, 2012.
 
82) Armengaud JB, Charkaluk ML, Trivin C, Tardy V, Breart G, Brauner R, ChalumeauM Precocious pubarche : distinguishing late-onset congenital adrenal hyperplasia from premature adrenarche. J Clin Endocrinol Metab. 2009 ; 94 : 2835-40.
PubMed
83) Bidet M, Bellanne-Chantelot C, Galand-Portier MB, Tardy V, Billaud L, Laborde K, Coussieu C, Morel Y, Vaury C, Golmard JL, Claustre A, Mornet E, Chakhtoura Z, Mowszowicz I, Bachelot A, Touraine P, Kuttenn F. Clinical and molecular characterization of a cohort of 161 unrelated women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency and 330 family members. J Clin Endocrinol Metab. 2009 ; 94 : 1570-8.
PubMed
84) Bonfig W, Schmidt H, Schwarz HP. Growth patterns in the first three years of life in children with classical congenital adrenal hyperplasia diagnosed by newborn screening and treated with low doses of hydrocortisone. Horm Res Paediatr. 2011 ; 75 : 32-7.
PubMed
85) Hargitai G, Solyom J, Battelino T, Lebl J, Pribilincova Z, Hauspie R, Kovacs J, Waldhauser F, Frisch H ; MEWPE-CAH Study Group. Growth patterns and final height in congenital adrenal hyperplasia due to classical 21-hydroxylase deficiency. Results of a multicenter study. Horm Res. 2001 ; 55 : 161-71.
 
86) Stikkelbroeck NM, Van't Hof-Grootenboer BA, Hermus AR, Otten BJ, Van't Hof MA. Growth inhibition by glucocorticoid treatment in salt wasting 21-hydroxylase deficiency : in early infancy and (pre) puberty. J Clin Endocrinol Metab. 2003 ; 88 : 3525-30.
PubMed
87) Balsamo A, Cicognani A, Baldazzi L, Barbaro M, Baronio F, GennariM, BalM, Cassio A, Kontaxaki K, Cacciari E. CYP21 genotype, adult height, and pubertal development in 55 patients treated for 21-hydroxylase deficiency. J Clin Endocrinol Metab. 2003 ; 88 : 5680-8.
 
88) Grigorescu-Sido A, Bettendorf M, Schulze E, Duncea I, Heinrich U. Growth analysis in patients with 21-hydroxylase deficiency influence of glucocorticoid dosage, age at diagnosis, phenotype and genotype on growth and height outcome. Horm Res. 2003 ; 60 : 84-90.
PubMed
89) Van der Kamp HJ, Otten BJ, Buitenweg N, De Muinck Keizer-Schrama SM, Oostdijk W, Jansen M, Delemarre-de Waal HA, Vulsma T, Wit JM. Longitudinal analysis of growth and puberty in 21-hydroxylase deficiency patients. Arch Dis Child. 2002 ; 87 : 139-44.
PubMed
90) 神野和彦. 新生児マス・スクリーニングで発見された21-水酸化酵素欠損症症例の成長経過. 日本マス・スクリーニング学会誌 2002 ; 12 : 21-6.
Medical*Online
91) 立花克彦, 安達昌功, 朝倉由美. 先天性副腎皮質過形成症患児の成長の検討. 成長科学協会年報 2002 ; 26 : 255-8.
 
92) Takasawa K, Ono M, Miyai K, Matsubara Y, Takizawa F, Onishi T, Kashimada K, Mizutani S. Initial high dose hydrocortisone (HDC) treatment for 21-hydroxylase deficiency (21-OHD) does not affect linear growth during the first three years of life. Endocr J. 2012 ; 59 : 1001-6.
 
93) Punthakee Z, Legault L, Polychronakos C. Prednisolone in the treatment of adrenal insufficiency : a re-evaluation of relative potency. J Pediatr. 2003 ; 143 : 402-5.
PubMed
94) Rivkees SA, Crawford JD. Dexamethasone treatment of virilizing congenital adrenal hyperplasia : the ability to achieve normal growth. Pediatrics. 2000 ; 106 : 767-73.
PubMed
95) German A, Suraiya S, Tenenbaum-Rakover Y, Koren I, Pillar G, Hochberg Z. Control of childhood congenital adrenal hyperplasia and sleep activity and quality with morning or evening glucocorticoid therapy. J Clin Endocrinol Metab. 2008 ; 93 : 4707-10.
PubMed
96) Kerrigan JR, Veldhuis JD, Leyo SA, Iranmanesh A, Rogol AD. Estimation of daily cortisol production and clearance rates in normal pubertal males by deconvolution analysis. J Clin Endocrinol Metab. 1993 ; 76 : 1505-10.
PubMed
97) Linder BL, Esteban NV, Yergey AL, Winterer JC, Loriaux DL, Cassorla F. Cortisol production rate in childhood and adolescence. J Pediatr. 1990 ; 117 : 892-6.
PubMed
98) Esteban NV, Loughlin T, Yergey AL, et al. Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry. J Clin Endocrinol Metab. 1991 ; 72 : 39-45.
PubMed
99) Bonfig W, Pozza SB, Schmidt H, Pagel P, Knorr D, Schwarz HP. Hydrocortisone dosing during puberty in patients with classical congenital adrenal hyperplasia : an evidence based recommendation. J Clin Endocrinol Metab. 2009 ; 94 : 3882-8.
PubMed
100) Muthusamy K, Elamin MB, Smushkin G, MuradMH, Lampropulos JF, Elamin KB, Elnour NOA, Gallegos-Orozco JF, Fatourechi MM, Agrwal N, LaneMA, Albuquerque FN, Erwin PJ, Montori VM. Adult height in patients with congenital adrenal hyperplasia : a systematic review and metaanalysis. J Clin Endocrinol Metab. 2010 ; 95 : 4161-72.
 
101) Charmandari E, Hindmarsh PC, Johnston A, BrookCG. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency : alterations in cortisol pharmacokinetics at puberty. J Clin Endocrinol Metab. 2001 ; 86 : 2701-8.
PubMed
102) Frisch H, Battelino T, Schober E, Baumgartner-Parzer S, Nowotny P, Vierhapper H. Salt wasting in simple virilizing congenital adrenal hyperplasia. J Pediatr Endocrinol Metab. 2001 ; 14 : 1649-55.
PubMed
103) Miller WL. Genetics, diagnosis and management of 21-hydroxylasae deficiency. J Clin Endocrinol Metab. 1994 ; 78 : 241-6.
 
104) 立花克彦, 諏訪城三. 酢酸フルドロコルチゾンの新生児・乳児における至適投与量の再検討. 日本小児科学会雑誌 1998 ; 102 : 880-4.
 
105) Charmandari E, Lichtarowicz-Krynska EJ, Hindmarsh PC, Johnston A, Aynsley-Green A, Brook CG. Congenital adrenal hyperplasia : management during critical illness. Arch Dis Child. 2001 ; 85 : 26-8.
PubMed
106) Reisch N, Willige M, Kohn D, Schwarz HP, Allolio B, Reincke M, Quinkler M, Hahner S, Beuschlein F. Frequency and causes of adrenal crises over lifetime in patients with 21-hydroxylase deficiency. Eur J Endocrinol. 2012 ; 167 : 35-42.
PubMed
107) Weise M, Drinkard B, Mehlinger SL, Holzer SM, Eisenhofer G, Charmandari E, Chrousos GP, Merke DP. Stress dose of hydrocortisone is not beneficial in patients with classic congenital adrenal hyperplasia undergoing short-term, high-intensity exercise. J Clin Endocrinol Metab. 2004 ; 89 : 3679-84.
 
108) Kaufman FR, Sy JP. Regular monitoring of bone age is useful in children treated with growth hormone. Pediatrics. 1999 ; 104 : 1039-42.
PubMed
109) Zerah M, Ueshiba H, Wood E, Speiser PW, Crawford C, McDonald T, Pareira J, Gruen D, New MI. Prevalence of nonclassical steroid 21-hydroxylase deficiency based on a morning salivary 17-hydroxyprogesterone screening test : a small sample study. J Clin Endocrinol Metab. 1990 ; 70 : 1662-7.
 
110) Charmandari E, Matthews DR, Johnston A, Brook CG, Hindmarsh PC. Serum cortisol and 17-hydroxyprogesterone interrelation in classic 21-hydroxylase deficiency : is current replacement therapy satisfactory? J Clin Endocrinol Metab. 2001 ; 86 : 4679-85.
PubMed
111) Merke DP, Bornstein SR. Congenital adrenal hyperplasia. Lancet. 2005 ; 365 : 2125-36.
PubMed
112) Erhardt E, Solyom J, Homoki J, Juricskay S, Solte-sz G. Correlation of blood-spot 17-hydroxyprogesterone daily profiles and urinary steroid profiles in congenital adrenal hyperplasia. J Pediatr Endocrinol Metab. 2000 ; 13 : 205-10.
 
113) Izawa M, Aso K, Higuchi A, Aruiyasu D, Hasegawa Y. Pregnanetriol in the range of 1.2-2.1 mg/m2/day as an index of optimal control in CYP21A2 deficiency. Clin Pedair Endocrinol. 2007 ; 16 : 75-80.
 
114) Izawa M, Aso K, Higuchi A, Ariyasu D, Hasegawa Y. The range of 2.2-3.3 mg/gCr of pregnanetriol in the first morning urine sample as an index of optimal control on CYP21 deficiency. Clin Pediatr Endocrinol. 2008 ; 17 : 75-80.
PubMed
115) Roche EF, Charmandari E, Dattani MT, Hindmarsh PC. Blood pressure in children and adolescents with congenital adrenal hyperplasia (21-hydroxylase deficiency) : a preliminary report. Clin Endocrinol (Oxf). 2003 ; 58 : 589-96.
PubMed
116) 棚橋祐典. 副腎ホルモン産生異常症の全国疫学調査における, 21-水酸化酵素欠損症の成人身長および成人期副腎ホルモン補充療法についての解析. 厚生労働科学研究費補助金難治性疾患克服研究事業 副腎ホルモン産生異常に関する調査研究 平成23年度総括・分担研究報告書. p.55-62, 2012.
 
117) Riepe FG, Krone N, Viemann M, Partsch CJ, Sippell WG. Management of congenital adrenal hyperplasia : results of the ESPE questionnaire. Horm Res. 2002 ; 58 : 196-205.
PubMed
118) Arlt W, Willis DS, Wild SH, Krone N, Doherty EJ, Hahner S, Han TS, Carroll PV, Conway GS, Rees DA, Stimson RH, Walker BR, Connell JM, Ross RJ ; United Kingdom Congenital Adrenal Hyperplasia Adult Study Executive (CaHASE). Health status of adults with congenital adrenal hyperplasia : a cohort study of 203 patients. J Clin Endocrinol Metab. 2010 ; 95 : 5110-21.
PubMed
119) Finkielstain GP, Kim MS, Sinaii N, Nishitani M, Van Ryzin C, Hill SC, Reynolds JC, Hanna RM, Merke DP. Clinical characteristics of a cohort of 244 patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab. 2012 ; 97 : 4429-38.
PubMed
120) Merke DP. Approach to the adult with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab. 2008 ; 93 : 653-60.
 
121) Han TS, Krone N, Willis DS, Conway GS, Hahner S, Rees DA, Stimson R, Walker BR, Arlt W, Ross RJ. Quality of life in adults with congenital adrenal hyperplasia relates to glucocorticoid treatment, adiposity and insulin resistance : United Kingdom Congenital adrenal Hyperplasia Adult Study Executive (CaHASE). Eur J Endocrinol. 2013 ; 168 : 887-93.
PubMed
122) Arlt W, Krone N. Adult consequences of congenital adrenal hyperplasia. Horm Res. 2007 ; 68 (Suppl 5) : 158-64.
 
123) Falhammar H, Filipsson H, Holmdahl G, Janson PO, Nordenskjo ld A, Hagenfeldt K, Thoren M. Fractures and bone mineral density in adult women with 21-hydroxylase deficiency. J Clin Endocrinol Metab. 2007 ; 92 : 4643-9.
 
124) Christiansen P, Molgaard C, Muller J. Normal bone mineral content in young adults with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Horm Res. 2004 ; 61 : 133-6.
PubMed
125) Falhammar H, Filipsson H, Holmdahl G, Janson PO, Nordenskjold A, Hagenfeldt K, Thoren M Metabolic profile and body composition in adult women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 2006 ; 92 : 110-6.
PubMed
126) Sartorato P, Zulian E, Benedini S, Mariniello B, Schiavi F, Bilora F, Pozzan G, Greggio N, Pagnan A, Mantero F, Scaroni C. Cardiovascular risk factors and ultrasound evaluation of intima-media thickness at common carotids, carotid bulbs, and femoral and abdominal aorta arteries in patients with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab. 2007 ; 92 : 1015-8.
PubMed
127) Reisch N, Arlt W, Krone N. Health problems in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Horm Res Paediatr. 2011 ; 76 : 73-85.
PubMed
128) David M, Forest MG. Prenatal treatment of congenital adrenal hyperplasia resulting from 21-hydroxylase deficiency. J Pediatr. 1984 ; 105 : 799-803.
PubMed
129) Evans MI, Chrousos GP, Mann DW, Larsen Jr JW, Green I, McCluskey J, Loriaux DL, Fletcher JC, Koons G, Overpeck J, Schulman JD. Pharmacologic suppression of the fetal adrenal gland in utero. Attempted prevention of abnormal external genital masculinization in suspected congenital adrenal hyperplasia. JAMA. 1985 ; 253 : 1015-20.
 
130) Forest MG, David M, Morel Y. Prenatal diagnosis and treatment of 21-hydroxylase deficiency. J Steroid Biochem Mol Biol. 1993 ; 45 : 75-82.
PubMed
131) New MI, Carlson A, Obeid J, Marshall I, Cabrera MS, Goseco A, Lin-Su K, Putnam AS, Wei JQ, Wilson RC. Prenatal diagnosis for congenital adrenal hyperplasia in 532 pregnancies. J Clin Endocrinol Metab. 2001 ; 86 : 5651-7.
PubMed
132) Tajima T, Fujieda K. Prenatal diagnosis and treatment of steroid 21-hydroxylase deficiency Clin Pedaitr Endcorinol. 2008 ; 17 : 95-102.
PubMed
133) Goto M, Piper Hanley K, Marcos J, Wood PJ, Wright S, Postle AD, Cameron IT, Mason JI, Wilson DI, Hanley NA. In humans, early cortisol biosynthesis provides a mechanism to safeguard female sexual development. J Clin Invest. 2006 ; 116 : 953-60.
PubMed
134) Kari MA, Raivio KO, Stenman UH, Voutilainen R. Serum cortisol, dehydroepiandrosterone sulfate, and steroid-binding globulins in preterm neonates : effect of gestational age and dexamethasone therapy. Pediatr Res. 1996 ; 40 : 319-24.
PubMed
135) Partsch CJ, Sippell WG, MacKenzie IZ, Aynsley-Green A. The steroid hormonal milieu of the undisturbed human fetus and mother at 16-20 weeks gestation. J Clin Endocrinol Metab. 1991 ; 73 : 969-74.
PubMed
136) White PC. Ontogeny of adrenal steroid biosynthesis : why girls will be girls. J Clin Invest. 2006 ; 116 : 872-4.
 
137) Coleman MA, Honour JW. Reduced maternal dexamethasone dosage for the prenatal treatment of congenital adrenal hyperplasia. BJOG. 2004 ; 111 : 176-8.
PubMed
138) White PC, Mune T, Agarwal AK. 11-Hydroxysteroid dehydrogenase dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocr Rev. 1997 ; 18 : 135-56.
PubMed
139) Rijnders RJ, van der Schoot CE, Bossers B, de Vroede MA, Christiaens GC. Fetal sex determination from maternal plasma in pregnancies at risk for congenital adrenal hyperplasia. Obstet Gynecol. 2001 ; 98 : 374-8.
PubMed
140) Bartha JL, Finning K, Soothill PW. Fetal sex determination from maternal blood at 6 weeks of gestation when at risk for 21-hydroxylase deficiency. Obstet Gynecol. 2003 ; 101 : 1135-6.
PubMed
141) Clayton PE, Miller WL, Oberfield SE, Ritzen EM, Sippell WG, Speiser PW. Consensus statement on 21-hydroxylase deficiency from the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology. J Clin Endocrinol Metab. 2002 ; 87 : 4048-53.
 
142) Miller WL. Genetics, diagnosis, and management of 21-hydroxylase deficiency. J Clin Endocrinol Metab. 1994 ; 78 : 241-6.
PubMed
143) 木下英一, 猪股弘明, 岡田泰助, 小川英伸, 楠田聡, 税所純敬, 田島敏広, 立花克彦, 田中敏章, 西美和, 藤枝憲二. 先天性副腎皮質過形成症の出生前診断・治療に関するアンケート調査. ホルモンと臨床 2002 ; 50 : 1157-63.
 
144) 田島敏広, 長谷川奉延, 小川英伸, 堀川玲子, 木下英一, 原田正平, 猪俣弘明, 安達昌功, 西美和, 楠田聡, 大関武彦, 藤枝憲二. 日本小児内分泌学会マス・スクリーニング委員会. 日本における21-水酸化酵素欠損症の出生前診断・治療の現状調査. ホルモンと臨床 2009 ; 57 : 1021-3.
 
145) Trautman PD, Meyer-Bahlburg HF, Postelnek J, New MI. Effects of early prenatal dexamethasone on the cognitive and behavioral development of young children : results of a pilot study. Psychoneuroendocrinology. 1995 ; 20 : 439-49.
PubMed
146) Meyer-Bahlburg HF, Dolezal C, Baker SW, Carlson AD, Obeid JS, New MI. Cognitive and motor development of children with and without congenital adrenal hyperplasia after early-prenatal dexamethasone. J Clin Endocrinol Metab. 2004 ; 89 : 610-4.
PubMed
147) Hirvikoski T, Nordenstrom A, Lindholm T, Lindblad F, Ritzen EM, Wedell A, Lajic S Cognitive functions in children at risk for congenital adrenal hyperplasia treated prenatally with dexamethasone. J Clin Endocrinol Metab. 2007 ; 92 : 542-8.
PubMed
148) Hirvikoski T, Nordenstrom A, Lindholm T, Lindblad F, Ritzen EM, Lajic S. Long-term follow-up of prenatally treated children at risk for congenital adrenal hyperplasia : does dexamethasone cause behavioural problems? Eur J Endocrinol. 2008 ; 159 : 309-16.
PubMed
149) Hirvikoski T, Lindholm T, Lajic S, Nordenstrom A. Gender role behaviour in prenatally dexamethasone-treated children at risk for congenital adrenal hyperplasia-a pilot study. Acta Paediatr. 2011 ; 100 : e112-9.
PubMed
150) Meyer-Bahlburg HF, Dolezal C, Haggerty R, Silverman M, New MI. Cognitive outcome of offspring from dexamethasone-treated pregnancies at risk for congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Eur J Endocrinol. 2012 ; 167 : 103-10.
PubMed
151) Fernandez-Balsells MM, Muthusamy K, Murad MH, Smushkin G, Lampropulos JF, Elamin MB, Abu Elnour NO, Elamin KB, Agrwal N, Gallegos-Orozco JF, Erwin PJ, Montori VM. Prenatal dexamethasone use for the prevention of virilization in pregnancies at risk for classical congenital adrenal hyperplasia due to 21 hydroxylase (CYP21A2) deficiency : a systematic review and meta-analyses. Clin Endocrinol (Oxf). 2010 ; 73 : 436-44.
 

(IV) 甲状腺疾患

P.143 掲載の参考文献
1) Rastogi MV, LaFranchi SH. Congenital hypothyroidism. Orphanet J Rare Dis 2010 Jun 10 ; 5 : 17. doi : 10.1186/1750-1172-5-17.
 
2) Grosse SD, Van Vliet G. Prevention of intellectual disability through screening for congenital hypothyroidism : how much and at what level? Arch Dis Child 2011 ; 96 : 374-9.
PubMed
3) 中島博徳, 佐藤浩一, 猪股弘明ほか. マス・スクリーニングで発見された先天性甲状機能低下症患児における精神神経学的予後全国調査成績. 日本小児科学会雑誌 1989 ; 93 ; 2011-6.
 
4) Niimi H. Neonatal screening for congenital hypothyrodism and hyperthyrotropinemia without hypothyroxinemia. Clin Pedair Endocrinol 1994 ; 3 : 73-7.
 
5) 猪股弘明, 青木菊麿. クレチン症マス・スクリーニングの全国追跡 (1994～1999年度) 日本マス・スクリーニング学会誌 2003 ; 13 : 27-32.
Medical*Online
6) 先天性甲状腺機能低下症のマス・スクリーニング・ガイドライン作成委員会. 先天性甲状腺機能低下症 マス・スクリーニングのガイドライン (1998年版). 日本小児科学会雑誌 1998 ; 102 ; 817-8.
 
7) Inomata H, Matsuura N, Tachibana K, Kusuda S, Fukushi M, Umehashi H, Suwa S, Niimi H, Fujieda K. (Working Group on Congenital Hypothyroidism of the Japanese Society for Pediatric Endocrinology and the Japanese Society for Mass-screening). Guideline for Neonatal Mass-screening for Congenital Hypothyroidism. Clin Pediatr Endocrinol 1999 ; 8 : 51-5.
 
8) Gu YH, Kato T, Harada S, Inomata H, Aoki K. Time trend and geographic distribution of treated patients with congenital hypothyroidism relative to the number of available endocrinologists in Japan. J Pediatr 2010 ; 157 : 153-7.
 
9) Nagasaki K, Asami T, Ogawa Y, Kikuchi T, Uchiyama M. A study of the etiology of congenital hypothyroidism in the Niigata prefecture of Japan in patients born between 1989 and 2005 and evaluated at ages 5-19. Thyroid 2011 ; 21 : 361-5.
 
10) American Academy of Pediatrics, Rose SR ; Section on Endocrinology and Committee on Genetics, American Thyroid Association, Brown RS ; Public Health Committee, Lawson Wilkins Pediatric Endocrine Society, Foley T, Kaplowitz PB, Kaye CI, Sundararajan S, Varma SK. Update of newborn screening and therapy for congenital hypothyroidism. Pediatrics. 2006 ; 117 : 2290-303.
 
11) Working Group on Neonatal Screening of the European Society for Paediatric Endocrinology. Revised guidelines for neonatal screening programmes for primary congenital hypothyroidism. Horm Res 1999 ; 52 : 49-52.
 
12) Leger J, Olivieri A, Donaldson M, Torresani T, Krude H, van Vliet G, Polak M, Butler G. ESPE-PES-SLEP-JSPE-APEG-APPES-ISPAE, and the Congenital Hypothyroidism Consensus Conference Group. European society for paediatric endocrinology consensus guidelines on screening, diagnosis, and management of congenital hypothyroidism. J Clin Endocrinol Metab 2014 ; 99 : 363-84.
 
13) Kohler B, Schnabel D, Biebermann H, Gruters A. Transient congenital hypothyroidism and hyperthyrotropinemia : normal thyroid function and physical development at the ages of 6-14 years. J Clin Endocrinol Metab 1996 ; 81 : 1563-7.
PubMed
14) 原田正平, 市原侃, 藤枝憲二ほか. クレチン症マス・スクリーニングで発見された新生児一過性甲状腺機能異常症の病因. 日本小児科学会雑誌 1995 ; 99 : 1079-85.
 
15) Calaciura F, Motta RM, Miscio G, Fichera G, Leonardi D, Carta A, Trischitta V, Tassi V, Sava L, Vigneri R. Subclinical hypothyroidism in early childhood : a frequent outcome of transient neonatal hyperthyrotropinemia. J Clin Endocrinol Metab 2002 ; 87 : 3209-14.
PubMed
16) Moreno JC, Bikker H, Kempers MJ, van Trotsenburg AS, Baas F, de Vijlder JJ, Vulsma T, Ris-Stalpers C. Inactivating mutations in the gene for thyroid oxidase 2 (THOX2) and congenital hypothyroidism. N Engl J Med 2002 ; 347 : 95-102.
PubMed
17) Maruo Y, Takahashi H, Soeda I, Nishikura N, Matsui K, Ota Y, Mimura Y, Mori A, Sato H, Takeuchi Y. Transient congenital hypothyroidism caused by biallelic mutations of the dual oxidase 2 gene in Japanese patients detected by a neonatal screening program. J Clin Endocrinol Metab 2008 ; 93 : 4261-7.
 
18) Satoh M, Aso K, Ogikubo S, Ogasawara A, Saji T. Genetic analysis in children with transient thyroid dysfunction or subclinical hypothyroidism detected on neonatal screening. Clin Pediatr Endocrinol 2009 ; 18 : 95-100.
PubMed
19) Gaudino R, Garel C, Czernichow P, Leger J. Proportion of various types of thyroid disorders among newborns with congenital hypothyroidism and normally located gland : a regional cohort study. ClinEndocrinol (Oxf) 2005 ; 62 : 444-8.
PubMed
20) Matsuura N, Harada S, Ohyama Y, Shibayama K, Fukushi M, Ishikawa N, Yuri K, Nakanishi M, Yokota Y, Kazahari K, Oguchi H. The mechanisms of transient hypothyroxinemia in infants born to mothers with Graves' disease. Pediatr Res 1997 ; 42 : 214-8.
PubMed
21) Matsuura N, Yamada Y, Nohara Y, Konishi J, Kasagi K, Endo K, Kojima H, Wataya K. Familial neonatal transient hypothyroidism due to maternal TSH-binding inhibitor immunoglobulins. N Engl J Med 1980 ; 303 : 738-41.
PubMed
22) 長崎啓祐, 浅見直, 野村道代, 帆苅恵, 小田辺なお子. 先天性甲状腺機能低下症スクリーニング陽性者における母体の阻害型TSH 受容体抗体の関与の検討. 日本マス・スクリーニング学会誌 2011 ; 21 : 227-31.
Medical*Online
23) Delange F, Dalhem A, Bourdoux P, Lagasse R, Glinoer D, Fisher DA, Walfish PG, Ermans AM. Increased risk of primary hypothyroidism in preterm infants. J Pediatr 1984 ; 105 : 462-9.
PubMed
24) Srinivasan R, Harigopal S, Turner S, Cheetham T. Permanent and transient congenital hypothyroidism in preterm infants. Acta Paediatr 2012 ; 101 : e179-82.
PubMed
25) 原田正平, 市原侃, 藤枝憲二. マス・スクリーニングで発見された未熟児の甲状腺機能異常症. 日本小児科学会雑誌 1994 ; 98 : 2000-7.
 
26) 原田正平, 市原侃, 松浦信夫, 藤枝憲二, 福士勝, 菊池由生子. クレチン症マススクリーンニング精密検査時の尿中ヨウ化物イオン濃度測定の有用性. 日本小児科学会雑誌 1998 ; 99 : 1924-31.
 
27) Nishiyama S, Mikeda T, Okada T, Nakamura K, Kotani T, Hishnuma A. Transient hypothyroidism or persistent hyperthyrotropinemia in neonates born to mothers with excessive iodine intake. Thyroid 2004 ; 14 : 1077-83.
PubMed
28) 荒田尚子, 原田正平. 母親の影響による新生児甲状腺機能低下症. 小児内科 2007 ; 39 : 713-6.
Medical*Online
29) 小田洋一郎, 真船亮, 柴村美帆, 笹野明子, 堀江豪, 小島あきら, 佐藤研, 森史子, 大野田晋, 中島祐子, 三沢昭彦, 高山慶一郎, 篠塚正一. 子宮卵管造影後妊娠から出生した新生児における甲状腺機能の検討. 日本内分泌学会雑誌 2012 ; 88 (suppl) : 28-30.
Medical*Online
30) Narumi S, Muroya K, Asakura Y, Aachi M, Hasegawa T. Molecular basis of thyroid dyshormonogenesis : genetic screening in population-based Japanese patients. J Clin Endocrinol Metab 2011 ; 96 : E1838-42.
PubMed
31) Zamproni I, Grasberger H, Cortinovis F, Vigone MC, Chiumello G, Mora S, Onigata K, Fugazzola L, Refetoff S, Persani L, et al : Biallelic inactivation of the dual oxidase maturation factor 2 (DUOXA2) gene as a novel cause of congenital hypothyroidism. J Clin Endocrinol Metab 2008 ; 93 : 605-10.
PubMed
32) Calaciura F, Mendorla G, Distefano M, Castorina S, Fazio T, Motta RM, Sava L, Delange F, Vigneri R. Childhood IQ measurements in infants with transient congenital hypothyroidism. Clin Endocrinol (Oxf) 1995 ; 43 : 473-7.
PubMed
33) Azizi F, Afkhami M, Sarshar A, Nafarabadi M. Effects of transient neonatal hyperthyrotropinemia on intellectual quotient and psychomotor performance. Int J Vitam Nutr Res 2001 ; 71 : 70-3.
PubMed
34) 原田正平, 松浦信夫, 藤枝憲二, 大柳和彦, 奥野晃正, 市原侃, 福士勝, 菊池由生子. マス・スクリーニングで発見された軽症クレチン症. ホルモンと臨床 1991 ; 39 : 1063-8.
 
35) Harada S, Ichihara N, Arai J. Later manifestation of congenital hypothyroidism predicted by slightly elevated thyrotropin levels in neonatal screening. Screening 1995 ; 3 : 181-92.
 
36) Daliva AL, Linder B, DiMartino-Nardi J, Saenger P. Three-year follow-up of borderline congenital hypothyroidism. J Pediatr 2000 ; 136 : 53-6.
PubMed
37) Leonardi D, Polizzotti N, Carta A, Gelsomino R, Sava L, Vigneri R, Calaciura F. Longitudinal study of thyroid function in children with mild hyperthyrotropinemia at neonatal screening for congenital hypothyroidism. J Clin Endocrinol Metab 2008 ; 93 : 2679-85.
PubMed
38) 原田正平, 松浦夫. マス・スクリーニングで発見された軽症クレチン症の診断・治療についての全国調査日本マス・スクリーニング学会誌 2000 ; 10 : 43-50.
 
39) 原田正平, 松浦信夫, 柴山啓子. 軽症クレチン症に関するコンセンサスガイドラインの作成平成15年度厚生労働省科学研究 (難治性疾患克服事業) マス・スクリーニングの効率的実施及び開発に関する研究報告書. p.43-7, 2004.
 
40) Krude H, Blankenstein O. Treating patients not numbers : the benefit and burden of lowering TSH newborn screening cut-offs. Arch Dis Child 2011 ; 96 : 121-2.
 
41) 西山宗六, 諸園なきさ, 菱沼昭, 田尻淳一, 木脇弘二, 中村公俊, 中村俊郎. 小児期軽症クレチン症の成因に関与する尿中ヨードの検討. 日本小児科学会雑誌 2000 ; 110 ; 912-8.
 
42) 薮内百治, 野瀬宰, 三木和典, 宮井潔, 畑直成. 乳児一過性高TSH血症の長期予後. 厚生省心身障害研究. マススクリーニングに関する研究. 昭和60年度研究報告書. p.147-9.
 
43) Minamitani K, Inomata H. Neonatal screening for congenital hypothyroidism in Japan. Pediatr Endocr Rev 2012 ; 10 : 79-88.
 
44) 中島博徳, 牧野定夫. 本邦におけるクレチン症の実態調査成績 (マス・スクリーニング以前). 小児科 1980 ; 21 : 65-71.
 
45) 福士勝. クレチン症スクリーニング検査の現状. 平成15年度マス・スクリーニング学会技術部会.
 
46) 猪股弘明, 中島博徳, 佐藤浩一. マス・スクリーニングで発見された先天性甲状腺機能低下症患児における精神神経学的予後全国調査成績 : WISC・R 1989年度尺度修正版による知能指数. 日本小児科学会雑誌 1991 ; 95 : 2336-9.
 
47) 猪股弘明, 中島博徳, 佐藤浩一, 大西尚志, 新美仁男. マス・スクリーニングで発見された先天性甲状腺機能低下症の知能予後 : 第2回全国調査成績および通算成績. 日本小児科学会雑誌 1994 ; 98 : 33-8.
 
48) 猪股弘明, 黒田泰弘. マス・スクリーニングで発見された先天性甲状腺機能低下症の知能予後 : 第3回全国調査成績 (中間成績) 厚生科学研究 (こども家庭総合事業. 平成12年度研究報告書). p.487-9, 2001.
 
49) LaFranchi SH. Approach to the diagnosis and treatment of neonatal hypothyroidism. J Clin Endocrinol Metab 2011 ; 96 : 2959-67.
 
50) 新美仁男, 上瀧邦雄. クレチン症マス・スクリーニング即精検基準値の再評価-各検査施設に対するアンケート集計結果について. 厚生省心身障害研究「新しいスクリーニングのあり方に関する研究」平成7年度研究報告書, p.149-51, 1996.
 
51) 南谷幹史, 杉原茂孝, 猪股弘明, 原田正平. 先天性甲状腺機能低下症マス・スクリーニング運用の各検査施設での状況調査-「ガイドライン 2009 (仮称)」作成に向けて. 日本マス・スクリーニング学会誌 2009 ; 19 : 51-7.
 
52) 島悠子, 杉原茂孝, 松岡尚史, 小野真, 鹿島田健一, 浦上達彦, 鈴木潤一, 櫻井恭子, 穴沢昭, 大和田操. 東京都における先天性甲状腺機能低下症スクリーニングのカットオフ値の検討. 日本マス・スクリーニング学会誌 2011 ; 21 : 29-35.
Medical*Online
53) 南谷幹史, 鹿島京子, 高谷具純, 木下香, 皆川真規, 上瀧邦雄, 渡邉智之, 真山和徳, 大西尚志, 安片恭子, 猪股弘明. 千葉県で病型が確定している先天性甲状腺機能低下症69例の解析-新生児マス・スクリーニングで発見された症例-. ホルモンと臨床 2009 ; 57 : 1077-81.
 
54) Corbetta C, Weber G, Cortinovis F, Calebiro D, Passoni A, Vigone MC, Beck-Peccoz P, Chiumello G, Persani L. A 7-year experience with low blood TSH cutoff levels for neonatal screening reveals an unsuspected frequency of congenital hypothyroidism (CH). Clin Endocrinol (Oxf) 2009 ; 71 : 739-45.
PubMed
55) Grunieiro-Papendieck L, Chiesa A, Mendez V, Prieto L.Neonatal screening for congenital adrenal hyperplasia : experience and results in Argentina. J Pediatr Endocrinol Metab 2008 ; 21 (1) : 73-8.
PubMed
56) Korada SM, Pearce M, Ward Platt MP, Avis E, Turner S, Wastell H, Cheetham T. Difficulties in selecting an appropriate neonatal thyroid stimulating hormone (TSH) screening threshold. Arch Dis Child 2010 ; 95 : 169-73.
PubMed
57) 原田正平, 由利賢次, 藤枝憲二, 松浦信夫, 大柳和彦, 福士勝, 高杉信男. 札幌市におけるTSH-T4測定によるクレチン症マス・スクリーニング. 日本小児科学会雑誌 1989 ; 93 : 2742-9.
 
58) Fukushi M, Fujikura K, Hanai J, Yano K, Tajima T, Fujieda K. Neonatal screening for congenital hypothyroidism by measurement of TSH and free T4. Rev Invest Clin 2009 ; 61 (Suppl 1) : 30.
 
59) Adachi M, Soneda A, Asakura Y, Muroya K, Yamagami Y, Hirahara F. Mass screening of newborns for congenital hypothyroidism of central origin by free thyroxine measurement of blood samples on filter paper. Eur J Endocrinol 2012 ; 166 : 829-38.
PubMed
60) Fujiwara F, Fujikura K, Okuhara K, Tsubaki J, Fukushi M, Fujita K, Fujieda K, Tajima T. Central congenital hypothyroidism detected by neonatal mass screening in Sapporo, Japan 2000-2004 ; Its prevalence and clinical characteristics. Clin Pediatr Endocrinol 2008 ; 17 : 65-9.
PubMed
61) Lanting CI, van Tijn DA, Loeber JG, Vulsma T, de Vijlder JJ, VerkerkPH. Clinical effectiveness and cost-effectiveness of the use of the thyroxine/thyroxine-binding globulin ratio to detect congenital hypothyroidism of thyroidal and central origin in a neonatal screening program. Pediatrics 2005 ; 116 : 168-73.
 
62) Hanna CE, Krainz PL, Skeels MR, Miyahira RS, Sesser DE, LaFranchi SH. Detection of congenital hypopituitary hypothyroidism : ten-year experience in the Northwest Regional Screening Program. J Pediatr 1986 ; 109 : 959-64.
 
63) Hunter MK, Mandel SH, Sesser DE, Miyabira RS, Rien L, Skeels MR, LaFranchi SH. Follow-up of newborns with low thyroxine and nonelevated thyroid-stimulating hormone-screening concentrations : results of the 20-year experience in the Northwest Regional Newborn Screening Program. J Pediatr 1998 ; 132 : 70-4.
 
64) 安達昌功. 先天性甲状腺機能低下症 (CH) のマス・スクリーニング-現在までの実績およびCH周辺疾患. 日本マス・スクリーニング学会誌 2006 : 16 : 27-38.
Medical*Online
65) 猪股弘明, 中島博徳, 青木菊麿, 立花克彦, 黒田泰弘. 新生児マス・スクリーニングで発見されなかった先天性原発性甲状腺機能低下症35例の解析. ホルモンと臨床 2001 ; 49 : 1141-5.
 
66) 長崎啓祐, 浅見 直, 小田部なお子. 新生児マス・スクリーニングで発見されなかった家族性の先天性甲状腺機能低下症の4例. 日本マス・スクリーニング学会雑誌 2008 ; 18 : 69-72.
 
67) Fisher DA. Thyroid function and dysfunction in premature infants. Pedaitr Endocrinol Rev 2007 ; 4 : 317-28.
PubMed
68) Larson C, Hermos R, Delaney A, Daley D, Mitchell M. Risk factors associated with delayed thyrotropin elevations in congenital hypothyroidism. J Pediatr 2003 ; 143 : 587-91.
PubMed
69) Mitchell ML, Walraven C, Rojas DA, McIntosh KF, Hermos RJ. Screening very-low-birthweight infants for congenital hypothyroidism. Lancet 1994 ; 343 : 60-1.
PubMed
70) Mandel SJ, Hermos RJ, Larson CA, Prigozhin AB, Rojas DA, Mitchell ML. Atypical hypothyroidism and the very low birth weight infant. Thyroid 2000 ; 10 : 693-5.
PubMed
71) 福士勝. 新生児マス・スクリーニングにおける未熟児の採血時期について. 代謝異常スクリーニング研究会会報 1987 ; 10 ; 29.
 
72) 上瀧邦雄, 猪股弘明. 新生児マス・スクリーニングにおける未熟児2回採血により診断の見逃しが防止できた症例に関する全国調査. 日本マス・スクリーニング学会誌 2002 ; 12 : 17-20.
Medical*Online
73) 山上祐次, 戸田雅子, 福田律子, 青木芳和, 森雄一, 春木英一, 立花克彦, 住吉好雄, 諏訪城三. 先天性甲状腺機能低下症検査における低出生体重児2回目採血の有用性について. 日本マス・スクリーニング学会誌 2003 ; 13 (3) : 21-6.
 
74) Woo HC, Lizarda A, Tucker R, Mitchell ML, Vohr B, Oh W, Phornphutkul C. Congenital hypothyroidism with a delayed thyroid-stimulating hormone elevation in very premature infants : incidence and growth and developmental outcomes. J Pediatr 2011 ; 158 : 538-42.
PubMed
75) Bijarnia S, Wilcken B, Wiley VC. Newborn screening for congenital hypothyroidism in very-low-birth-weight babies : the need for a second test. J Inherit Metab Dis 2011 ; 34 : 827-33.
 
76) Deming DD, Rabin CW, Hopper AO, Peverini RL, Vyhmeister NR, Nelson JC. Direct equilibrium dialysis compared with two non-dialysis free T4 methods in premature infants. J Pediatr 2007 ; 151 : 404-8.
PubMed
77) Chowdhry P, Scanlon JW, Auerbach R, Abbassi V. Results of controlled double blind study of thyroid replacement in very low-birth-weight premature infants with hypothyroxinemia. Pediatrics 1984 ; 73 : 301-5.
PubMed
78) Smith LM, Leake RD, Berman N, Villanueva S, Brasel JA. Postnatal thyroxine supplementation in infants less than 32 weeks' gestation : effects on pulmonary morbidity. J Perinatol 2000 ; 20 : 427-31.
PubMed
79) van Wassenaer AG, Kok JH, de Vijlder JJ, Briet JM, Smit BJ, Tamminga P, van Baar A, Dekker FW, Vulsma T. Effects of thyroxine supplementation on neurologic development in infants born at less than 30 weeks' gestation. N Engl J Med 1997 ; 336 : 21-6.
PubMed
80) Yagasaki H, Kobayashi K, Nemoto A, Naito A, Sugita K, Ohyama K. Late-onset circulatory dysfunction after thyroid hormone treatment in an extremely low birth weight infant. J Pediatr Endocrinol Metab 2010 ; 23 : 153-8.
 
81) Kawai M, Kusuda S, Cho K, Horikawa R, Takizawa F, Ono M, Hattori T, Oshiro M. Nationwide surveillance of circulatory collapse associated with levothyroxine administration in very-low-birth weight infants in Japan. Pediatr Int 2012 ; 54 : 177-81.
PubMed
82) Ohnishi H, Inomata H, Watanabe T, Wataki K, Sato H, Sanayama K, Noda H, Yasuda T, Niimi H. Clinical utility of thyroid ultrasonography in the diagnosis of congenital hypothyroidism. Endocr J 2002 ; 49 : 293-7.
PubMed
83) 新美仁男, 上瀧邦雄, 猪股弘明, 青木菊麿. クレチン症マス・スクリーニング陽性者の精検初診時の所見と甲状腺機能について-全国追跡調査成績による検討-厚生省心身障害研究「効果的なマス・スクリーニングの施策に関する研究」平成9年度研究報告書, p.111-3, 1998.
 
84) 田丸清恵, 猪股弘明, 佐々木望, 新美仁男, 中島博徳. 甲状腺機能正常児およびクレチン症における乳児期早期の大腿骨遠位端骨核の大きさ. 日本小児科学会雑誌 1986 ; 10 : 2289-93.
 
85) Glorieux J, Desjardins M, Letarte J, Morissette J, Dussault JH. Useful parameters to predict the eventual mental outcome of hypothyroid children. Pediatr Res 1998 ; 24 : 6-8.
 
86) Wasniewska M, De Luca F, Cassio A, Oggiaro N, Gianino P, Delvecchio M, Aiazzi R, Stoppioni V, Lombardo F, Messina MF, Valenzise M, Arrigo T. In congenital hypothyroidism bone maturation at birth may be a predictive factor of psychomotor development during the first year of life irrespective of other variables related to treatment. Eur J Endocrinol 2003 ; 149 : 1-6.
PubMed
87) Selva KA, Mandel SH, Rien L, Sesser D, Miyahira R, Skeels M, Nelson JC, Lafranchi SH. Initial treatment dose of L-thyroxine in congenital hypothyroidism. J Pediatr 2002 ; 141 : 786-92.
PubMed
88) Heyerdahl S. Treatment variables as predictors of intellectual outcome in children with congenital hypothyroidism. Eur J Pediatr 1996 ; 155 : 357-61.
PubMed
89) Rovet JF, Ehrlich RM. Long-term effects of L-thyroxine therapy for congenital hypothyroidism. J Pediatr 1995 ; 126 : 380-6.
PubMed
90) 佐々木望, 佐藤浩一, 中村伸枝, 掛江直子, 原田正平. 「マス・スクリーニングで発見された先天性甲状腺機能低下症患者の長期的QOL調査-平成18年度追跡調査を加えての成績のまとめ-」 (分担研究課題 : 現行マス・スクリーニングの問題解決に関する研究, 平成18年度厚生労働科学研究費補助金 <子ども家庭総合研究事業> 分担報告書).
 
91) Grant DB. Monitoring TSH concentrations during treatment for congenital hypothyroidism. Arch Dis Child 1991 ; 66 : 669-70.
PubMed
92) Abusrewil SS, Tyfield L, Savage DC. Serum thyroxine and thyroid stimulating hormone concentrations after treatment of congenital hypothyroidism. Arch Dis Child 1988 ; 63 : 1368-71.
PubMed
93) Balhara B, Misra M, Levitsky LL. Clinical monitoring guidelines for congenital hypothyroidism : laboratory outcome data in the first year of life. J Pediatr 2011 ; 158 : 532-7.
 
94) Zeitler P, Solberg P. Pharmacy and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society. Food and levothyroxine administration in infants and children. J Pediatr 2010 ; 157 : 13-4.
 
95) Bolk N, Visser TJ, Nijman J, Jongste IJ, Tijssen JG, Berghout A. Effects of evening vs morning levothyroxine intake : a randomized double-blind crossover trial. Arch Intern Med 2010 ; 170 : 1996-2003.
PubMed
96) Olivieri A, Stazi MA, Mastroiacovo P, Fazzini C, Medda E, Spagnolo A, De Angelis S, Grandolfo ME, Taruscio D, Cordeddu V, Sorcini M. A population-based study on the frequency of additional congenital malformations in infants with congenital hypothyroidism : data from the Italian Registry for Congenital Hypothyroidism (1991-1998). J Clin Endocrinol Metab 2002 ; 87 : 557-62.
 
97) Roberts HE, Moore CA, Fernhoff PM, Brown AL, Khoury MJ. Population study of congenital hypothyroidism and associated birth defects, Atlanta, 1979-1992. Am J Med Genet 1997 ; 71 : 29-32.
PubMed
98) Gu YH, Harada S, Kato T, Inomata H, Aoki K, Hirahara F. Increased incidence of extrathyroidal congenital malformations in Japanese patients with congenital hypothyroidism and their relationship with Down syndrome and other actors. Thyroid 2009 ; 19 : 869-79.
 
99) van Trotsenburg AS, Vulsma T, van Santen HM, Cheung W, de Vijlder JJ. Lower neonatal screening thyroxine concentrations in Down syndrome newborns. J Clin Endocrinol Metab 2003 ; 88 : 1512-5.
PubMed
100) van Trotsenburg AS, Vulsma T, van Rozenburg-Marres SL, van Baar AL, Ridder JC, Heymans HS, Tijssen JG, de Vijlder JJ. The effect of thyroxine treatment started in the neonatal period on development and growth of two-year-old Down syndrome children : a randomized clinical trial. J Clin Endocrinol Metab 2005 ; 90 : 3304-11.
PubMed
101) Carroll KN, Arbogast PG, Dudlet JA, Cooper WO. Increase incidence of medically treated thyroid disease in children with Down syndrome after rerelease of American academy of pediatric health supervision guideline. Pediatrics 2008 ; 122 : e493.
 
102) Bizhanova A, Kopp P. Genetics and phenomics of Pendred syndrome. Mol Cell Endocrinol 2010 ; 322 : 83-90.
PubMed
103) Yokoro S, Matsuo M, Ohtsuka T, Ohzeki T. Hyperthyrotropinemia in a neonate with normal thyroid hormone levels : the earliest diagnostic clue for pseudohypoparathyroidism. Biol Neonate 1990 ; 58 : 69-72.
 
104) Ohnishi H, Sato H, Noda H, Inomata H, Sasaki N. Color Doppler ultrasonography : diagnosis of ectopic thyroid gland in patients with congenital hypothyroidism caused by thyroid dysgenesis. J Clin Endocrinol Metab 2003 ; 88 : 5145-9.
PubMed
105) Bubuteishvili L, Garel C, Czernichow P, Leger J. Thyroid abnormalities by ultrasonography in neonates with congenital hypothyroidism. J Pediatr 2003 ; 143 : 759-64.
PubMed
106) Perry RJ, Maroo S, Maclennan AC, Jones JH, Donaldson MD. Combined ultrasound and isotope scanning is more informative in the diagnosis of congenital hypothyroidism than single scanning. Arch Dis Child 2006 ; 91 : 972-6.
PubMed
107) Karakoc-Aydiner E, Turan S, Akpinar I, Dede F, Isguven P, Adal E, Guran T, Akcay T, Bereket A. Pitfalls in the diagnosis of thyroid dysgenesis by thyroid ultrasonography and scintigraphy. Eur J Endocrinol 2012 ; 166 : 43-8.
PubMed
108) Kobayashi H, Tashita H, Hara H, Hasegawa Y. Utility of computed tomography in identifying an ectopic thyroid in infants and pre-school children. Endocr J 2005 ; 52 : 189-92.
PubMed
109) Jones JH, Attaie M, Maroo S, Neumann D, Perry R, Donaldson MD. Heterogeneous tissue in the thyroid fossa on ultrasound in infants with proven thyroid ectopia on isotope scan-a diagnostic trap. Pediatr Radiol 2010 ; 40 : 725-31.
PubMed
110) Panoutsopoulos G, Mengreli C, Ilias I, Batsakis C, Christakopoulou I. Scintigraphic evaluation of primary congenital hypothyroidism : results of the Greek screening program. Eur J Nucl Med 2001 ; 28 : 529-33.
PubMed
111) Schoen EJ, Clapp W, To TT, Fireman BH. The key role of newborn thyroid scintigraphy with isotopic iodide (123I) in defining and managing congenital hypothyroidism. Pediatrics 2004 ; 114 : e683-8.
PubMed
112) Clerc J, Monpeyssen H, Chevalier A, Amegassi F, Rodrigue D, Leger FA, Richard B. Scintigraphic imaging of paediatric thyroid dysfunction. Horm Res 2008 ; 70 : 1-13.
PubMed
113) Szinnai G, Kosugi S, Derrien C, Lucidarme N, David V, Czernichow P, Polak M. Extending the clinical heterogeneity of iodide transport defect (ITD) : a novel mutation R124H of the sodium/iodide symporter gene and review of genotype-phenotype correlations in ITD. J Clin Endocrinol Metab 2006 ; 91 : 1199-204.
PubMed
114) Eugster EA, LeMay D, Zerin JM, Pescovitz OH. Definitive diagnosis in children with congenital hypothyroidism. J Pediatr 2004 ; 144 : 643-7.
PubMed
115) Parazzini C, Baldoli C, Scotti G, Triulzi F. Terminal zones of myelination : MR evaluation of children aged 20-40 months. Am J Neuroradiol 2002 ; 23 : 1669-73.
PubMed
116) Dimitropoulos A, Molinari L, Etter K, Torresani T, Lang-Muritano M, Jenni OG, Largo RH, Latal B. Children with congenital hypothyroidism : long-term intellectual outcome after early high-dose treatment. Pediatr Res 2009 ; 65 : 242-8.
PubMed
117) Kempers MJ, van der Sluijs Veer L, Nijhuis-van der Sanden RW, Lanting CI, Kooistra L, Wiedijk BM, Last BF, de Vijlder JJ, Grootenhuis MA, Vulsma T. Neonatal screening for congenital hypothyroidism in the Netherlands : cognitive and motor outcome at 10 years of age. J Clin Endocrinol Metab 2007 ; 92 : 919-24.
 
118) Rovet JF. Children with congenital hypothyroidism and their siblings : do they really differ- Pediatrics 2005 ; 115 : e52-7.
PubMed
119) Leger J, Larroque B, Norton J. Influence of severity of congenital hypothyroidism and adequacy of treatment on school achievement in young adolescents : a population-based cohort study. Acta Paediatr 2001 ; 90 : 1249-56.
PubMed
120) Alvarez M, Iglesias Fernandez C, Rodriguez Sanchez A, Dulin Lniguez E, Rodriguez Arnao MD. Episodes of overtreatment during the first six months in children with congenital hypothyroidism and their relationships with sustained attention and inhibitory control at school age. Horm Res Paediatr 2010 ; 74 : 114-20.
 
121) 朝倉由美, 安達昌功, 加藤進昌, 立花克彦. 先天性甲状腺機能低下症マス・スクリーニング陽性児の情緒と行動の異常に関する検討. 日本小児科学会雑誌 2006 ; 110 : 406-11.
 
122) Sato H, Nakamura N, Harada S, Kakee N, Sasaki N. Quality of life of young adults with congenital hypothyroidism. Pediatr Int 2009 ; 51 : 126-31.
PubMed
123) Dickerman Z, De Vries L. Prepubertal and pubertal growth, timing and duration of puberty and attained adult height in patients with congenital hypothyroidism (CH) detected by the neonatal screening programme for CH-a longitudinal study. Clin Endocrinol (Oxf) 1997 ; 47 : 649-54.
 
124) Adachi M, Asakura Y, Tachibana K. Final height and pubertal growth in Japanese patients with congenital hypothyroidism detected by neonatal screening. Acta Paediatr 2003 ; 92 : 698-703.
PubMed
125) Sato H, Sasaki N, Aoki K, Kuroda Y, Kato T. Growth of patients with congenital hypothyroidism detected by neonatal screening in Japan. Pediatr Int 2007 ; 49 : 443-6.
PubMed
126) Salerno M, Micillo M, Di Maio S, Capalbo D, Ferri P, Lettiero T, Tenore A. Longitudinal growth, sexual maturation and final height in patients with congenital hypothyroidism detected by neonatal screening. Eur J Endocrinol 2001 ; 145 : 377-83.
PubMed
127) van der Sluijs Veer L, Kempers MJ, Last BF, Vulsma T, Grootenhuis MA. Quality of life, developmental milestones, and self-esteem of young adults with congenital hypothyroidism diagnosed by neonatal screening. J Clin Endocrinol Metab 2008 ; 93 : 2654-61.
PubMed
128) Leger J, Ecosse E, Roussey M, Lanoe JL, Larroque B. French Congenital Hypothyroidism Study Group. Subtle health impairment and socioeducational attainment in young adult patients with congenital hypothyroidism diagnosed by neonatal screening : a longitudinal population-based cohort study. J Clin Endocrinol Metab 2011 ; 96 : 1771-82.
 
129) Hassani Y, Larroque B, Dos Santos S, Ecosse E, Bouyer J, Leger J. Fecundity in young adults treated early for congenital hypothyroidism is related to the initial severity of the disease : a longitudinal population-based cohort study. J Clin Endocrinol Metab 2012 ; 97 : 1897-04.
 
130) 鬼形和道. 甲状腺機能低下症の分子基盤. 小児科臨床 2009 ; 62 : 1813-21.
Medical*Online
131) 鳴海覚志, 長谷川奉延. 先天性甲状腺機能低下症の分子遺伝学. ホルモンと臨床 2010 ; 7 : 565-71.
 
132) Castanet M, Polak M, Bonaiti-Pellie C, Lyonnet S, Czernichow P, Leger J ; AFDPHE Nineteen years of national screening for congenital hypothyroidism : familial cases with thyroid dysgenesis suggest the involvement of genetic factors. J. Clin Endocrinol Metab 2001 ; 86 : 2009-14.
PubMed
133) Leger J, Marinovic D, Garel C, Bonaiti-Pellie C, Polak M, Czernichow P. Thyroid developmental anomalies in first degree relatives of children with congenital hypothyroidism. J Clin Endocrinol Metab 2002 ; 87 : 575-80.
PubMed
134) Grasberger H, Refetoff S. Genetic causes of congenital hypothyroidism due to dyshormonogenesis. Curr Opin Pediatr 2011 ; 23 : 421-8.
PubMed
135) Narumi S, Muroya K, Asakura Y, Adachi M, Hasegawa T. Transcription factor mutations and congenital hypothyroidism : systematic genetic screening of a population-based cohort of Japanese patients. J Clin Endocrinol Metab 2010 ; 95 : 1981-5.
PubMed
136) Krude H, Schutz B, Biebermann H, von Moers A, Schnabel D, Neitzel H, Tonnies H, Weise D, Lafferty A, Schwarz S, DeFelice M, von Deimling A, van Landeghem F, DiLauro R, Gruters A. Choreoathetosis, hypothyroidism, and pulmonary alterations due to human NKX2-1 haploinsufficiency. J Clin Invest 2002 ; 109 : 475-80.
PubMed
137) Macchia PE, Lapi P, Krude H, Pirro MT, Missero C, Chiovato L, Souabni A, Baserga M, Tassi V, Pinchera A, Fenzi G, Gruters A, Busslinger M, Di Lauro R. PAX8 mutations associated with congenital hypothyroidism caused by thyroid dysgenesis. Nat Genet 1998 ; 19 : 83-6.
 
138) Hishinuma A, Fukata S, Kakudo K, Murata Y, Ieiri T. High incidence of thyroid cancer in long-standing goiters with thyroglobulin mutations. Thyroid 2005 ; 15 : 1079-84.
PubMed
139) Chertok Shacham E, Ishay A, Irit E, Pohlenz J, Tenenbaum-Rakover Y. Minimally invasive follicular thyroid carcinoma developed in dyshormonogenetic multinodular goiter due to thyroid peroxidase gene mutation. Thyroid 2012 ; 22 : 542-6.
PubMed
140) Mantovani G. Clinical review : Pseudohypoparathyroidism : diagnosis and treatment. J Clin Endocrinol Metab 2011 ; 96 : 3020-30.
PubMed
P.198 掲載の参考文献
1) 日本甲状腺学会編. バセドウ病薬物治療のガイドライン 2006. 東京 : 南江堂 ; 2006.
 
2) 佐藤浩一, 佐々木望, 原田正平, 田中敏章, 赤須文人, 朝山光太郎, 荒田尚子, 猪股弘明, 大江秀美, 鬼形和道, 神崎晋, 杉原茂孝, 田尻淳一, 田中弘之, 西山宗六, 長谷川奉延, 長谷川行洋, 深田修司, 百渓尚子, 横谷進, 吉村弘, 森昌朋, 藤枝憲二. 小児期発症バセドウ病薬物治療のガイドライン 2008. 日本小児科学会雑誌 2008 ; 112 : 946-52.
 
3) 日本甲状腺学会. バセドウ病131I内用療法の手引き. 京都 : 日本甲状腺学会 ; 2007.
 
4) 日本甲状腺学会編. バセドウ病治療ガイドライン 2011. 東京 : 南江堂 ; 2011.
 
5) Ruiz JK, Rossi GV, Vallejos HA, Brenet RW, Lopez IB, Escribano AA. Fulminant hepatic failure associated with propylthiouracil. Ann Pharmacother 2003 ; 37 : 224-8.
PubMed
6) Bahn RS, Burch HS, Cooper DS, Garber JR, Greenlee CM, Klein IL, Laurberg P, McDougall IR, Rivkees SA, Ross D, Sosa JA, Stan MN. The role of propylthiouracil in the management of Graves' disease in adults : report of a meeting jointly sponsored by the American Thyroid Association and the Food and Drug Administration. Thyroid 2009 ; 19 : 673-4.
 
7) FDA. U. S. Food and Drug Administration information for healthcare professionals- propylthiouracil-induced liver failure. 2009. www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm162701.htm
 
8) UpToDate patient information. antithyroid drugs. www.uptodate.com/patients/content/topic.do?topicKey=~K7dgOAIby0pAB7&source=see_link.
 
9) Eunice Kennedy Shriver National Institute of Child Health and Human Development 2008 Conference Proceeding. Hepatic Toxicity Following Treatment for Pediatric Graves' Disease Meeting : October 28, 2008. https://bpca.nichd.nih.gov/collaborativeefforts/Documents/Hepatic_Toxicity_10-28-2008.pdf#search=Hepatic%20Toxicity%20Following%20Treatment%20for%20Pediatric
 
10) Rivkees SA, Mattison DR. Propylthiouracil (PTU) hepatoxicity in children and recommendations for discontinuation of use. Int J Pediatr Endocrinol 2009 : 132041.
PubMed
11) Cooper DS, Rivkees SA. Putting propylthiouracil in perspective. J Clin Endocrinol Metab 2009 ; 94 : 1881-2.
PubMed
12) Rivkees SA, Mattison DR. Ending propylthiouracil-induced liver faikure in children. N Engl J Med 2009 ; 360 : 1574-5.
PubMed
13) Bahn RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, Laurberg P, McDougall IR, Montori VM, Rivkees SA, Ross DS, Sosa JA, Stan MN. Hyperthyroidism and Other Causes of Thyrotoxicosis : Management Guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 2011 ; 21 : 593-646.
 
14) Marino M, Vitti P, Chiovato L. Graves' disease. Jameson Jr, De Groot LJ, eds. Endocrinology : adult and pediatric, 7th Ed. Philadelphia, PA : Saunders and Elsevier, 2016 ; 1437-64.
 
15) LaFranchi SH, Hanna CE. Hyperthyroidism in the neonatal period and childhood. Braverman LE, Cooper DS, eds. Werner and Ingbar's The thyroid : A Fundamental and Clinical Text, 10th Ed. Philadelphia, PA : Lippincott Williams & Wilkins, 2013 ; 803-14.
 
16) Huang SA, LaFranchi SH. Graves disease. Kliegman RM, Stanton BF, St. Geme III JW, Schor NF, Behrman RE, eds. Nelson textbook of pediatrics. 20th ed. Philadelphia : Elsevier, Inc. 2016 ; 2681-4.
 
17) Fisher DA. Hyperthyroidism. Rudolph CD, Rudolph AM, Lister GE, First LR, Gershon AA, eds. Rudolph's Pediatrics. 22nd ed. New York : McGraw-Hill Companies Inc. 2011 ; 2039-40.
 
18) 日本甲状腺学会. 甲状腺疾患診断ガイドライン 2010. バセドウ病の診断ガイドライン. http://www.japanthyroid.jp/doctor/guideline/japanese.html
 
19) Sato H, Harada S, Yokoya S, Tanaka T, Asayama K, Mori M, Sasaki N. Treatment for childhood-onset Graves' disease in Japan : results of a nationwide questionnaire survey of pediatric endocrinologists and thyroidologists. Thyroid 2007 ; 17 : 67-72.
PubMed
20) Sato H, Minagawa M, Sasaki N, Sugihara S, Kazukawa I, Minamitani K, Wataki K, Konda S, Inomata H, Sanayama K, Kohno Y. Comparison of methimazole and propylthiouracil in the management of children and adolescents with Graves' disease : efficacy and adverse reactions during initial treatment and long-term outcome. J Pediatr Endocrinol Metab 2011 ; 24 : 257-63.
PubMed
21) Sato H, Sasaki N, Minamitani K, Minagawa M, Sugihara S, Kazukawa I, Wataki K, Konda S, Inomata H, Sanayama K, Kohno Y. Higher dose of methimazole causes frequent adverse effects in the management of Graves' disease in children and adolescents. J Pediatr Endocrinol Metab 2012 ; 25 : 863-7.
PubMed
22) Minamitani K, Oikawa J, Wataki K, Kashima K, Hoshi M, Inomata H, Ota S. A report of three girls with antithyroid drug-induced agranulocytosis ; Retrospective analysis of 18 cases aged 15 years or younger reported between 1995 and 2009. Clin Pediatr Endocrinol 2011 ; 20 : 39-46.
PubMed
23) Ohye H, Minagawa A, Noh JY, Mukasa K, Kunii Y, Watanabe N, Matsumoto M, Suzuki M, Yoshihara A, Ito K, Ito K. Antithyroid Drug treatment for Graves' disease in children : a long-term retrospective study at a single institution. Thyroid 2014 ; 24 : 200-7.
 
24) Sato H, Minamitani K, Minagawa M, Kazukawa I, Sugihara S, Wataki K, Konda S, Inomata H, Sanayama K, Kohno Y, Sasaki N. Clinical features at diagnosis and responses to antithyroid drugs in younger children with Graves' disease compared with adolescent patients. J Pediatr Endocrinol Metab 2014 ; 27 : 677-83.
PubMed
25) Burch HB. Overview of the clinical manifestations of thyrotoxicosis. Braverman LE, Cooper DS, eds. Werner and Ingbar's The thyroid : A Fundamental and Clinical Text, 10th Ed. Philadelphia, PA : Lippincott Williams & Wilkins, 2013 ; 434-40.
 
26) Nandi-Munshi D, Taplin CE. Thyroid-related neurological disorders and complications in children. Pediatr Neurol 2015 ; 52 : 373-82.
PubMed
27) Cassio A, Corrias A, Gualandi S, Tato' L, Cesaretti G, Volta C, Weber G, Bona G, Cappa M, Bal M, Bellone J, Cicognani A. Influence of gender and pubertal stage at diagnosis on growth outcome in childhood thyrotoxicosis : results of a collaborative study. Clin Endocrinol (Oxf) 2006 ; 64 : 53-7.
PubMed
28) Takamatsu J, Kobe N, Ito M, Ohsawa N. Body height and weight of patients with childhood onset and adult onset thyrotoxicosis. Endocr J 1999 ; 46 Suppl : S101-3.
 
29) Lazar L, Kalter-Leibovici O, Pertzelan A, Weintrob N, Josefsberg Z, Phillip M. Thyrotoxicosis in prepubertal children compared with pubertal and postpubertal patients. J Clin Endocrinol Metab 2000 ; 85 : 3678-82.
PubMed
30) Krassas GE, Segni M, Wiersinga WM. Childhood Graves' ophthalmopathy : results of a European questionnaire study. Eur J Endocrinol 2005 ; 153 : 515-21.
PubMed
31) Gogakos AI, Boboridis K, Krassas GE. Pediatric aspects in Graves' orbitopathy. Pediatr Endocrinol Rev 2010, 7 (Suppl 2) : 234-44.
 
32) Villanueva R, Greenberg DA, Davies TF, Tomer Y. Sibling recurrence risk in autoimmune thyroid disease. Thyroid 2003 ; 13 : 761-4.
PubMed
33) Brix TH, Kyvik KO, Christensen K, Hegedus L. Evidence for a major role of heredity in Graves' disease : a population-based study of two Danish twin cohorts. J Clin Endocrinol Metab 2001 ; 86 : 930-4.
 
34) Simmonds MJ. GWAS in autoimmune thyroid disease : redefining our understanding of pathogenesis. Nat Rev Endocrinol 2013 ; 9 : 277-87.
PubMed
35) Ban Y. Genetic factors of autoimmune thyroid diseases in Japanese. Autoimmune Dis 2012 ; 2012 : 236981. doi : 10.1155/2012/236981. Epub 2011 Dec 27.
 
36) Davies TF, Latif R, Yin X. New genetic insights from autoimmune thyroid disease. J Thyroid Res 2012 : 623852.
PubMed
37) Iwama S, Ikezaki A, Kikuoka N, Kim HS, Matsuoka H, Yanagawa T, Sato H, Hoshi M, Sakamaki T, Sugihara S. Association of HLA-DR, -DQ genotype and CTLA-4 gene polymorphism with Graves' disease in Japanese children. Horm Res 2005 ; 63 : 55-60.
PubMed
38) Brent GA. Environmental exposures and autoimmune thyroid disease. Thyroid 2010 ; 20 : 755-61.
PubMed
39) Iwaku K, Noh JY, Minagawa A, Kosuga Y, Suzuki M, Sekiya K, Matsumoto M, Ohye H, Kunii Y, Yoshihara A, Watanabe N, Mukasa K, Ito K, Ito K. Determination of pediatric reference levels of FT3, FT4 and TSH measured with ECLusys kits. Endocr J 2013 ; 60 : 799-804.
PubMed
40) Uchida T, Takeno K, Goto M, Kanno R, Kubo S, Takahashi S, Azuma K, Sakai K, Fujitani Y, Hirose T, Kawamori R, Watada H. Superior thyroid artery mean peak systolic velocity for the diagnosis of thyrotoxicosis in Japanese patients. Endocrine J 2010 ; 57 : 439-43.
PubMed
41) Kamijo K. Study on cutoff value setting for differential diagnosis between Graves' disease and painless thyroiditis using the TRAb (Elecsys TRAb) measurement via the fully automated electrochemiluminescence immunoassay system. Endocrine J 2010 ; 57 : 895-902.
 
42) 紫芝良昌, 上條桂一, 栗原英夫, 佐々木純, 石川直文, 小澤安則, 清水多恵子, 小西淳二, 御前隆, 網野信行, 高野 徹, 深田修司, 野口志郎, 村上司, 入江實. 甲状腺中毒症患者における尿中ヨウ素測定法を用いたバセドウ病と無痛性甲状腺の鑑別診断. ホルモンと臨床 2002 ; 50 : 629-40.
 
43) Franklyn JA, Boelaert K. Thyrotoxicosis. Lancet 2012 ; 379 : 1155-66.
PubMed
44) Smith J, Brown RS. Persistence of thyrotropin (TSH) receptor antibodies in children and adolescents with Graves' disease treated using antithyroid medication. Thyroid 2007 ; 17 : 1103-7.
PubMed
45) Nagasaki T, Inaba M, Kumeda Y, Fujiwara-Ueda M, Hiura Y, Nishizawa Y. Significance of thyroid blood flow as a predictor of methimazole sensitivity in untreated hyperthyroid patients with Graves' disease. Biomed Pharmacother 2007 ; 61 : 472-6.
PubMed
46) Cooper DS. Antithyroid drugs in the management of patients with Graves' disease : An evidence-based approach to therapeutic controversies. J Clin Endocrinol Metab 2003 ; 88 : 3474-81.
PubMed
47) Muldoon BT, Mai VQ, Burch HB. Management of Graves' disease : an overview and comparison of clinical practice guidelines with actual practice trends. Endocrinol Metab Clin North Am 2014 ; 43 : 495-516.
 
48) Burch HB, Burman KD, Cooper DS. A 2011 survey of clinical practice patterns in the management of Graves' disease. Clin Endocrinol Metab 2012 ; 97 : 4549-58.
PubMed
49) Wartofsky L, Glinoer D, Solomon B, Nagataki S, Lagasse R, Nagayama Y, Izumi M. Differences and similarities in the diagnosis and treatment of Graves' disease in Europe, Japan, and the United States. Thyroid 1991 ; 1 : 129-35.
PubMed
50) Perrild H, Gruters-Kieslich A, Feldt-Rasmussen U, Grant D, Martino E, Kayser L, Delange F. Diagnosis and treatment of thyrotoxicosis in childhood. A European questionnaire study. Eur J Endocrinol 1994 ; 131 : 467-73.
PubMed
51) Lee HS, Hwang JS. The treatment of Graves' disease in children and adolescents. Ann Pediatr Endocrinol Metab 2014 ; 19 : 122-6.
 
52) Leger J, Kaguelidou F, Alberti C, Carel JC. Graves' disease in children. Best Pract Res Clin Endocrinol Metab 2014 ; 28 : 233-43.
PubMed
53) Cooper DS. Antithyroid drugs. N Engl J Med 2005 ; 352 : 905-17.
PubMed
54) Saberi M, Sterling FH, Utiger RD. Reduction in extrathyroidal triiodothyronine production by propylthiouracil in man. J Clin Invest 1975 ; 55 : 218-23.
 
55) Stanley MM, Astwood EB. 1-methyl-2-mercaptoimidazole : An antithyroid compound highly active in man. Endocrinology 1949 ; 44 : 588-9.
PubMed
56) Nicholas WC, Fischer RG, Stevenson RA, Bass JD. Single daily dose of methimazole compared to every 8 hours propylthiouracil in the treatment of hyperthyroidism. South Med J 1995 ; 88 : 973-6.
PubMed
57) He CT, Hsieh AT, Pei D, Hung YJ, Wu LY, Yang TC, Lian WC, Huang WS, Kuo SW. Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism. Clin Endocrinol (Oxf) 2004 ; 60 : 676-81.
PubMed
58) Emiliano AB, Governale L, Parks M, Cooper DS. Shifts in propylthiouracil and methimazole prescribing practices : antithyroid drug use in the United States from 1991 to 2008. J Clin Endocrinol Metab 2010 ; 95 : 2227-33.
PubMed
59) Cooper DS. The side effects of antithyoird drugs. Endocrinologist 1999 ; 9 : 457-76.
 
60) Rivkees SA, Stephenson K, Dinauer C. Adverse events associated with methimazole therapy of Graves' disease in children. Int J Pediatr Endocrinol 2010 : 176970.
PubMed
61) Hamburger JI. Management of hyperthyroidism in children and adolescents. J Clin Endocrinol Metab 1985 ; 60 : 1019-24.
PubMed
62) Nakamura H, Noh JY, Itoh K, Fukata S, Miyauchi A, Hamada N, Working Group of the Japan Thyroid Association for the Guideline of the Treatment of Graves' Disease. Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves' disease. J Clin Endocrinol Metab 2007 ; 92 : 2157-62.
 
63) Gunton JE, Stiel J, Caterson RJ, McElduff A. Anti-thyroid drugs and antineutrophil cytoplasmic antibody positive vasculitis. A case report and review of the literature. J Clin Endocrinol Metab 1999 ; 84 : 13-6.
PubMed
64) Sato H, Hattori M, Fujieda M, Sugihara S, Inomata H, Hoshi M, Miyamoto S. High prevalence of antineutrophil cytoplasmic antibody positivity in childhood onset Graves' disease treated with propylthiouracil. J Clin Endocrinol Metab 2000 ; 85 : 4270-3.
PubMed
65) Yoshimura JN, Yasuda S, Sato S, Matsumoto M, Kunii Y, Noguchi Y, Mukasa K, Ito K, Ito K, Sugiyama O, Kobayashi H, Nihojima S, Okazaki M, Yokoyama S. Clinical characteristics of myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis caused by antithyroid drugs. J Clin Endocrinol Metab 2009 ; 94 : 2806-11.
 
66) Chen YX, Zhang W, Chen XN, Yu HJ, Ni LY, Xu J, Pan XX, Ren H, Chen N. Propylthiouracil-induced antineutrophil cytoplasmic antibody (ANCA) -associated renal vasculitis versus primary ANCA associated renal vasculitis : a comparative study. J Rheumatol 2012 ; 39 : 558-63.
 
67) Mandel SJ, Brent GA, Larsen PR. Review of antithyoid drug use during pregnancy and report of a case of aplasia cutis. Thyroid 1994 ; 4 : 129-33.
 
68) Yoshihara A, Noh J, Yamaguchi T, Ohye H, Sato S, Sekiya K, Kosuga Y, Suzuki M, Matsumoto M, Kunii Y, Watanabe N, Mukasa K, Ito K, Ito K. Treatment of Graves' disease with antithyroid drugs in the first trimester of pregnancy and the prevalence of congenital malformation. J Clin Endocrinol Metab 2012 ; 97 : 2396-403.
PubMed
69) Dotsch J, Rascher W, Dorr HG. Graves' disease in childhood : a review of the options for diagnosis and treatment. Paediatr Drugs 2003 ; 5 : 95-102.
PubMed
70) Dotsch J, Siebler T, Hauffa BP, Doeker B, Andler W, Bettendorf M, Heinrich U, Gohlke B, Albers N, Willgerodt H, Kiess W. Diagnosis and management of juvenile hyperthyroidism in Germany : a retrospective multicenter study. J Pediatr Endocrinol Metab 2000 ; 13 : 879-85.
 
71) Mussa GC, Corrias A, Silvestro L, Battan E, Mostert M, Mussa F, Pellegrino D. Factors at onset predictive of lasting remission in pediatric patients with Graves' disease followed for at least three years. J Pediatr Endocrinol Metab 1999 ; 12 : 537-41.
PubMed
72) Slyper AH, Wyatt D, Boudreau C. Effective methimazole dose for childhood Graves' disease and use of free triiodothyronine combined with concurrent thyroid-stimulating hormone level to identify mild hyperthyroidismand delayed pituitary recovery. J Pediatr Endocrinol Metab 2005 ; 18 : 597-602.
 
73) Maia AL, Scheffel RS, Meyer EL, Mazeto GM, Carvalho GA, Graf H, Vaisman M, Maciel LM, Ramos HE, Tincani AJ, Andrada NC, Ward LS. The Brazilian consensus for the diagnosis and treatment of hyperthyroidism : recommendations by the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism. Arq Bras Endocrinol Metab 2013 ; 57 : 205-32.
 
74) Kaguelidou F, Carel JC, Leger J. Graves' disease in childhood : Advances in management with antithyroid drug therapy. Horm Res 2009 ; 71 : 310-7.
PubMed
75) Stafford D, Vaidyanathan P, Kaplowitz P. Children with hyperthyroidism younger than age 7 require higher mg/kg doses of methimazole to normalize free T4 compared to older children. J Pediatr Endocrinol Metab 2015 ; 28 : 1339-42.
 
76) Shulman DI, Muhar I, Jorgensen EV, Diamond FB, Bercu BB, Root AW. Autoimmune hyperthyroidism in prepubertal children and adolescents : comparison of clinical and biochemical features at diagnosis and responses to medical therapy. Thyroid 1997 ; 7 : 755-60.
PubMed
77) Vitti P, Rago T, Chiovato L, Pallini S, Santini F, Fiore E, Rocchi R, Martino E, Pinchera A. Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment. Thyroid 1997 ; 7 : 369-75.
PubMed
78) Benker G, Reinwein D, Kahaly G, Tegler L, Alexander WD, Fassbinder J, Hirche H. Is there a methimazole dose effect on remission rate in Graves' disease? Results from a long-term prospective study. Clin Endocrinol (Oxf) 1998 ; 49 : 451-7.
 
79) Michelangeli V, Poon C, Taft J, Newnham H, Topliss D, Colman P. The prognostic value of thyrotropin receptor antibody measurement in the early stages of treatment of Graves' disease with antithyroid drugs. Thyroid 1998 ; 8 : 119-24.
PubMed
80) Jafarzadeh A, Poorgholami M, Izadi N, Nemati M, Rezayati M. Immunological and hematological changes in patients with hyperthyroidism or hypothyroidism. Clin Invest Med 2010 ; 33 : 271-9.
PubMed
81) Kubota S, Amino N, Matsumoto Y, Ikeda N, Morita S, Kudo T, Ohye H, Nishihara E, Ito M, Fukata S, Miyauchi A. Serial changes in liver function tests in patients with thyrotoxicosis induced by Graves' disease and painless thyroiditis. Thyroid 2008 ; 18 : 283-7.
PubMed
82) Sarinnapakorn V, Noppavetchwich P, Sunthorntepwarakul T, Deerochanawong C, Ngongamrut S. Abnormal liver function test in Graves' disease : a prospective study of comparison between the hyperthyroid state and the euthyroid state. J Med Assoc Thai 2011 ; 94 (Suppl 2) : S11-6.
 
83) Sato S, Noh JY, Sato S, Suzuki M, Yasuda S, Matsumoto M, Kunii Y, Mukasa K, Sugino K, Ito K, Nagataki S, Taniyama M. Comparison of efficacy and adverse effects between methimazole 15 mg+inorganic iodine 38 mg/day and methimazole 30 mg/day as initial therapy for Graves' disease patients with moderate to severe hyperthyroidism. Thyroid 2015 ; 25 : 43-50.
 
84) Reinwein D, Benker G, Lazarus JH, Alexander WD. A prospective randomized trial of antithyoid drug dose in Graves' disease therapy. J Clin Endocrinol Metab 1993 ; 76 : 1516-21.
 
85) Takata K, Kubota S, Fukata S, Kudo T, Nishihara E, Ito M, Amino N, Miyauchi A. Methimazole-induced agranulocytosis in patients with Graves' disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily. Thyroid 2009 ; 19 : 559-63.
 
86) Salpeter SR, Ormiston TM, Salpeter EE. Cardioselectivebeta-blockers in patients with reactive airway disease : a meta-analysis. Ann Intern Med 2002 ; 137 : 715-25.
PubMed
87) 佐藤真理, 麻生敬子, 中山智孝, 松裏裕行, 小原明, 舘野昭彦, 佐地勉. ヨウ化カリウムによる治療を長期間施行したバセドウ病の3例. 日本小児科学会雑誌 2010 ; 114 : 1713-7.
 
88) Okamura K, Sato K, Fujikawa M, Bandai S, Ikenoue H, Kitazono T. Remission after potassium iodide therapy in patients with Graves' hyperthyroidism exhibiting thionamide-associated side effects. J Clin Endocrinol Metab 2014 ; 99 : 3995-4002.
PubMed
89) Uchida T, Goto H, Kasai T, Komiya K, Takeno K, Abe H, Shigihara N, Sato J, Honda A, Mita T, Kanazawa A, Fujitani Y, Watada H. Therapeutic effectiveness of potassium iodine in drug-naive patients with Graves' disease : a single-center experience. Endocrine 2014 ; 47 : 506-11.
PubMed
90) Takata K, Amino N, Kubota S, Sasaki I, Nishihara E, Kudo T, Ito M, Fukata S, Miyauchi A. Benefit of short-term iodide supplementation to antithyroid drug treatment of thyrotoxicosis due to Graves' disease. Clin Endocrinol (Oxf) 2010 ; 72 : 845-50.
PubMed
91) Jeong KU, Lee HS, Hwang JS. Effects of short-term potassium iodide treatment for thyrotoxicosis due to Graves' disease in children and adolescents. Ann Pediatr Endocrinol Metab 2014 ; 19 : 197-201.
 
92) Raza J, Hindmarsh PC, Brook CG. Thyrotoxicosis in children : thirty years' experience. Acta Paediatr 1999 ; 88 : 937-41.
PubMed
93) Abraham P, Avenell A, Park CM, Watson WA, Bevan JS. A systematic review of drug therapy for Graves' hyperthyroidism. Eur J Endocrinol 2005 ; 153 : 489-98.
PubMed
94) Razvi S, Vaidya B, Perros P, Pearce SH. What is the evidence behind the evidence-base? The premature death of block-replace antithyroid drug regimens for Graves' disease. Eur J Endocrinol 2006 ; 154 : 783-6.
PubMed
95) Abraham P, Avenell A, Watson WA, Park CM, Bevan JS. Antithyroid drug regimen for treating Graves' hyperthyroidism. Cochrane Database Syst Rev 2004 ; (2) : CD003420.
 
96) Abraham P, Avenell A, McGeoch SC, Clark LF, Bevan JS. Antithyroid drug regimen for treating Graves' hyperthyroidism. Cochrane Database Syst Rev 2010 ; (1) : CD003420.
PubMed
97) Solomon BL, Wartofsky L, Burman KD. Adjunctive cholestyramine therapy for thyrotoxicosis. Clin Endocrinol (Oxf) 1993 ; 38 : 39-43.
PubMed
98) Heemstra KA, Toes RE, Sepers J, Pereira AM, Corssmit EP, Huizinga TW, Romijn JA, Smit JW. Rituximab in relapsing Graves' disease, a phase II study. Eur J Endocrinol 2008 ; 159 : 609-15.
PubMed
99) 露崎俊明. 抗甲状腺剤治療による小児バセドウ病の予後. 千葉医学誌 1989 ; 65 : 227-34.
 
100) Lippe BM, Landaw EM, Kaplan SA. Hyperthyroidism in children treated with long term medical therapy : twenty-five percent remission every two years. J Clin Endocrinol Metab 1987 ; 64 : 1241-5.
PubMed
101) Konishi T, Okamoto Y, Ueda M, Fukuda Y, Harusato I, Tsukamoto Y, Hamada N. Drug discontinuation after treatment with minimum maintenance dose of an antithyroid drug in Graves' disease : a retrospective study on effects of treatment duration with minimum maintenance dose on lasting remission. Endocr J 2011 ; 58 : 95-100.
PubMed
102) Weetman AP. Graves' hyperthyroidism : how long should antithyroid drug therapy be continued to achieve remission? Nat Clin Pract Endocrinol Metab 2006 ; 2 : 2-3.
PubMed
103) Glaser NS, Styne DM. Predictors of early remission of hyperthyroidism in children. J Clin Endocrinol Metab 1997 ; 82 : 1719-26.
 
104) Maugendre D, Gatel A, Campion L, Massart C, Guilhem I, Lorcy Y, Lescouarch J, Herry JY, Allannic H. Antithyroid drugs and Graves' disease- prospective randomized assessment of long-term treatment. Clinical Endocrinology 1999 ; 50 : 127-32.
PubMed
105) Bauer AJ. Approach to the pediatric patient with Graves' disease : when is definitive therapy warranted? J Clin Endocrinol Metab 2011 ; 96 : 580-8.
 
106) Rivkees SA. Pediatric Graves' disease : management in the post-propylthiouracil Era. Int J Pediatr Endocrinol 2014 ; (1) : 10 doi : 10.1186/1687-9856-2014-10.
 
107) Leger J, Gelwane G, Kaguelidou F, Benmerad M, Alberti C, and the French Childhood Graves' Disease Study Group. Positive impact of long-term antithyroid drug treatment on the outcome of children with Graves' disease : National long-term cohort study. J Clin Endocrinol Metab 2012 ; 97 : 110-9.
 
108) Hiraiwa T, Ito M, Imagawa A, Takamatsu J, Kuma K, Miyauchi A, Hanafusa T. Restriction of dietary Iodine does not ameliorate the early effect of anti-thyroid drug therapy for Graves' disease in an area of excessive iodine intake. J Endocrinol Invest 2006 ; 29 : 380-4.
PubMed
109) Park SM, Cho YY, Joung JY, Sohn SY, Kim SW, Chung JH. Excessive iodine intake does not increase the recurrence rate of Graves' disease after withdrawal of the antithyroid drug in an iodine-replete area. Eur Thyroid J 2015 ; 4 : 36-42.
 
110) Tamai H, Takaichi Y, Morita T, et al. Methimazole-induced agranulocytosis in Japanese patients with Graves' disease. Clin Endocrinol (Oxf) 1989 ; 30 : 525-30.
PubMed
111) Cooper DS, Goldminz D, Levin AA, Ladenson PW, Daniels GH, Molitch ME, Ridgway EC. Agranulocytosis associated with antithyroid drugs. Effects of patient age and drug dose. Ann Intern Med 1983 ; 98 : 26-9.
 
112) Hamerschlak N, Maluf E, Biasi Cavalcanti A, Avezum Junior A, Eluf-Neto J, Passeto Falcao R, Lorand-Metze IG, Goldenberg D, Leite Santana C, de Oliveira Werneck Rodriges D, Nascimento da Motta Passos L, Oliveira de Miranda Coelho E, Tostes Pintao MC, Moraes de Souza H, Borbolla JR, Pasquini R. Incidence and risk factors for agranulocytosis in Latin American countries--the Latin Study : a multicenter study. Eur J Clin Pharmacol 2008 ; 64 : 921-9.
 
113) Tajiri J, Noguchi S, Murakami N. Usefulness of granulocyte count measurement four hours after injection of granulocyte colony-stimulating factor for detecting recovery from antithyroid drug-induced granulocytopenia. Thyroid 1997 ; 7 : 575-8.
PubMed
114) Tajiri J, Noguchi S. Antithyroid drug-induced agranulocytosis : how has granulocyte colony-stimulating factor changed therapy- Thyroid 2005 ; 15 : 292-7.
PubMed
115) Rivkees SA, Szarfman A. Dissimilar hepatotoxicity profiles of propylthiouracil and methimazole in children. J Clin Endocrinol Metab 2010 ; 95 : 3260-7
 
116) Williams KV, Nayak S, Becker D, Reyes J, Burmeister LA. Fifty years of experience with propylthiouracil-associated hepatotoxicity : what have we learned? J Clin Endocrinol Metab 1997 ; 82 : 1727-33.
 
117) 原田正平, 有阪治, 横谷進, 雨宮伸, 田中敏章, 長谷川奉延, 田中弘之, 猪股弘明, 鬼形和道, 佐々木望, 佐藤浩一, 杉原茂孝, 西山宗六, 長谷川行洋, 田尻淳一, 藤枝憲二, 森昌朋. 抗甲状腺剤による小児期バセドウ病の重篤肝障害に関する日米の対応の違いについて. 第43回日本小児内分泌学会学術集会抄録集 2009. p.71.
 
118) 高野忠将, 岡崎実, 鍵本聖一, 城宏輔, 大石勉, 甲田直也, 望月弘, 山森浩之, 小島明. プロピルチオウラシル (PTU) による重症肝炎の1例. 埼玉県医学会雑誌 2000 ; 35 : 467-70.
 
119) Umemoto M, Sawada H, Sugiyama K, Higashigawa M, Sakurai M. Propylthiouracil-induced hepatic failure with fatal outcome. Clin Pediatr Endocrinol 1997 ; 6 : 73-5.
 
120) Otsuka F, Noh JY, Chino T, Shimizu T, Mukasa K, Ito K, Taniyama M. Hepatotoxicity and cutaneous reactions after antithyroid drug administration. Clin Endocrinol (Oxf) 2012 ; 77 : 310-5.
PubMed
121) Glaser NS, Styne DM. Organization of Pediatric Endocrinologists of Northern California Collaborative Graves' Disease Study Group. Predicting the likelihood of remission in children with Graves' disease : a prospective, multicenter study. Pediatrics 2008 ; 121 : e481-8.
 
122) Poyrazoglu S, Saka N, Bas F, Isguven P, Dogu A, Turan S, et al. Evaluation of diagnosis and treatment results in children with Graves' disease with emphasis on the pubertal status of patients. J Pediatr Endocrinol Metab 2008 ; 21 : 745-51.
PubMed
123) Kaguelidou F, Alberti C, Castanet M, Guitteny MA, Czernichow P, Leger J. French Childhood Graves' Disease Study Group. Predictors of autoimmune hyperthyroidism relapse in children after discontinuation of antithyroid drug treatment. J Clin Endocrinol Metab 2008 ; 93 : 3817-26.
 
124) Takasu N, Yamashiro K, Komiya I, Ochi Y, Sato Y, Nagata A. Remission of Graves' hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment. Thyroid 2000 ; 10 : 891-6.
PubMed
125) Quadbeck B, Hoermann R, Roggenbuck U, Hahn S, Mann K, Janssen OE. Sensitive thyrotropin and thyrotropinreceptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease. Thyroid 2005 ; 15 : 1047-54.
PubMed
126) Bhadada S, Bhansali A, Velayutham P, Masoodi SR. Juvenile hyperthyroidism : an experience. Indian Pediatr 2006 ; 43 : 301-7.
PubMed
127) Gastaldi R, Poggi E, Mussa A, Weber G, Vigone MC, Salerno M, Delvecchio M, Peroni E, Pistorio A, Corrias A. Graves disease in children : thyroid-stimulating hormone receptor antibodies as remission markers. J Pediatr 2014 ; 164 : 1189-94.
PubMed
128) Gruneiro-Papendieck L, Chiesa A, Finkielstain G, Heinrich JJ. Pediatric Graves' disease : outcome and treatment. J Pediatr Endocrinol Metab 2003 ; 16 : 1249-55.
PubMed
129) Lazar L, Kalter-Leibovici O, Pertzelan A, Weintrob N, Josefsberg Z, Phillip M. Thyrotoxicosis in prepubertal children compared with pubertal and postpubertal patients. J Clin Endocrinol Metab 2000 ; 85 : 3678-82.
PubMed
130) Somnuke PH, Pusuwan P, Likitmaskul S, Santiprabhob J, Sawathiparnich P. Treatment outcome of Graves' disease in Thai children. J Med Assoc Thai 2007 ; 90 : 1815-20.
 
131) Brownlie BE, Hunt PJ, Turner JG. Juvenile thyrotoxicosis- a South Island, New Zealand experience with long-term outcome. N Z Med J 2010 ; 123 : 23-31.
PubMed
132) Barrio R, Lopez-Capape M, Martinez-Badas I, Carrillo A, Moreno JC, Alonso M. Graves' disease in children and adolescents : response to long-term treatment. Acta Paediatr 2005 ; 94 : 1583-9.
 
133) Kashiwai T, Hidaka Y, Takano T, Tatsumi K-I, Izumi Y, Shimaoka Y, Tada H, Takeoka K, Amino N. Practical treatment with minimum maintenance dose of anti-thyroid drugs for prediction of remission in Graves' disease. Endocr J 2003 ; 50 : 45-9.
PubMed
134) 原田正平. 小児期バセドウにおけるTSH受容体抗体に関する研究 第2編 抗甲状腺剤治療による変動と臨床的意義の検討. 日本小児科学会雑誌 1991 ; 95 : 1751-7.
 
135) Laurberg P, Wallin G, Tallstedt L, Abraham-Nordling M, Lundell G, Torring O. TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine : a 5-year prospective randomized study. Eur J Endocrinol 2008 ; 158 : 69-75.
PubMed
136) Okamoto Y, Tanigawa S-i, Ishikawa K, Hamada N. TSH receptor antibody measurements and prediction of remission in Graves' disease patients treated with minimum maintenance doses of antithyroid drugs. Endocr J 2006 ; 53 : 467-72.
PubMed
137) Takasu N, Akamine H, Komiya I, Yamada T. Simple and reliable method for predicting the remission of Graves' disease : revised triiodothyronine-suppression test, indexed by serum thyroxine. J Endocrinol Invest 1995 ; 18 : 288-94.
PubMed
138) Sugino K, Ito K, Mimura T, Fukunari N, Nagahama M, Ito K. Surgical treatment of Graves' disease in children. Thyroid 2004 ; 14 : 447-52.
PubMed
139) Lee JA, Grumbach MM, Clark OH. The optimal treatment for pediatric Graves' disease is surgery. J Clin Endocrinol Metab 2007 ; 92 : 801-3.
PubMed
140) Sosa JA, Tuggle CT, Wang TS, Thomas DC, Boudourakis L, Rivkees S, Roman SA. Clinical and economic outcomes of thyroid and parathyroid surgery in children. J Clin Endocrinol Metab 2008 ; 93 : 3058-65.
 
141) Tuggle CT, Roman SA, Wang TS, Boudourakis L, Thomas D, Udelsman R, Ann Sosa J. Pediatric endocrine surgery : who is operating on our children- Surgery 2008 ; 144 : 869-77.
PubMed
142) Sherman J, Thompson GB, Lteif A, Schwenk WF 2nd, van Heerden J, Farley DR, Kumar S, Zimmerman D, Churchward M, Grant CS. Surgical management of Graves disease in childhood and adolescence : an institutional experience. Surgery 2006 ; 140 : 1056-61 ; discussion 1061-2.
 
143) Bergman P, Auldist AW, Cameron F. Review of the outcome of management of Graves' disease in children and adolescents. J Paediatr Child Health 2001 ; 37 : 176-82.
PubMed
144) Sugino K, Ito K, Nagahama M, Kitagawa W, Shibuya H, Ito K. Surgical management of Graves' disease- 10-year prospective trial at a single institution. Endocr J 2008 ; 55 : 161-7.
 
145) Miccoli P, Vitti P, Rago T, Iacconi P, Bartalena L, Bogazzi F, Fiore E, Valeriano R, Chiovato L, Rocchi R, Pinchera A. Surgical treatment of Graves' disease : subtotal or total thyroidectomy? Surgery 1996 ; 120 : 1020-4 ; discussion 1024-5.
PubMed
146) Rudberg C, Johansson H, Akerstrom G, Tuvemo T, Karlsson FA. Graves' disease in children and adolescents. Late results of surgical treatment. Eur J Endocrinol 1996 ; 134 : 710-5.
PubMed
147) Feliciano DV, Lyons JD. Thyroidectomy is optimal treatment for Graves' disease. J Am Coll Surg 2011 ; 212 : 714-20.
PubMed
148) Liu J, Bargren A, Schaefer S, Chen H, Sippel RS. Total thyroidectomy : a safe and effective treatment for Graves' disease. J Surg Res 2011 ; 168 : 1-4.
PubMed
149) Cheetham TD, Hughes IA, Barnes ND, Wraight EP. Treatment of hyperthyroidism in young people. Arch Dis Child 1998 ; 78 : 207-9.
PubMed
150) Peters H, Fischer C, Bogner U, Reiners C, Schleusener H. Reduction in thyroid volume after radioiodine therapy of Graves' hyperthyroidism : results of a prospective, randomized, multicentre study. Eur J Clin Invest 1996 ; 26 : 59-63.
PubMed
151) Peters H, Fischer C, Bogner U, Reiners C, Schleusener H. Treatment of Graves' hyperthyroidism with radioiodine : results of a prospective randomized study. Thyroid 1997 ; 7 : 247-51.
PubMed
152) Rivkees SA, Sklar C, Freemark M. Clinical review 99 : The management of Graves' disease in children, with special emphasis on radioiodine treatment. J Clin Endocrinol Metab 1998 ; 83 : 3767-76.
PubMed
153) Kraiem Z, Newfield RS. Graves' disease in childhood. J Pediatr Endocrinol Metab 2001 ; 14 : 229-43.
PubMed
154) Ma C, Xie JW, Kuang AR, Liu GJ. Radioiodine treatment for pediatric Graves' disease. Cochrane Database Syst Rev 2006 ; (4) : CD006294.
 
155) Rivkees SA, Dinauer C. An optimal treatment for pediatric Graves' disease is radioiodine. J Clin Endocrinol Metab 2007 ; 92 : 797-800.
PubMed
156) 小川尚洋, 合志和人, 田尻淳一. 18歳以下のバセドウ病に対する放射性ヨード治療. 日本小児科学会雑誌 2008 ; 112 : 15-21.
 
157) 大久保忠. シンチグラムによる甲状腺重量測定法に関する研究. 日本医学放射線学会雑誌 1959 ; 19 : 120-8.
 
158) Ma C, Kuang A, Xie J, Liu G. Radioiodine treatment for pediatric Graves' disease. Cochrane Database Syst Rev 2008 ; (16) : CD006294.
PubMed
159) Levy WJ, Schumacher OP, Gupta M. Treatment of childhood Graves' disease. A review with emphasis on radioiodine treatment. Cleve Clin J Med 1988 ; 55 : 373-82.
PubMed
160) Freitas JE, Swanson DP, Gross MD, Sisson JC. Iodine-131 : optimal therapy for hyperthyroidism in children and adolescents? J Nucl Med 1979 ; 20 : 847-50.
PubMed
161) Kalinyak JE, McDougall IR. How should the dose of iodine-131 be determined in the treatment of Graves' hyperthyroidism? J Clin Endocrinol Metab 2003 ; 88 : 975-7.
PubMed
162) Zantut-Wittmann DE, Ramos CD, Santos AO, Lima MM, Panzan AD, Facuri FV, Etchebehere EC, Lima MC, Tambascia MA, Camarqo EE. High pre-therapy [99mTc] pertechnetate thyroid uptake, thyroid size and thyrostatic drugs : predictive factors of failure in [131I] iodide therapy in Graves' disease. Nucl Med Commun. 2005 ; 26 : 957-63.
 
163) Nebesio TD, Siddiqui AR, Pescovitz OH, Eugster EA. Time course to hypothyroidism after fixed-dose radioablation therapy of Graves' disease in children. J Pediatr 2002 ; 141 : 99-103.
 
164) Ueda D. Normal volume of the thyroid gland in children. J Clin Ultrasound 1990 ; 18 : 455-62.
 
165) Rivkees SA. Graves' disease therapy in children : truth and inevitable consequences. J Pediatr Endocrinol Metab 2007 ; 20 : 953-5.
PubMed
166) Kadmon PM, Noto RB, Boney CM, Goodwin G, Gruppuso PA. Thyroid storm in a child following radioactive iodine (RAI) therapy : a consequence of RAI versus withdrawal of antithyroid medication. J Clin Endocrinol Metab 2001 ; 86 : 1865-7.
 
167) Bonnema SJ, Bennedbaek FN, Gram J, Veje A, Marving J, Hegedus L. Resumption of methimazole after 131I therapy of hyperthyroid diseases : effect on thyroid function and volume evaluated by a randomized clinical trial. Eur J Endocrinol 2003 ; 149 : 485-92.
PubMed
168) Nakajo M, Tsuchimochi S, Tanabe H, Nakabeppu Y, Jinguji M. Three basic patterns of changes in serum thyroid hormone levels in Graves' disease during the one-year period after radioiodine therapy. Ann Nucl Med 2005 ; 19 : 297-308.
 
169) Rivkees SA, Cornelius EA. Influence of iodine-131 dose on the outcome of hyperthyroidism in children. Pediatrics 2003 ; 111 : 745-9.
PubMed
170) Cury AN, Meira VT, Monte O, Marone M, Scalissi NM, Kochi C, Calliari LE, Longui CA. Clinical experience with radioactive iodine in the treatment of childhood and adolescent Graves' disease. Endocr Connect. 2012 ; 2 : 32-7.
PubMed
171) Freitas JE, Swanson DP, Gross MD, Sisson JC. Iodine-131 : optimal therapy for hyperthyroidism in children and adolescents- J Nucl Med 1979 ; 20 : 847-50.
PubMed
172) Sheline GE, Lindsay S, McCormack KR, Galante M. Thyroid nodules occurring late after treatment of thryotoxicosis with radioiodine. J Clin Endocrinol Metab 1962 ; 22 : 8-18.
 
173) Boice JD Jr. Thyroid disease 60 years after Hiroshima and 20 years after Chernobyl. JAMA 2006 ; 295 : 1060-2.
PubMed
174) Boice JD Jr. Radiation-induced thyroid cancer- what's new? J Natl Cancer Inst 2005 ; 97 : 703-5.
 
175) Dobyns BM, Sheline GE, Workman JB, Tompkins EA, McConahey WM, Becker DV. Malignant and benign neoplasms of the thyroid in patients treated for hyperthyroidism : a report of the Cooperative Thyrotoxicosis Therapy Follow-up Study. J Clin Endocrinol Metab 1974 ; 38 : 976-98.
PubMed
176) Boice JD Jr. Radiation and thyroid cancer : what more can be learned? Acta Oncol 1998 ; 37 : 321-4.
PubMed
177) Dolphin GW. The risk of thyroid cancers following irradiation. Health Phys 1968 ; 15 : 219-28.
PubMed
178) Sigurdson AJ, Ronckers CM, Mertens AC, Stovall M, Smith SA, Liu Y, Berkow RL, Hammond S, Neglia JP, Meadows AT, Sklar CA, Robison LL, Inskip PD. Primary thyroid cancer after a first tumour in childhood (the Childhood Cancer Survivor Study) : a nested case-control study. Lancet 2005 ; 365 : 2014-23.
PubMed
179) Davis S, Kopecky KJ, Hamilton TE, Onstad L. Hanford Thyroid Disease Study Team. Thyroid neoplasia, autoimmune thyroiditis, and hypothyroidism in persons exposed to iodine 131 from the Hanford nuclear site. JAMA 2004 ; 292 : 2600-13.
 
180) Dickman PW, Holm LE, Lundell G, Boice JD Jr., Hall P. Thyroid cancer risk after thyroid examination with 131I : a population-based cohort study in Sweden. Int J Cancer 2003 ; 106 : 580-7.
PubMed
181) Toohey RE, Stabin MG, Watson EE. The AAPM/RSNA physics tutorial for residents : internal radiation dosimetry : principles and applications. Radiographics 2000 ; 20 : 533-46.
 
182) Committee to Assess Health Risks from Exposure to Low Levels of Ionizing Radiation, Board on Radiation Effects, Research Division on Earth and Life Studies, National Research Council of the National Academies. 2006 Health Risks from Exposure to Low Levels of Ionizing Radiation : BEIR VII-Phase 2. National Academies Press, Washington DC.
 
183) Read CH, Jr., Tansey MJ, Menda Y. A 36 year retrospective analysis of the efficacy and safety of radioactive iodine in treating young Graves' patients. J Clin Endocrinol Metab 2004 ; 89 : 4229-33.
PubMed
184) Turner N, Driver I, Salotti JA, Pearce MS, Cheetham T. Increasing use of radioiodine in young people with thyrotoxicosis in Great Britain. Eur J Endocrinol. 2012 ; 167 : 715-8.
PubMed
185) Shore RE. Issues and epidemiological evidence regarding radiation-induced thyroid cancer. Radiat Res 1992 ; 131 : 98-111.
PubMed
186) Ron E, Lubin JH, Shore RE, Mabuchi K, Modan B, Pottern LM, Schneider AB, Tucker MA, Boice JD Jr. Thyroid cancer after exposure to external radiation : a pooled analysis of seven studies. Radiat Res 1995 ; 141 : 259-77.
PubMed
187) Imaizumi M, Usa T, Tominaga T, Neriishi K, Akahoshi M, Nakashima E, Ashizawa K, Hida A, Soda M, Fujiwara S, Yamada M, Ejima E, Yokoyama N, Okubo M, Sugino K, Suzuki G, Meda R, Nagataki S, Eguchi K. Radiation dose-response relationships for thyroid nodules and autoimmune thyroid diseases in Hiroshima and Nagasaki atomic bomb survivors 55-58 years after radiation exposure. JAMA 2006 ; 295 : 1011-22.
 
188) Akamizu T, Satoh T, Isozaki O, Suzuki A, Wakino S, Iburi T, Tsuboi K, Monden T, Kouki T, Otani H, Teramukai S, Uehara R, Nakamura Y, Nagai M, Mori M. Diagnostic criteria, clinical features, and incidence of thyroid storm based on nationwide surveys. Thyroid 2012 ; 22 : 661-79.
PubMed
189) Agus MS. Endocrine emergencies. Textbook of Pediatric Emergency Medicine 6th ed. Fleisher GR, Ludwig S eds. 758-782, Lippincott Williams & Wilkins, Philadelphia, PA, 2010.
 
190) Wartofsky L. Thyrotoxic storm. Werner & Ingbar's The Thyroid : A Fundamental and Clinical Text 10th ed. Braverman LE, Cooper D eds. 481-486, Lippincott Williams & Wilkins, Philadelphia, PA, 2012.
 
191) Hecht T, Brand J, Vlaho S. Encephalopathy and sinustachycardia in childhood--a possible differential diagnosis. J Pediatr Endocrinol Metab 2012 ; 25 : 149-51.
PubMed
192) 南谷幹史, 荻田純子, 黒崎知道. 急性脳症を疑われ, 救命し得なかった, 甲状腺クリーゼの4歳女児例. 日本甲状腺学会雑誌 2014 ; 5 : 50-2.
Medical*Online
193) Burch HB, Wartofsky L. Life-threatening thyrotoxicosis. Thyroid storm. Endocrinol Metab Clin North Am 1993 ; 22 : 263-77.
PubMed

(V) カルシウムとビタミンD関連疾患

P.235 掲載の参考文献
1) Glorieux FH, et al. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998 ; 339 : 947-52.
PubMed
2) Astrom E, Soderhall S. Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch Dis Child 2002 ; 86 : 356-64.
PubMed
3) Rauch F, et al. The effects of intravenous pamidronate on the bone tissue of chiildren and adolescents with osteogenesis imperfecta. J Clin Invest 2002 ; 110 : 1293-9.
 
4) Adami S, et al. Intravenous neridronate in adults with osteogenesis imperfecta. J Bone Miner Res 2003 ; 18 : 126-30.
PubMed
5) Rauch F, et al. Osteogenesis imperfecta types I, III, and IV : effect of pamidronate therapy on bone and mineral metabolism. J Clin Endocrinol Metab 2003 ; 88 : 986-92.
 
6) Rauch F, et al. Bone mass, size, and density in children and adolescents with osteogenesis imperfecta : effect of intravenous pamidronate therapy. J Bone Miner Res 2003 ; 18 : 610-4.
PubMed
7) Zeitlin L, et al. Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IVI. Pediatrics 2003 ; 111 (5 Pt 1) : 1030-6.
 
8) Montpetit K, et al. Rapid increase in grip force after start of pamidronate therapy in children and adolescents with severe osteogenesis imperfecta. Pediatrics 2003 ; 111 (5 Pt 1) : e601-3.
 
9) Grissom LE, Harcke HT. Radiographic features of bisphosphonate therapy in pediatric patients. Pediatr Radiol 2003 ; 33 : 226-9.
PubMed
10) Maasalu K, et al. Treatment of children with Osteogenesis imperfecta in Estonia. Acta Paediatr 2003 ; 92 : 452-5.
PubMed
11) 篠原麻由. 骨形成不全症に対するビスフォスフォネートの効果. 日児誌 2002 ; 106 : 1427-33.
 
P.243 掲載の参考文献
1) Aggarwal V, Seth A, Aneja S, et al. Role of calcium deficiency in development of nutritional rickets in Indian children : a case control study. J Clin Endocrinol Metab 97 (10) : 3461-6, 2012.
PubMed
2) Beck-Nielsen SS. Rickets in Denmark. Dan Med J 59 (2) : B4384, 2012.
PubMed
3) Bikle DD. Vitamin D and bone. Curr Osteoporos Rep 10 (2) : 151-9, 2012.
PubMed
4) Carpenter TO, Herreros F, Zhang JH, et al. Demographic, dietary, and biochemical determinants of vitamin D status in inner-city children. Am J Clin Nutr 95 (1) : 137-46, 2012.
PubMed
5) Cianferotti L, Marcocci C. Subclinical vitamin D deficiency. Best Pract Res Clin Endocrinol Metab 26 (4) : 523-37, 2012.
PubMed
6) Holick MF, Lim R, Dighe AS. Case records of the Massachusetts General Hospital. Case 3-2009 : A 9-Month-Old Boy with Seizures. N Engl J Med 360 (4) : 398-407, 2009.
PubMed
7) Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, Treatment, and Prevention of Vitamin D Deficiency : an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 96 (7) : 1911-30, 2011.
PubMed
8) Kashyap AS, Anand KP, Kashyap S. Case 3-2009 : A 9-Month-Old Boy with Seizures. N Engl J Med 360 (15) : 1572-4, 2009.
PubMed
9) Kitanaka S, Isojima T, Takaki M, et al. Association of vitamin D-related gene polymorphisms with manifestation of vitamin D deficiency in children. Endocr J 59 (11) : 1007-14, 2012.
PubMed
10) Kubota T, Kotani T, Miyoshi Y, et al. A Spectrum of Clinical Presentations in Seven Japanese Patients with Vitamin D Deficiency. Clin Pediatr Endocrinol 15 (1) : 23-8, 2006.
PubMed
11) Lieben L, Carmeliet G, Masuyama R. Calcemic actions of vitamin D : Effects on the intestine, kidney and bone. Best Pract Res Clin Endocrinol Metab 25 (4) : 561-72, 2011.
PubMed
12) Matsuo K, Mukai T, Suzuki S, et al. Prevalence and risk factors of vitamin D deficiency rickets in Hokkaido, Japan. Pediatr Int 51 (4) : 559-62, 2009.
PubMed
13) Mehrotra P, Marwaha RK, Aneja S, et al. Hypovitaminosis D and Hypocalcemic Seizures in Infancy. Indian Pediatr 47 (7) : 581-6, 2010.
PubMed
14) Misra M, Pacaud D, Petryk A, et al. Vitamin D Deficiency in Children and Its Management : Review of Current Knowledge and Recommendations. Pediatrics 122 (2) : 398-417, 2008.
PubMed
15) Miyako K, Kinjo S, Kohno H. Vitamin D deficiency rickets caused by improper lifestyle in Japanese children. Pediatr Int 47 (2) : 142-6, 2005.
PubMed
16) Mughal MZ. Rickets. Curr Osteoporos Rep 9 (4) : 291-9, 2011.
PubMed
17) Munns CF, Simm PJ, Rodda CP, et al. Incidence of vitamin D deficiency rickets among Australian children : an Australian Paediatric Surveillance Unit study. Med J Aust 196 (7) : 466-8, 2012.
PubMed
18) Ozkan B. Nutritional Rickets. J Clin Res Pediatr Endocrinol 2 (4) : 137-43, 2010.
PubMed
19) Perez-Rossello JM, Feldman HA, Kleinman PK, et al. Rachitic Changes, Demineralization, and Fracture Risk in Healthy Infants and Toddlers with Vitamin D Deficiency. Radiology 262 (1) : 234-41, 2012.
PubMed
20) Rajah J, Thandrayen K, Pettifor JM. Clinical practice : Diagnostic approach to the rachitic child. Eur J Pediatr 170 (9) : 1089-96, 2011.
 
21) Rosen CJ, Abrams SA, Aloia JF, et al. IOM Committee Members Respond to Endocrine Society Vitamin D Guideline. J Clin Endocrinol Metab 97 (4) : 1146-52, 2012.
PubMed
22) Ross AC, Manson JE, Abrams SA, et al. The 2011 Report on Dietary Reference Intakes for Calcium and Vitamin D from the Institute of Medicine : What Clinicians Need to Know. J Clin Endocrinol Metab 96 (1) : 53-8, 2011.
 
23) Sahay M, Sahay R. Rickets-vitamin D deficiency and dependency. Indian J Endocrinol Metab 16 (2) : 164-76, 2012.
PubMed
24) Santos BR, Mascarenhas LP, Satler F, et al. Vitamin D deficiency in girls from South Brazil : a cross-sectional study on prevalence and association with vitamin D receptor gene variants. BMC Pediatr 12 : 62, 2012.
 
25) Thacher TD, Fischer PR, Isichei CO, et al. Prevention of nutritional rickets in Nigerian children with dietary calcium supplementation. Bone 50 (5) : 1074-80, 2012.
PubMed
26) Yorifuji J, Yorifuji T, Tachibana K, et al. Craniotabes in Normal Newborns : The Earliest Sign of Subclinical Vitamin D Deficiency. J Clin Endocrinol Metab 93 (5) : 1784-8, 2008.
PubMed

(VI) 糖代謝異常症

P.266 掲載の参考文献
1) Advances in diagnosis and treatment of hyperinsulinism in infants and children. Stanley CA. J Clin Endocrinol Metab. 2002 ; 87 : 4857-9. 「高」
 
2) Mechanisms of Disease : advances in diagnosis and treatment of hyperinsulinism in neonates. De Leon DD, Stanley CA. Nat Clin Pract Endocrinol Metab. 2007 ; 3 : 57-68. 「高」
 
3) 川北理恵, 杉峰啓憲, 長井静世, 河井昌彦, 楠田聡, 依藤亨. 本邦における先天性高インスリン血症の実態調査. 日児誌 2011 ; 115 ; 563-9. 「中」
 
4) Menni F, de Lonlay P, Sevin C, Touati G, Peigne C, Barbier V, Nihoul-Fekete C, Saudubray JM, Robert JJ. Neurologic outcomes of 90 neonates and infants with persistent hyperinsulinemic hypoglycemia. Pediatrics. 2001 ; 107 : 476-9. 「中」
 
5) Ludwig A, Ziegenhorn K, Empting S, Meissner T, Marquard J, Holl R ; Diabetes Patienten-Verlaufsdokumentationssystem (DPV) Group, Mohnike K. Glucose metabolism and neurological outcome in congenital hyperinsulinism. Semin Pediatr Surg. 2011 ; 20 : 45-9. 「中」
 
6) Arnoux JB, Verkarre V, Saint-Martin C, Montravers F, Brassier A, Valayannopoulos V, Brunelle F, Fournet JC, Robert JJ, Aigrain Y, Bellanne-Chantelot C, de Lonlay P. Congenital hyperinsulinism : current trends in diagnosis and therapy. Orphanet J Rare Dis. 2011 ; 6 : 63. 「高」
 
7) Senniappan S, Shanti B, James C, Hussain K. Hyperinsulinaemic hypoglycaemia : genetic mechanisms, diagnosis and management. J Inherit Metab Dis. 2012 ; 35 : 589-601. 「高」
 
8) Sweet CB, Grayson S, Polak M. Management strategies for neonatal hypoglycemia. J Pediatr Pharmacol Ther. 2013 ; 18 : 199-208. 「高」
 
9) Lord K, De Leon DD. Monogenic hyperinsulinemic hypoglycemia : current insights into the pathogenesis and management. Int J Pediatr Endocrinol. 2013 ; 2013 (1) : 3. 「高」
 
10) Arya VB, Mohammed Z, Blankenstein O, De Lonlay P, Hussain K. Hyperinsulinaemic hypoglycaemia. Horm Metab Res. 2014 ; 46 : 157-70. 「高」
 
11) Yorifuji T. congenital hyperinsulinism : current status and future perspectives. Ann Pediatr Endocrinol Metab. 2014 ; 19 : 57-68. 「高」
 
12) Yorifuji T, Masue M, Nishibori H. Congenital hyperinsulinism : global and Japanese perspectives. Pediatr Int. 2014 ; 56 : 467-76. 「高」
 
13) Shah P, Demirbilek H, Hussain K. Persistent hyperinsulinaemic hypoglycaemia in infancy. Semin Pediatr Surg. 2014 ; 23 : 76-82. 「高」
 
14) Guemes M, Hussain K. Hyperinsulinemic Hypoglycemia. Pediatr Clin North Am. 2015 ; 62 : 1017-36. 「高」
 
15) Vora S, Chandran S, Rajadurai VS, Hussain K. Hyperinsulinemic Hypoglycemia in Infancy : Current Concepts in Diagnosis and Management. Indian Pediatr. 2015 ; 52 : 1051-9. 「高」
 
16) Stanley CA. Perspective on the Genetics and Diagnosis of Congenital Hyperinsulinism Disorders. J Clin Endocrinol Metab. 2016 ; 101 : 815-26. 「高」
 
17) Arya VB, Senniappan S, Demirbilek H, Alam S, Flanagan SE, Ellard S, Hussain K. Pancreatic endocrine and exocrine function in children following near-totalpancreatectomy for diffuse congenital hyperinsulinism. PLoS One. 2014 ; 9 : e98054. 「中」
 
18) Beltrand J, Caquard M, Arnoux JB, Laborde K, Velho G, Verkarre V, Rahier J, Brunelle F, Nihoul-Fekete C, Saudubray JM, Robert JJ, de Lonlay P. Glucose metabolism in 105 children and adolescents after pancreatectomy for congenital hyperinsulinism. Diabetes Care. 2012 ; 35 : 198-203. 「中」
 
19) Gopal-Kothandapani JS, Hussain K. Congenital hyperinsulinism : Role of fluorine-18L-3, 4 hydroxyphenylalanine positron emission tomography scanning. World J Radiol. 2014 ; 6 : 252-60. 「高」
 
20) Yang J, Hao R, Zhu X. Diagnostic role of 18F-dihydroxyphenylalanine positron emission tomography in patients with congenital hyperinsulinism : a meta-analysis. Nucl Med Commun. 2013 ; 34 : 347-53. 「高」
 
21) Treglia G, Mirk P, Giordano A, Rufini V. Diagnostic performance of fluorine-18-dihydroxyphenylalanine positron emission tomography in diagnosing and localizing the focal form of congenital hyperinsulinism : a meta-analysis. Pediatr Radiol. 2012 ; 42 : 1372-9. 「高」
 
22) Blomberg BA, Moghbel MC, Saboury B, Stanley CA, Alavi A. The value of radiologic interventions and (18) F-DOPA PET in diagnosing and localizing focal congenital hyperinsulinism : systematic review and meta-analysis. Mol Imaging Biol. 2013 ; 15 : 97-105. 「高」
 
23) Banerjee I, Skae M, Flanagan SE, Rigby L, Patel L, Didi M, Blair J, Ehtisham S, Ellard S, Cosgrove KE, Dunne MJ, Clayton PE. The contribution of rapid KATP channel gene mutation analysis to the clinical management of children with congenital hyperinsulinism. Eur J Endocrinol. 2011 ; 164 : 733-40. 「中」
 
24) Banerjee I, Avatapalle B, Padidela R, Stevens A, Cosgrove KE, Clayton PE, Dunne MJ. Integrating genetic and imaging investigations into the clinical management of congenital hyperinsulinism. Clin Endocrinol (Oxf). 2013 ; 78 : 803-13. 「中」
 
25) Laje P, Stanley CA, Palladino AA, Becker SA, Adzick NS. Pancreatic head resection and Roux-en-Y pancreaticojejunostomy for the treatment of the focal form of congenital hyperinsulinism. J Pediatr Surg. 2012 ; 47 : 130-5. 「中」
 
26) Rahman SA, Nessa A, Hussain K. Molecular mechanisms of congenital hyperinsulinism. J Mol Endocrinol. 2015 ; 54 : R119-29. 「低」
 
27) Sempoux C, Capito C, Bellanne-Chantelot C, Verkarre V, de Lonlay P, Aigrain Y, Fekete C, Guiot Y, Rahier J. Morphological mosaicism of the pancreatic islets : a novel anatomopathological form of persistent hyperinsulinemic hypoglycemia of infancy. J Clin Endocrinol Metab. 2011 ; 96 : 3785-93. 「中」
 
28) Hussain K, Flanagan SE, Smith VV, Ashworth M, Day M, Pierro A, Ellard S. An ABCC8 gene mutation and mosaic uniparental isodisomy resulting in atypical diffuse congenital hyperinsulinism. Diabetes. 2008 ; 57 : 259-63. 「低」
 
29) Sheffield BS, Yip S, Ruchelli ED, Dunham CP, Sherwin E, Brooks PA, Sur A, Singh A, Human DG, Patel MS, Lee AF. Fatal congenital hypertrophic cardiomyopathy and a pancreatic nodule morphologically identical to focal lesion of congenital hyperinsulinism in an infant with costello syndrome : case report and review of the literature. Pediatr Dev Pathol. 2015 ; 18 : 237-44. 「低」
 
30) Gripp KW, Robbins KM, Sheffield BS, Lee AF, Patel MS, Yip S, Doyle D, Stabley D, Sol-Church K. Paternal uniparental disomy 11p15.5 in the pancreatic nodule of an infant with Costello syndrome : Shared mechanism for hyperinsulinemic hypoglycemia in neonates with Costello and Beckwith-Wiedemann syndrome and somatic loss of heterozygosity in Costello syndrome driving clonal expansion. Am J Med Genet A. 2016 ; 170 : 559-64. 「低」
 
31) Welters A, Lerch C, Kummer S, Marquard J, Salgin B, Mayatepek E, Meissner T. Long-term medical treatment in congenital hyperinsulinism : a descriptive analysis in a large cohort of patients from different clinical centers. Orphanet J Rare Dis. 2015 ; 10 : 150. 「中」
 
32) Gussinyer M, Clemente M, Cebrian R, Yeste D, Albisu M, Carrascosa A. Glucose intolerance and diabetes are observed in the long-term follow-up of nonpancreatectomized patients with persistent hyperinsulinemic hypoglycemia of infancy due to mutations in the ABCC8 gene. Diabetes Care. 2008 ; 31 : 1257-9. 「中」
 
33) Thornton PS, Stanley CA, De Leon DD, Harris D, Haymond MW, Hussain K, Levitsky LL, Murad MH, Rozance PJ, Simmons RA, Sperling MA, Weinstein DA, White NH, Wolfsdorf JI ; Pediatric Endocrine Society. Recommendations from the Pediatric Endocrine Society for Evaluation and Management of Persistent Hypoglycemia in Neonates, Infants, and Children. J Pediatr. 2015 ; 167 : 238-45. 「高」
 
34) Srinivasan G, Pildes RS, Cattamanchi G, Voora S, Lilien LD. Plasma glucose values in normal neonates : a new look. J Pediatr. 1986 ; 109 : 114-7. 「中」
 
35) Stanley CA, Rozance PJ, Thornton PS, De Leon DD, Harris D, Haymond MW, Hussain K, Levitsky LL, Murad MH, Simmons RA, Sperling MA, Weinstein DA, White NH, Wolfsdorf JI. Re-evaluating "transitional neonatal hypoglycemia" : mechanism and implications for management. J Pediatr. 2015 ; 166 : 1520-5. e1. 「中」
 
36) De Leon DD, Stanley CA. Determination of insulin for the diagnosis of hyperinsulinemic hypoglycemia. Best Pract Res Clin Endocrinol Metab. 2013 ; 27 : 763-9. 「高」
 
37) Placzkowski KA, Vella A, Thompson GB, Grant CS, Reading CC, Charboneau JW, Andrews JC, Lloyd RV, Service FJ. Secular trends in the presentation and management of functioning insulinoma at the Mayo Clinic, 1987-2007. J Clin Endocrinol Metab. 2009 ; 94 : 1069-73. 「中」
 
38) Nauck MA, Meier JJ. Diagnostic accuracy of an"amended"insulin-glucose ratio for the biochemical diagnosis of insulinomas. Ann Intern Med. 2012 ; 157 : 767-75. 「中」
 
39) Ferrara C, Patel P, Becker S, Stanley CA, Kelly A. Biomarkers of Insulin for the Diagnosis of Hyperinsulinemic Hypoglycemia in Infants and Children. J Pediatr. 2016 ; 168 : 212-9. 「中」
 
40) 日本小児内分泌学会薬事委員会. 高インスリン血性低血糖症の診断と治療ガイドライン. 日児誌 2006 ; 110 : 1472-4. 「高」
 
41) van Veen MR, van Hasselt PM, de Sain-van der Velden MG, Verhoeven N, Hofstede FC, de Koning TJ, Visser G. Metabolic profiles in children during fasting. Pediatrics. 2011 ; 127 : e1021-7. 「中」
 
42) Brady C, Palladino AA, Gutmark-Little I. A novel case of compound heterozygous congenital hyperinsulinism without high insulin levels. Int J Pediatr Endocrinol. 2015 ; 2015 : 16. 「低」
 
43) Finegold DN, Stanley CA, Baker L. Glycemic response to glucagon during fasting hypoglycemia : an aid in the diagnosis of hyperinsulinism. J Pediatr. 1980 ; 96 : 257-9. 「中」
 
44) Seaquist ER et al. : Hypoglycemia and diabetes : a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013 ; 36 : 1384-95e. 「高」
 
45) Ly TT, Maahs DM, Rewers A, Dunger D, Oduwole A, Jones TW. ISPAD Clinical Practice Consensus Guidelines-Hypoglycemia : Assessment and management of hypoglycemia in children and adolescents with diabetes. Pediatric Diabetes. 2014 : 15 (Suppl. 20) : 180-92. 「高」
 
46) Gataullina S, Dellatolas G, Perdry H, Robert JJ, Valayannopoulos V, Touati G, Ottolenghi C, Dulac O, De Lonlay P. Comorbidity and metabolic context are crucial factors determining neurological sequelae of hypoglycaemia. Dev Med Child Neurol. 2012 ; 54 : 1012-7. 「中」
 
47) Lucas A, Morley R, Cole TJ. Adverse neurodevelopmental outcome of moderate neonatal hypoglycaemia. BMJ. 1988 ; 297 : 1304-8. 「中」
 
48) McKinlay CJ, Alsweiler JM, Ansell JM, Anstice NS, Chase JG, Gamble GD, Harris DL, Jacobs RJ, Jiang Y, Paudel N, Signal M, Thompson B, Wouldes TA, Yu TY, Harding JE ; CHYLD Study Group. Neonatal Glycemia and Neurodevelopmental Outcomes at 2 Years. N Engl J Med. 2015 ; 373 : 1507-18. 「高」
 
49) Vannucci RC, Vannucci SJ. Glucose metabolism in the developing brain. Semin Perinatol. 2000 ; 24 : 107-15. 「高」
 
50) Arnoux JB, de Lonlay P, Ribeiro MJ, Hussain K, Blankenstein O, Mohnike K, Valayannopoulos V, Robert JJ, Rahier J, Sempoux C, Bellanne C, Verkarre V, Aigrain Y, Jaubert F, Brunelle F, Nihoul-Fekete C. Congenital hyperinsulinism. Early Hum Dev. 2010 ; 86 : 287-94. 「高」
 
51) Shah KK, O'Dell SD. Effect of dietary interventions in the maintenance of normoglycaemia in glycogen storage disease type 1a : a systematic review and meta-analysis. J Hum Nutr Diet. 2013 ; 26 : 329-39. 「高」
 
52) Mohamed Z, Arya VB, Hussain K. Hyperinsulinaemic hypoglycaemia : genetic mechanisms, diagnosis and management. J Clin Res Pediatr Endocrinol. 2012 ; 4 : 169-81. 「高」
 
53) 岩崎陽子, 鴨田知博, 滝沢文彦, 小野敏明, 大久保久美子, 松井陽. ジアゾキサイドおよびコーンスターチの併用療法を行っている乳児持続性高インスリン血症性低血糖 (PHHI) の1例. ホルモンと臨床. 2006 ; 54 (11) : 1037-41. 「低」
 
54) 松原康策, 和田珠希, 依藤亨, 増江道哉, 西堀弘記, 磯目賢一, 由良和夫, 仁紙宏之, 深谷隆. 3年間のオクトレオチド持続皮下注射により膵手術を回避できた先天性高インスリン血症. 日児誌. 2011 ; 115 (9) : 1445-50. 「低」
 
55) Froissart R, Piraud M, Boudjemline AM, Vianey-Saban C, Petit F, Hubert-Buron A, Eberschweiler PT, Gajdos V, Labrune P. Glucose-6-phosphatase deficiency. Orphanet J Rare Dis. 2011 ; 6 : 27. 「高」
 
56) 登録特殊ミルク共同安全事業安全開発委員会編. 2013年度改訂「わかりやすい肝型糖原病食事療法」母子愛育会. (http://www.boshiaiikukai.jp/img/milk/kangata-togenbyo.pdf)
 
57) Yildizdas D, Erdem S, Kucukosmanoglu O, Yilmaz M, Yuksel B. Pulmonary hypertension, heart failure and neutropenia due to diazoxide therapy. Adv Ther. 2008 ; 25 : 515-9. 「低」
 
58) Demirel F, Unal S, Cetin II, Esen I, Arasli A. Pulmonary hypertension and reopening of the ductus arteriosus in an infant treated with diazoxide. J Pediatr Endocrinol Metab. 2011 ; 24 : 603-5. 「低」
 
59) Ponmani C, Gannon H, Hussain K, Senniappan S. Paradoxical hypoglycaemia associated with diazoxide therapy for hyperinsulinaemic hypoglycaemia. Horm Res Paediatr. 2013 ; 80 : 129-33. 「低」
 
60) Yoshida K, Kawai M, Marumo C, Kanazawa H, Matsukura T, Kusuda S, Yorifuji T, Heike T. High prevalence of severe circulatory complications with diazoxide in premature infants. Neonatology. 2014 ; 105 : 166-71. 「中」
 
61) Glaser B, Hirsch HJ, Landau H. Persistent hyperinsulinemic hypoglycemia of infancy : long-term octreotide treatment without pancreatectomy. J Pediatr. 1993 ; 123 : 644-50. 「中」
 
62) Thornton PS, Alter CA, Katz LE, Baker L, Stanley CA. Short- and long-term use of octreotide in the treatment of congenital hyperinsulinism. J Pediatr. 1993 ; 123 : 637-43. 「中」
 
63) Yorifuji T, Kawakita R, Hosokawa Y, Fujimaru R, Matsubara K, Aizu K, Suzuki S, Nagasaka H, Nishibori H, Masue M. Efficacy and safety of long-term, continuous subcutaneous octreotide infusion for patients with different subtypes of KATP-channel hyperinsulinism. Clin Endocrinol (Oxf). 2013 ; 78 : 891-7. 「中」
 
64) Demirbilek H, Shah P, Arya VB, Hinchey L, Flanagan SE, Ellard S, Hussain K. Long-term follow-up of children with congenital hyperinsulinism on octreotide therapy. J Clin Endocrinol Metab. 2014 ; 99 : 3660-7. 「中」
 
65) Testoni D, Hornik CP, Neely ML, Yang Q, McMahon AW, Clark RH, Smith PB ; Best Pharmaceuticals for Children Act-Pediatric Trials Network Administrative Core Committee. Safety of octreotide in hospitalized infants. Early Hum Dev. 2015 ; 91 : 387-92. 「中」
 
66) Avatapalle B, Padidela R, Randell T, Banerjee I. Drug-induced hepatitis following use of octreotide for long-term treatment of congenital hyperinsulinism. BMJ Case Rep. 2012 ; 2012. 「低」
 
67) Ben-Ari J, Greenberg M, Nemet D, Edelstein E, Eliakim A. Octreotide-induced hepatitis in a child with persistent hyperinsulinemia hypoglycemia of infancy. J Pediatr Endocrinol Metab. 2013 ; 26 : 179-82. 「低」
 
68) Koren I, Riskin A, Barthlen W, Gillis D. Hepatitis in an infant treated with octreotide for congenital hyperinsulinism. J Pediatr Endocrinol Metab. 2013 ; 26 : 183-5. 「低」
 
69) Celik N, Cinaz P, Emeksiz HC, Hussain K, Camurdan O, Bideci A, Doger E, Yuce O, Turkyilmaz Z, Oguz AD. Octreotide-induced long QT syndrome in a child with congenital hyperinsulinemia and a novel missense mutation (p.Met115Val) in the ABCC8 gene. Horm Res Paediatr. 2013 ; 80 : 299-303. 「低」
 
70) Laje P, Halaby L, Adzick NS, Stanley CA. Necrotizing enterocolitis in neonates receiving octreotide for the management of congenital hyperinsulinism. Pediatr Diabetes. 2010 ; 11 : 142-7. 「低」
 
71) Hawkes CP, Adzick NS, Palladino AA, De Leon DD. Late Presentation of Fulminant Necrotizing Enterocolitis in a Child with Hyperinsulinism on Octreotide Therapy. Horm Res Paediatr. 2016 Feb 12. 「低」
 
72) Batra YK, Rajeev S, Samra T, Rao KL. Octreotide-induced severe paradoxical hyperglycemia and bradycardia during subtotal pancreatectomy for congenital hyperinsulinism in an infant. Paediatr Anaesth. 2007 ; 17 : 1117-9. 「低」
 
73) Neylon OM, Moran MM, Pellicano A, Nightingale M, O'Connell MA. Successful subcutaneous glucagon use for persistent hypoglycaemia in congenital hyperinsulinism. J Pediatr Endocrinol Metab. 2013 ; 26 : 1157-61. 「低」
 
74) Mohnike K, Blankenstein O, Pfuetzner A, Potzsch S, Schober E, Steiner S, Hardy OT, Grimberg A, van Waarde WM. Long-term non-surgical therapy of severe persistent congenital hyperinsulinism with glucagon. Horm Res. 2008 ; 70 : 59-64. 「低」
 
75) Bas F, Darendeliler F, Demirkol D, Bundak R, Saka N, Gunoz H. Successful therapy with calcium channel blocker (nifedipine) in persistent neonatal hyperinsulinemic hypoglycemia of infancy. J Pediatr Endocrinol Metab. 1999 ; 12 : 873-8. 「低」
 
76) Durmaz E, Flanagan SE, Parlak M, Ellard S, Akcurin S, Bircan I. A combination of nifedipine and octreotide treatment in an hyperinsulinemic hypoglycemic infant. J Clin Res Pediatr Endocrinol. 2014 ; 6 : 119-21. 「低」
 
77) Koklu E, Ozkan KU, Sayar H, Koklu S, Keskin M. Treatment of hyperinsulinemic hypoglycemia because of diffuse nesidioblastosis with nifedipine after surgical therapies in a newborn. J Pediatr Endocrinol Metab. 2013 ; 26 : 1153-6. 「低」
 
78) Snider KE, Becker S, Boyajian L, Shyng SL, MacMullen C, Hughes N, Ganapathy K, Bhatti T, Stanley CA, Ganguly A. Genotype and phenotype correlations in 417 children with congenital hyperinsulinism. J Clin Endocrinol Metab. 2013 ; 98 : E355-63. 「中」
 
79) Kapoor RR, Flanagan SE, Arya VB, Shield JP, Ellard S, Hussain K. Clinical and molecular characterisation of 300 patients with congenital hyperinsulinism. Eur J Endocrinol. 2013 ; 168 : 557-64. 「中」
 
80) 長井静世, 依藤亨, 土井拓, 河井昌彦, 百井亨, 岡本晋弥, 土井隆一郎, 中本裕士, 増江道哉, 加古伸雄, 岡本浩之, 加藤英治, 長沖優子, 上本伸二, 中畑龍俊. 集学的アプローチにより腫瘍核出術をしえた局所型先天性高インスリン血症. 日本小児科学会誌. 2009 ; 113 : 838-49. 「低」
 
81) Yorifuji T, Kawakita R, Nagai S, Sugimine A, Doi H, Nomura A, Masue M, Nishibori H, Yoshizawa A, Okamoto S, Doi R, Uemoto S, Nagasaka H. Molecular and clinical analysis of Japanese patients with persistent congenital hyperinsulinism : predominance of paternally inherited monoallelic mutations in the KATP channel genes. J Clin Endocrinol Metab. 2011 ; 96 : E141-5. 「中」
 
82) Ismail D, Hussain K. Role of 18F-DOPA PET/CT imaging in congenital hyperinsulinism. Rev Endocr Metab Disord. 2010 ; 11 : 165-9. 「高」
 
83) Capito C, Khen-Dunlop N, Ribeiro MJ, Brunelle F, Aigrain Y, Cretolle C, Jaubert F, De Lonlay P, Nihoul-Fekete C. Value of 18F-fluoro-L-dopa PET in the preoperative localization of focal lesions in congenital hyperinsulinism. Radiology. 2009 ; 253 : 216-22. 「中」
 
84) Mohnike K, Blankenstein O, Christesen HT, De Lonlay J, Hussain K, Koopmans KP, Minn H, Mohnike W, Mutair A, Otonkoski T, Rahier J, Ribeiro M, Schoenle E, Fekete CN. Proposal for a standardized protocol for 18F-DOPA-PET (PET/CT) in congenital hyperinsulinism. Horm Res. 2006 ; 66 : 40-2. 「中」
 
85) Mohnike K, Blankenstein O, Minn H, Mohnike W, Fuchtner F, Otonkoski T. [18F] -DOPA positron emission tomography for preoperative localization in congenital hyperinsulinism. Horm Res. 2008 ; 70 : 65-72. 「中」
 
86) Barthlen W, Blankenstein O, Mau H, Koch M, Hohne C, Mohnike W, Eberhard T, Fuechtner F, Lorenz-Depiereux B, Mohnike K. Evaluation of [18F] fluoro-L-DOPA positron emission tomography-computed tomography for surgery in focal congenital hyperinsulinism. J Clin Endocrinol Metab. 2008 ; 93 : 869-75. 「中」
 
87) Ribeiro MJ, Boddaert N, Delzescaux T, Valayannopoulos V, Bellanne-Chantelot C, Jaubert F, Verkarre V, Nihoul-Fekete C, Brunelle F, De Lonlay P. Functional imaging of the pancreas : the role of [18F] fluoro-L-DOPA PET in the diagnosis of hyperinsulinism of infancy. Endocr Dev. 2007 ; 12 : 55-66. 「中」
 
88) Hardy OT, Hernandez-Pampaloni M, Saffer JR, Scheuermann JS, Ernst LM, Freifelder R, Zhuang H, MacMullen C, Becker S, Adzick NS, Divgi C, Alavi A, Stanley CA. Accuracy of [18F] fluorodopa positron emission tomography for diagnosing and localizing focal congenital hyperinsulinism. J Clin Endocrinol Metab. 2007 ; 92 : 4706-11. 「中」
 
89) Kuhnen P, Matthae R, Arya V, Hauptmann K, Rothe K, Wachter S, Singer M, Mohnike W, Eberhard T, Raile K, Lauffer LM, Iakoubov R, Hussain K, Blankenstein O. Occurrence of giant focal forms of congenital hyperinsulinism with incorrect visualization by (18) F DOPA-PET/CT scanning. Clin Endocrinol (Oxf). 2014 ; 81 : 847-54. 「低」
 
90) Masue M, Nishibori H, Fukuyama S, Yoshizawa A, Okamoto S, Doi R, Uemoto S, Tokumi T, Kasai T, Yorifuji T. Diagnostic accuracy of [18F] -fluoro-L-dihydroxyphenylalanine positron emission tomography scan for persistent congenital hyperinsulinism in Japan. Clin Endocrinol (Oxf). 2011 ; 7 (5 3) : 342-6. 「中」
 
91) Barthlen W, Mohnike W, Mohnike K. Techniques in pediatric surgery : congenital hyperinsulinism. Horm Res Paediatr. 2011 ; 75 : 304-10. 「中」
 
92) 増江道哉, 西堀弘記, 高田勲矢, 依藤亨. 先天性高インスリン血症の18F-DOPA PETによる局在診断と治療予後. 日児誌. 2014 ; 118 : 1342-9. 「中」
 
93) Soheilipour F, Jesmi F, Ahmadi M, Pazouki A, Alibeigi P, Abdolhosseini M. Minimally invasive surgical interventions in the treatment of primary persistent hyperinsulinemic hypoglycemia of infancy. Arch Endocrinol Metab. 2015 ; 59 : 466-9. 「低」
 
94) Liem NT, Son TN, Hoan NT. Laparoscopic near-total pancreatectomy for persistent hyperinsulinemic hypoglycemia of infancy : report of two cases. J Laparoendosc Adv Surg Tech A. 2010 ; 20 : 115-7. 「低」
 
95) Blakely ML, Lobe TE, Cohen J, Burghen GA. Laparoscopic pancreatectomy for persistent hyperinsulinemic hypoglycemia of infancy. Surg Endosc. 2001 ; 15 : 897-8. 「低」
 
96) Al-Shanafey S. Laparoscopic vs open pancreatectomy for persistent hyperinsulinemic hypoglycemia of infancy. J Pediatr Surg. 2009 ; 44 : 957-61. 「中」
 
97) Murakami M, Mushiake S, Kashiwagi H, Etani Y, Miyoshi Y, Ozono K. A case of persistent hyperinsulinemic hypoglycemia of infancy successfully managed with subcutaneous octreotide injection and nocturnal intravenous glucose supply. Clin Pediatr Endocrinol. 2007 ; 16 : 75-80. 「低」
 
98) Mazor-Aronovitch K, Landau H, Gillis D. Surgical versus non-surgical treatment of congenital hyperinsulinism. Pediatr Endocrinol Rev. 2009 ; 6 : 424-30. 「低」
 
99) Mazor-Aronovitch K, Gillis D, Lobel D, Hirsch HJ, Pinhas-Hamiel O, Modan-Moses D, Glaser B, Landau H. Long-term neurodevelopmental outcome in conservatively treated congenital hyperinsulinism. Eur J Endocrinol. 2007 ; 157 : 491-7. 「中」
 
100) Lovvorn HN 3rd, Nance ML, Ferry RJ Jr, Stolte L, Baker L, O'Neill JA Jr, Schnaufer L, Stanley CA, Adzick NS. Congenital hyperinsulinism and the surgeon : lessons learned over 35 years. J Pediatr Surg. 1999 ; 34 : 786-92. 「中」
 
101) de Lonlay-Debeney P, Poggi-Travert F, Fournet JC, Sempoux C, Dionisi Vici C, Brunelle F, Touati G, Rahier J, Junien C, Nihoul-Fekete C, Robert JJ, Saudubray JM. Clinical features of 52 neonates with hyperinsulinism. N Engl J Med. 1999 ; 340 : 1169-75. 「中」
 
102) Suchi M, Thornton PS, Adzick NS, MacMullen C, Ganguly A, Stanley CA, Ruchelli ED. Congenital hyperinsulinism : intraoperative biopsy interpretation can direct the extent of pancreatectomy. Am J Surg Pathol. 2004 ; 28 : 1326-35. 「中」
 
103) Leibowitz G, Glaser B, Higazi AA, Salameh M, Cerasi E, Landau H. Hyperinsulinemic hypoglycemia of infancy (nesidioblastosis) in clinical remission : high incidence of diabetes mellitus and persistent beta-cell dysfunction at long-term follow-up. J Clin Endocrinol Metab. 1995 ; 80 : 386-92. 「中」
 
104) Shilyansky J, Fisher S, Cutz E, Perlman K, Filler RM. Is 95% pancreatectomy the procedure of choice for treatment of persistent hyperinsulinemic hypoglycemia of the neonate? J Pediatr Surg. 1997 ; 32 (2) : 342-6. 「低」
 
105) Cherian MP, Abduljabbar MA. Persistent hyperinsulinemic hypoglycemia of infancy (PHHI) : Long-term outcome following 95% pancreatectomy. J Pediatr Endocrinol Metab. 2005 ; 18 : 1441-8. 「中」
 
106) Barthlen W, Mohnike W, Mohnike K. Techniques in pediatric surgery : congenital hyperinsulinism. Horm Res Paediatr. 2010 ; 74 : 438-43. 「中」
 
107) Palladino AA, Stanley CA. A specialized team approach to diagnosis and medical versus surgical treatment of infants with congenital hyperinsulinism. Semin Pediatr Surg. 2011 ; 20 : 32-7. 「中」
 
108) McAndrew HF, Smith V, Spitz L. Surgical Complications of Pancreatectomy for Persistent Hyperinsulinaemic Hypoglycaemia of Infancy. J Pediatr Surg. 2003 ; 38 : 13-6. 「低」
 
109) Fekete CN, de Lonlay P, Jaubert F, Rahier J, Brunelle F, Saudubray. The surgical management of congenital hyperinsulinemic hypoglycemia in infancy. J Pediatr Surg. 2004 ; 39 : 267-9. 「中」
 
110) Adzick NS, Thornton PS, Stanley CA, Kaye RD, Ruchelli E. A multidisciplinary approach to the focal form of congenital hyperinsulinism leads to successful treatment by partial pancreatectomy. J Pediatr Surg. 2004 ; 39 : 270-5. 「中」
 
111) Pierro A, Nah SA. Surgical management of congenital hyperinsulinism of infancy. Semin Pediatr Surg. 2011 ; 20 : 50-3. 「中」
 
112) Ferry RJ Jr, Kelly A, Grimberg A, Koo-McCoy S, Shapiro MJ, Fellows KE, Glaser B, Aguilar-Bryan L, Stafford DE, Stanley CA. Calcium-stimulated insulin secretion in diffuse and focal forms of congenital hyperinsulinism. J Pediatr. 2000 ; 137 : 239-46. 「中」
 
113) Barthlen W. Surgery in congenital hyperinsulinism-tips and tricks not only for surgeons. A practical guide. Semin Pediatr Surg. 2011 ; 2 (0 1) : 56-9. 「中」
 
114) Zani A, Nah SA, Ron O, Totonelli G, Ismail D, Smith VV, Ashworth M, Blankenstein O, Mohnike W, De Coppi P, Eaton S, Hussain K, Pierro A. The predictive value of preoperative fluorine-18-L-3, 4-dihydroxyphenylalanine positron emission tomography-computed tomography scans in children with congenital hyperinsulinism of infancy. J Pediatr Surg. 2011 ; 46 : 204-8. 「中」
 
115) von Rohden L, Mohnike K, Mau H, Eberhard T, Mohnike W, Blankenstein O, Empting S, Koch M, Fuchtner F, Barthlen W. Visualization of the focus in congenital hyperinsulinism by intraoperative sonography. Semin Pediatr Surg. 2011 ; 20 : 28-31. 「低」
 
116) Arya VB, Flanagan SE, Kumaran A, Shield JP, Ellard S, Hussain K, Kapoor RR. Clinical and molecular characterisation of hyperinsulinaemic hypoglycaemia in infants born small-for-gestational age. Arch Dis Child Fetal Neonatal Ed. 2013 ; 98 : F356-8. 「中」
 
117) Touati G, Poggi-Travert F, Ogier de Baulny H, Rahier J, Brunelle F, Nihoul-Fekete C, Czernichow P, Saudubray JM. Long-term treatment of persistent hyperinsulinaemic hypoglycaemia of infancy with diazoxide : a retrospective review of 77 cases and analysis of efficacy-predicting criteria. Eur J Pediatr. 1998 ; 157 : 628-33. 「中」
 
118) Le Quan Sang KH, Arnoux JB, Mamoune A, Saint-Martin C, Bellanne-Chantelot C, Valayannopoulos V, Brassier A, Kayirangwa H, Barbier V, Broissand C, Fabreguettes JR, Charron B, Thalabard JC, de Lonlay P. Successful treatment of congenital hyperinsulinism with long-acting release octreotide. Eur J Endocrinol. 2012 ; 166 : 333-9. 「低」
 
119) Calabria AC, Li C, Gallagher PR, Stanley CA, De Leon DD. GLP-1 receptor antagonist exendin- (9-39) elevates fasting blood glucose levels in congenital hyperinsulinism owing to inactivating mutations in the ATP-sensitive K+ channel. Diabetes. 2012 ; 61 : 2585-91. 「中」
 
120) Modan-Moses D, Koren I, Mazor-Aronovitch K, Pinhas-Hamiel O, Landau H. Treatment of congenital hyperinsulinism with lanreotide acetate (Somatuline Autogel). J Clin Endocrinol Metab. 2011 ; 96 : 2312-7. 「低」
 
121) Kuhnen P, Marquard J, Ernert A, Meissner T, Raile K, Wannenmacher G, Blankenstein O. Long-term lanreotide treatment in six patients with congenital hyperinsulinism. Horm Res Paediatr. 2012 ; 78 : 106-12. 「低」
 
122) Corbin JA, Bhaskar V, Goldfine ID, Issafras H, Bedinger DH, Lau A, Michelson K, Gross LM, Maddux BA, Kuan HF, Tran C, Lao L, Handa M, Watson SR, Narasimha AJ, Zhu S, Levy R, Webster L, Wijesuriya SD, Liu N, Wu X, Chemla-Vogel D, Lee SR, Wong S, Wilcock D, Rubin P, White ML. Inhibition of insulin receptor function by a human, allosteric monoclonal antibody : a potential new approach for the treatment of hyperinsulinemic hypoglycemia. MAbs. 2014 ; 6 : 262-72. 「低」
 
123) de Heide LJ, Laskewitz AJ, Apers JA. Treatment of severe postRYGB hyperinsulinemic hypoglycemia with pasireotide : a comparison with octreotide on insulin, glucagon, and GLP-1. Surg Obes Relat Dis. 2014 ; 10 : e31-3. 「低」
 
124) Skae M, Avatapalle HB, Banerjee I, Rigby L, Vail A, Foster P, Charalambous C, Bowden L, Padidela R, Patel L, Ehtisham S, Cosgrove KE, Dunne MJ, Clayton PE. Reduced Glycemic Variability in Diazoxide-Responsive Children with Congenital Hyperinsulinism Using Supplemental Omega-3-Polyunsaturated Fatty Acids ; A PilotTrial with MaxEPA (R.). Front Endocrinol (Lausanne). 2014 ; 5 : 31. 「中」
 
125) Senniappan S, Alexandrescu S, Tatevian N, Shah P, Arya V, Flanagan S, Ellard S, Rampling D, Ashworth M, Brown RE, Hussain K. Sirolimus therapy in infants with severe hyperinsulinemic hypoglycemia. N Engl J Med. 2014 ; 370 : 1131-7. 「中」
 

(VII) 疾患と内分泌異常

P.286 掲載の参考文献
1) Darzy KH, et al. Pituitary 2009 ; 12 : 40-50.
PubMed
2) Nandagopal R, et al. Horm Res 2008 ; 69 : 57-74.
 
3) Brownstein CM, et al. J Clin Endopcrinol Metab 2004 ; 89 : 4422-7.
 
4) Chrousos GP, et al. J Clin Endocrinol Metab 1982 ; 54 : 1135-9.
PubMed
5) Radovick S, et al. J Clin Endocrinol Metab 2007 ; 92 : 1195-200.
PubMed
P.290 掲載の参考文献
1) Oberfield SE, et al. Arch Pediatr Adolesc Med 1996 ; 150 : 589-92.
PubMed
2) Muller HL, et al. Eur J Pediatr 1996 ; 155 : 763-9.
PubMed
3) Green Dm, et al. Am J Obstr Gynecol 2002 ; 187 : 1070-80.
 
4) Sklar CJ. National Cancer Inst Monogr 2005 ; 34 : 25-7.
 
5) Gleeson HK, et al. Endocr Relat Cancer 2004 ; 11 : 589-602.
PubMed
6) Schmiegelow M, et al. J Clin Endocrinol Metab 2001 ; 86 : 2446-52.
PubMed
P.291 掲載の参考文献
1) Oberfield SE, et al. Horm Res 1997 ; 47 : 9-16.
PubMed
2) Schmiegelow M, et al. J Clin Endocrinol Metab 2003 ; 88 : 3149-54.
PubMed
3) Gleeson HK, et al. Endocrine Related Cancer 2004 ; 11 : 589-602.
PubMed
4) Nandagopal R, et al. Horm Res 2008 ; 69 : 57-74.
 
5) Rose SR, et al. Pediatr Blood Cancer 2005 ; 45 : 808-13.
PubMed
6) Linder BL, et al. J Pediatr 1990 ; 117 : 892-6.
PubMed
7) 林美恵, 他. ホルモンと臨床 2009 ; 57 : 75-8.
 
P.293 掲載の参考文献
1) Lando A, et al. Clin Endocrinol (Oxf) 2001 ; 55 : 21-5.
PubMed
2) Rose SR, et al. J Clin Endocrinol Metab 1999 ; 84 : 4472-9.
PubMed
3) Schmiegelow M, et al. J Clin Endocrinol Metab 2003 ; 88 : 136-40.
PubMed
4) Sigurdson AJ, et al. Lancet 2005 ; 365 (9476) : 2014-23.
PubMed
5) Sklar C, et al. J Clin Endocrinol Metab 2000 ; 85 : 3227-32.
 
6) Jereczek-Fossa BA, et al. Cancer Treat Rev 2004 ; 30 : 369-84.
PubMed
7) Ishiguro H, et al. J Clin Endocrinol Metab 2004 ; 89 : 5981-6.
PubMed
8) Acharya S, et al. Cancer 2003 ; 97 : 2397-403.
PubMed
P.295 掲載の参考文献
1) Lustig RH. Ped Endocrinol Rev 2006 ; 3 (Supple 2) : 306-11.
 
2) Raghavan D, et al. J Clin Oncol 1992 ; 10 : 1386-9.
PubMed
3) de Haas EC, et al. Lancet Oncol 2010 ; 11 : 193-203.
PubMed
4) Srinivasan S, et al. J Clin Endcrinol Metab 2004 ; 89 : 81-6.
 
5) Tomita Y, et al. Bone Marrow Transplant 2010 ; 46 : 416-25.
PubMed
6) Taskinen M, et al. Lancet 2000 ; 356 : 993-7.
PubMed
7) Lustig RH, et al. J Clin Endcrinol Metab 2003 ; 88 : 2586-92.
 
8) American Academy of Pediatrics. Pediatrics 1992 ; 89 : 525-84.
 
9) Okada T, et al. Pediatr Int 2002 ; 44 : 596-601.
PubMed
P.299 掲載の参考文献
1) Wing L, et al. A Multidisciplinary Approach. 2nd. New York : Springer Berlin Heidelberg ; 2005. p.51-80.
 
2) 日本肥満学会編. 小児の肥満症マニュアル. 東京 : 医歯薬出版 ; 2004.
 
3) 磯島豪, 他. 肥満研究 2008 ; 14 : 159-65.
Medical*Online
P.302 掲載の参考文献
1) Wasilewski-Masker K, et al. Pediatrics 2008 ; 121 (2) : 705-13.
 
2) Sala A, et al. Cancer 2007 ; 109 (7) : 1420-31.
PubMed
3) 骨粗鬆症の予防と治療ガイドライン 2015年版. 東京 : ライフサイエンス出版 ; 2015. http://jsbmr.umin.jp/pdf/GL2015.pdf
 
4) 日本人の食事摂取基準 (2015年版). 厚生労働省「日本人の食事摂取基準」策定検討会報告書. 東京 : 第一出版 ; 2014.
 
5) Suzuki Y, et al. J Bone Miner Metab 2014 ; 32 : 337-50. (日本語版 http://jsbmr.umin.jp/guide/pdf/gioguideline.pdf)
 
6) Bachrach LK, et al. J Clin Endocrinol Metab 2009 ; 94 : 400-9.
PubMed
7) 日本骨代謝学会, 日本骨粗鬆症学会合同原発性骨粗鬆症診断基準改訂検討委員会. Osteoporosis Japan 2013 ; 21 : 9-17. http://jsbmr.umin.jp/guide/pdf/g-guideline.pdf
 
8) 田中弘之. 小児科 2005 ; 別冊 46 : 17-9.
 
P.304 掲載の参考文献
1) 田苗綾子, 他. 専門医による新小児内分泌疾患の治療. 東京 : 診療と治療社 ; 2007.
 
2) バゾプレシン分泌低下症 (中枢性尿崩症) の診断と治療の手引き (平成22年度改訂). 厚生労働科学研究費補助金難治性疾患克服研究事業間脳下垂体機能障害に関する調査研究班平成22年度 総括・分担研究報告書, 2011.
 
3) バゾプレシン分泌過剰症 (SIADH) の診断と治療の手引き (平成22年度改訂). 厚生労働科学研究費補助金難治性疾患克服研究事業間脳下垂体機能障害に関する調査研究班平成22年度 総括・分担研究報告書, 2011.
 
4) 田島輝隆, 井澤雅子, 長谷川行洋. 尿崩症小児の治療指針. 小児科診療 2010 ; 73 巻増刊 (866) : 537-9.
 
5) Kim RJ, Malattia C, Allen M, Moshang T Jr, Maghnie M. Vasopressin and desmopressin in central diabetes insipidus : adverse effects and clinical considerations. Pediatr Endocrinol Rev 2004 ; 2 (Suppl 1) : 115-23.
 
P.305 掲載の参考文献
1) 日本高血圧学会高血圧治療ガイドライン作成委員会編. 高血圧治療ガイドライン 2014. 東京 : ライフサイエンス社 ; 2014.
 
2) Haddy TB, et al. Pediatric Blood Cancer 2006 ; 49 : 79-83.
 
3) Finklestein JZ, et al. Am J Clin Oncol 1993 ; 16 : 201-5.
PubMed
4) Talvensaari KK, et al. J Clin Endocrinol Metab 1996 ; 81 : 3051-5.
PubMed
P.308 掲載の参考文献
1) 伊藤善也, 加藤則子, 立花克彦, 藤枝憲二. 小児慢性特定疾患治療研究事業において採用された身長基準に準拠した2000年度版「標準身長表」および「標準成長曲線」, 小児科診療 2005 ; 7 : 1343-51.
Medical*Online
2) 諏訪城三. 小児の成長障害. 大阪 : 永井書店 ; 1976 (一部改変).
 
3) 小児基準値研究班編. 日本人小児の臨床検査基準値. 東京 : (財) 日本公衆衛生協会出版 ; 1997.
 
4) 生魚薫, 橋本令子, 村田光範. 学校保健における新しい体格判定基準の検討 新基準と旧基準の比較, および新基準による肥満傾向児並びに痩身傾向児の出現頻度にみられる1980年度から2006年度にかけての年次推移について. 小児保健研究 2010 ; 69 : 6-13.
 
5) (財) 日本学校保健会. 児童生徒等の健康診断マニュアル (平成27年度改訂), 2015.
 
6) 日本小児内分泌学会編. 小児内分泌学. 東京 : 診断と治療社 ; 2010. p.563.
 
7) Kato N. The cubic function for spline smoothed L, S, M values for BMI reference data of Japanese children. Clin Pediatr Endocrinol 2011 ; 20 : 47-9.
 
8) 日本高血圧学会高血圧治療ガイドライン作成委員会編. 高血圧治療ガイドライン2014. 東京 : ライフサイエンス出版 ; 2014.
 

付録

P.337 掲載の参考文献
1) 原子力災害時における安定ヨウ素剤予防服用の考え方について. 原子力安全委員会, 原子力施設等防災専門部会, 平成14年4月.
 
2) Bennett B., et al. Health Effects of the Chernobyl Accident and Special Health Care Programmes. WHO Library, Geneva, 2006.
 
3) Guidance : Potassium iodide as a thyroid blocking agent in radiation emergencies. U. S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), December 2001, Procedural.
 
4) Verger P., et al. Iodine Kinetics and Effectiveness of Stable Iodine Prophylaxis After Intake of Radioactive Iodine : A Review. Thyroid 2001 ; 11 : 353-60.
PubMed
5) Nauman J, Wolff J Iodide prophylaxis in Poland after the Chernobyl reactor accident : Benefits and risks. Am J Med 1993 ; 94 : 524-32.
PubMed
6) 先天性甲状腺機能低下症マススクリーニングのガイドライン (1998年版). 日本小児科学会雑誌1998 ; 102 : 817-9.
 

書評

最近チェックした商品履歴

Loading...